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American Heart Association officials and other expert cardiologists recommend omega-3 
(n-3) dietary supplementation for the secondary prevention of cardiovascular disease, a 
prevalent health problem in the United States. Physicians’ lack of understanding of 
possible n-3 preventive health benefits results in underprescribing  n-3 dietary 
supplements and lower n-3 dietary supplement product sales. N-3 dietary supplement 
marketers do not understand physician n-3 prescribing decision criteria enough to 
optimize high-impact communication to physicians to increase n-3 dietary supplement 
product use. The purpose of this phenomenological research study was to improve n-3 
marketers’ understanding of how physicians reach decisions to prescribe or recommend 
products including n-3 dietary supplements. Argyris’ ladder of inference theory provided 
the study framework to facilitate understanding physicians’ decision criteria. Rich data 
collected and analyzed from 20 primary care physician interviews in Kentucky, Indiana, 
and Tennessee revealed physicians use similar decision criteria for drugs and n-3s. Three 
essential influencers of physician decisions included clinical evidence, personal 
experience, and cost. Other influencers were opinions of peers, pharmaceutical 
representatives, samples, direct-to-consumer advertising, and knowledge of dietary 
supplements. Study outcomes may inform pharmaceutical marketers regarding 
presentation of clinical evidence, cost emphasis, and pharmaceutical representative skills 
and may facilitate competitive advantage for n-3 marketers. The social benefit of this 
study is improved physician understanding of n-3s may result in more accurate and 





Physician Decision Criteria Regarding Omega-3 Dietary Supplements 
by  
Warren P. Lesser 
 
MBA, Centenary College of Louisiana, 1987 
BA, Taylor University, 1976 
 
 
Doctoral Study Submitted in Partial Fulfillment 
of the Requirements for the Degree of 






INFORMATION TO ALL USERS
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted.  Also,  if material had to be removed, 
a note will indicate the deletion.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against
unauthorized copying under Title 17, United States Code
ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor,  MI 48106 - 1346
UMI  3611495
Published by ProQuest LLC (2014).  Copyright in the Dissertation held by the Author.





Many thanks to my committee members for their guidance, especially my Chair, 
Dr. Robert Miller; Second Chair, Dr. Michael Ewald; and methodologists Dr. Gene Fusch 
and Dr. Doug Campbell, and URR Dr. Judith Blando. Special thanks also go to my 
classmate and friend, Dr. Gregory Banks. Most importantly, I thank my wife, Mary, for 




Table of Contents 












Significance of the Study .............................................................................................19
Reduction of Gaps................................................................................................. 19
Implications for Social Change ............................................................................. 19
Study Prospects for Improving Society ................................................................ 20
A Review of the Professional and Academic Literature ..............................................21
Complementary and Alternative Medicine ........................................................... 22
Omega-3 Cardiovascular Efficacy and Safety ...................................................... 24
Customer Needs and Ladder of Inference ............................................................ 41
Dietary Supplement Physician Education ............................................................. 49
 
ii 
Factors Affecting Patient Compliance .................................................................. 55
Drug and CAM Marketers’ Methods to Physicians .............................................. 60
Method and Design ............................................................................................... 67
Transition and Summary ..............................................................................................74
Section 2: The Project ........................................................................................................76
Purpose Statement ........................................................................................................76
Role of the Researcher .................................................................................................77
Participants ...................................................................................................................79
Research Method and Design ......................................................................................79
Method .................................................................................................................. 79
Research Design and Method Justification ........................................................... 80
Population and Sampling ...................................................................................... 83
Data Collection ............................................................................................................84
Instruments ............................................................................................................ 84
Data Collection Technique ................................................................................... 88
Data Organization Techniques .............................................................................. 93
Data Analysis Technique .............................................................................................94
Reliability and Validity ................................................................................................97
Reliability .............................................................................................................. 97
Validity ................................................................................................................. 98
Transition and Summary ..............................................................................................99
Section 3: Application to Professional Practice and Implications for Change ................100
 
iii 
Overview of Study .....................................................................................................100
Presentation of the Findings.......................................................................................103
Theme 1: Clinical Trial Rigor, Practice Relevancy, Degree of Influence .......... 103
Theme 2: Physicians’ Experience and the Test of Time Determine 
Prescribing Habits ................................................................................... 108
Theme 5: Competent and Incompetent Pharmaceutical Representatives 
Have Antithetical Effects Influencing Physicians’ Prescribing 
Decisions ................................................................................................. 121
Theme 6: Samples Are a Valuable Influencer to Some Physicians .................... 132
Theme 7:  Most Physicians Have Negative Opinions Regarding Direct-to-
Consumer (DTC) Advertising but DTC Increases Product 
Awareness ............................................................................................... 135
Theme 8: Lost Influencer Opportunities: Physicians Need More Dietary 
Supplement Education (Including N-3 Education) and Lack of 
Dietary Supplement Curricula in Medical Schools ................................ 141
Implications for Social Change ..................................................................................155
Reflections .................................................................................................................156
Summary and Study Conclusions ..............................................................................157
References ........................................................................................................................159
Appendix B: Active Diet Ingredients ..............................................................................192
Appendix C: Informed Consent Form .............................................................................193




Section1: Foundation of the Study 
 The American Heart Association recommends omega-3 (n-3) dietary 
supplementation for the secondary prevention of cardiovascular disease (Lee, O’Keefe, 
Lavie, Marchiolo, & Harris, 2008) but physicians’ lack of understanding of possible n-3 
preventive health benefits results in the underprescribing of n-3 dietary supplements and 
lower n-3 dietary supplement product sales (Dickinson, Shao, Boyon, & Franco, 2011). 
N-3 dietary supplement marketers do not understand physician n-3 prescribing decision 
criteria. The purpose of this study was to explore the ladder of inference physicians 
cognitively ascend when deciding if they will recommend or prescribe omega-3 fatty acid 
(n-3) dietary supplements to their patients. The ladder of inference is a decision criteria 
model theory (Argyris, 1976) consisting of sequential, logical steps individuals take to 
reach logical conclusions. By analyzing each decision logic step among study subjects 
(physicians), I discovered and gained a better understanding of physician decision 
processes and concluded critical communication links useful for n-3 marketers to help 
solve marketers’ business problem of low physician cognizance of n-3 health benefits and 
their commitment to n-3 utilization. Adams, Kohlmeier, and Zeisel, (2010) supported the 
lack of sufficient physician education regarding n-3s. The business problem included the 
difficulty in communicating the complex mechanisms of n-3s to physicians and 
subsequently from physicians to their patients.  
In this study, I explained the study topic, applied business research to a business 
problem, specified the research study plan including its design and methods, and 




society. In this research study, I followed the Onwuegbuzie et al.’s (2012) exemplar for 
teaching and learning qualitative research. According to Onwuegbuzie et al., the 
qualitative research process involves 13 distinct and dynamic components: (a) 
determining the study goal, (b) formulating research objectives, (c) determining rationale, 
(d) determining purpose of research, (e) defining the research question, (f) selecting the 
sample design and size, (g) selecting research design, (h) collecting data, (i) analyzing 
data, (j) validating data, (k) interpreting data, (l) writing the final report, and (m) 
reformulating the research question as appropriate. I addressed and satisfied these 13 
qualitative componentsin the following six subsections: (a) background, (b) problem 
statement, (c) purpose statement, (e) data research methods and reliability, (f) data 
analysis and validity, and (g) application to business practice and implications for social 
change.  
Background 
 Although cardiologists and knowledgeable primary care physicians can 
understand n-3 health benefits, the business problem for n-3 marketers is a deficiency in 
understanding why many primary care physicians do not regularly recommend n-3 
dietary supplements to their patients (Dickinson, Boyon, & Shao, 2009; Dickinson, Shao, 
Boyon, & Franco, 2011). In one survey of 109 U.S. medical schools, 79% of instructors 
reported deficient dietary supplement education; only 30% of medical schools had a 
separate dietary supplement course (Adams, Kohlmeier, & Zeisel, 2010). 
 Regarding the background of n-3 safety and efficacy, many but not all clinical 




epidemiology. For example, Siddiqui, Harvey, Ruzmetov, Miller, and Zaloga (2009) 
reported n-3 dietary supplements counter health consequences of red meat consumption 
containing arachidonic acid (AA), an omega-6 (n-6) fatty acid that exacerbates systemic 
inflammation and clogs arteries in humans (atherosclerosis is the number one cause of 
death in the United States; Venes, 2009). Investigators such as Cottin, Sanders, and Hall 
(2011) and Lee, O’Keefe, Lavie, Marchiolo, and Harris (2008) explained n-3s, 
specifically docosahexanoic acid (DHA) and eicosapentanoic acid (EPA), compete with 
arachidonic acid and other n-6s for phospholipid membrane positions in human cells. 
These investigators concluded ample EPA and DHA consumption mitigate n-6 health 
consequences. Other supporting evidence includes the Food and Drug Administration 
(FDA) approval of Lovaza, a prescription n-3 supplement containing 465 mg EPA and 
375 mg DHA for hypertriglyceridemia (Serebruany et al., 2011). 
 Other clinical trial results support the positive preventive impact of consuming 
sufficient amounts of quality n-3s. For example, medical investigators reported the n-3 
long-chain (LC) polyunsaturated fatty acids (PUFA): EPA and DHA, abundant in marine 
fish, act to lower lipid blood levels to reduce cardiac events and decrease the progression 
of atherosclerosis (Kopecky, Rossmeisl, Flachs, & Kuda, 2009, p. 361). Kopecky et al. 
(2009) linked adipose tissue to the beneficial effects of n-3s on health, explaining a 
reduction in the inflammation of adipose tissue and improved glucose and lipid 
metabolism. Kopecky et al. further concluded the dietary intake of fish oil or concentrates 




regulation, ancillary benefits not addressed in this study. They concluded that in human 
subjects, n-3s achieve steady-state serum levels within 1 month. 
 In another example, Mayo Clinic Proceedings cardiologists reported results from 
thousands of published clinical trials over three decades indicated cardiovascular 
protective effects (Lee et al., 2008) reported clinical trial evidence (n = 32,000) of 
cardiovascular events reduction in 19–45% of patients ingesting n-3s versus placebo. Lee 
et al. cited the results of three specific large trials (n = 32,000) demonstrating the positive 
benefits associated with n-3s, either from oily fish or fish oil gel caps (Lee et al., 2008). 
Simopoulos (2011) noted how human beings evolved on a diet with a ratio of n-6s to n-3s 
of approximately 1:1 whereas in modern times, Westerners consume diets with ratios of 
10:1 to 25:1, (n-6s to n-3s). Simopoulos  also noted how industrialized societies increase 
energy intake while decreasing energy expenditure and consume a diet rich in saturated 
fat, n-6s, trans-fatty acids, and decreased n-3s. Mirmiran et al. (2012) cited a substantial 
body of evidence to support a balanced dietary ratio of n-6:n-3 for the prevention of 
cardiovascular disease and lower incidence of metabolic syndrome.   
 The American Heart Association recommends a diet of fatty fish at least twice per 
week (London et al., 2011). London et al. (2011) noted patients with coronary heart 
disease should consume more than 1 gram daily of combined EPA and DHA. In addition, 
London et al. also opined indisputable evidence exists n-3s have a positive impact on 
cardiac electric activity. The American Heart Association (AHA) has endorsed n-3s for 
secondary prevention of cardiovascular disease and the AHA, American College of 




enough to issue public recommendations for increased n-3 dietary intake (Lee et al. 
2008).  
Some investigators reported conflicting results and offer opposing viewpoints of 
n-3 safety and efficacy. Regarding n-3 safety, De Caterina (2011) noted the AHA advised 
caution with respect to fish contaminants. Brasky et al. (2013) linked high n-3 blood 
levels to increased prostate cancer. Other investigators attributed prostate carcinogenesis 
and other cancers to environmental toxins potentially in fish oil and unpurified fish oil 
supplements including pesticides, trace minerals, or methylmercury (Ginsberg & Toal, 
2009; Mullins & Loeb, 2012). 
Other investigators expressed skepticism regarding n-3 efficacy. For example, 
Chen et al. (2011) determined no significant differences in lowered epidemiology of 
sudden cardiac death, cardiac death, and all-cause mortality. Whelan, Gouffon, and Zhao 
(2012) determined one substance converted by the body to EPA (SDA) was not effective 
in lowering triglycerides, HDL, or LDL levels. Borghi and Pareo (2012) raised 
skepticism regarding the efficacy of n-3s in reducing ventricular arrhythmias. Vlablik, 
Prusikova, Snejdrlova, and Zlatohlavek (2009) raised the possibility n-3 dietary 
supplementation may raise undesirable low-density lipoprotein (LDL) cholesterol levels 
when used in high doses for patients with hypertriglyceridemia.  
In a large study (n = 12,356), Bosch et al. (2012) evaluated high-risk patients 
including those with impaired fasting glucose, impaired glucose tolerance, or diabetes 
and concluded n-3s had no effect on reducing cardiovascular events in this high-risk 




supplementation (226 mg EPA and 150 mg DHA) did not reduce fatal or nonfatal 
cardiovascular events. In a quantitative method analysis of 20 studies, Rizos, Ntzani, 
Bika, Kostapanos, and Elisaf (2012) determined no statistically significant correlation 
between n-3 supplementation and lower risk of all-cause mortality, cardiac death, sudden 
death, MI, or stroke. It is important for n-3 marketers to understand objectively although 
substantial clinical evidence exists to support n-3 efficacy and safety, a number of 
investigators offer credible and contradictory evidence.   
 Perhaps because of this contradictory evidence or perhaps because physicians do 
not have sufficient knowledge, survey results indicated primary care physicians do not 
routinely recommend n-3 dietary supplements to patients (Dickinson, et al., 2011). Two 
studies reported most physicians acknowledged they did not have sufficient education 
regarding dietary supplements but expressed a desire to acquire more knowledge 
(Dickinson, et al., 2009). These findings provided the foundation for the problem 
statement in this study. 
Problem Statement 
Marketers of n-3s understand important cardiovascular disease statistics in the 
United States: More than 120,000 Americans under the age of 65 die prematurely from 
heart disease each year (Centers for Disease Control [CDC], 2011) and U.S. health care 
costs rose from $714 billion in 1990 to $2.3 trillion in 2008 (CDC, 2011). Health care 
cost increases may result from a deficiency in cardiovascular disease preventive 
medicine. Physicians understand cardiovascular consequences of high cholesterol and 




efficacy of n-3s, results from more than 100 clinical studies demonstrated reduced 
cholesterol and triglycerides after concentrated n-3 dietary supplementation (London et 
al., 2011).  
The general business problem for pharmaceutical marketers is physicians’ lack of 
understanding of possible n-3 preventive health benefits (Dickinson et al., 2009; 
Dickinson et al., 2011) resulting in the under-prescribing of n-3 dietary supplements and 
lower n-3 dietary supplement product sales. The specific business problem is n-3 
marketers do not understand physician n-3 prescribing decision criteria so n-3 marketers 
can optimize high-impact communication to physicians to increase n-3 prescribing and n-
3 dietary supplement product use. 
Purpose Statement 
The purpose of this phenomenological research study was to improve n-3 
marketers’ understanding of how physicians reach decisions to prescribe or recommend 
products including omega-3 (n-3) dietary supplements and which product characteristics 
may be the most important to physicians. I explored physicians’ n-3 dietary supplement 
knowledge, and decision criteria (ladder of inference; Argyris, 1976). Understanding 
these complexities may help n-3 marketers to develop learning tools (predictors) to 
influence physician decisions (criteria) to recommend patient consumption of quality n-
3s.   
Appropriate for a qualitative phenomenological study design, I interviewed 20 
primary care physicians located in Kentucky, Indiana, and Tennessee. Interviewing 




patient health (Ashar & Rowland-Seymour, 2008). The marketing context study objective 
answered the primary research question to determine the n-3 ladder of inference 
physicians ascend. The business implication may facilitate n-3 marketers’ understanding 
of physician customers’ thinking and needs. An improved understanding by n-3 
marketers may culminate in more effective n-3 marketing, clearer communication, and 
increased preventive medicine behaviors by physicians. Increased n-3 use among the 
general population may result in improved health, reduced cardiac disease, and reduced 
U.S. healthcare spending.  
Nature of the Study 
I used the qualitative method to gather data and analyze the data to find useful 
information and understand thought processes and decision criteria among physician 
subjects. Bertolotti and Tagliaventi (2007) employed qualitative methods to identify 
complex views, opinions, and perceptions of participants. According to Bertolotti and 
Tagliaventi, the purpose of a qualitative study is to identify themes and constructs among 
the words used by participants in response to open-ended questions. In this study, without 
prompting, all physician subjects used words to indicate they did have some knowledge 
of n-3 benefits preventing cardiovascular disease. Even so, I used words such as “Please 
tell me your opinion regarding…” to encourage open expression and opposing 
viewpoints.  
According to Csordas, Dole, Tran, Strickland, and Storck (2010), interviewers 
should choose words based upon careful assessment of the pretext, subtext, and context 




study subject, and the possible influence of those conversations. Subtext refers to the 
influence of subjects’ hidden agendas and relevant to this study, meant allowing subjects 
to voice their hidden agendas to support or reject n-3 safety and efficacy in the prevention 
of cardiovascular disease.  
Regarding the context of the setting, I insisted upon a quiet, private interview 
room free of interruptions to protect the interview setting. Additional steps included 
carefully planning interview questions, electronically recording and transcribing data 
verbatim, and using detailed, descriptive text. I documented my personal bias in favor of 
n-3 efficacy and safety but described steps I took to prevent bias during interviews. I was 
careful not to contradict any physician subjects who questioned n-3 safety and efficacy. 
Regarding data analysis, Bertolotti and Tagliaventi (2007) emphasized the 
importance of data analysis objectification, a critical element to support study validity. In 
this study I used inter-coder agreement, triangulation, peer review, and member checking 
to ensure study validity. The complexity of collected data did not necessitate coding 
software such as HyperRESEARCH (Textor & Hedrick, 2012) to facilitate coding 
efficiency and objectivity. Approved by an Institutional Review Board (IRB approval 
05-29-13-0265406), one other coder and I worked independently but collaboratively to 
drive convergent and divergent themes from data collected from physician subjects 
(inter-coder agreement). The other coder signed a Confidentiality Agreement to protect 
subjects’ anonymity and privacy. 
I selected physician participants based upon their willingness to participate 




criteria necessitated the inclusion of some physicians who already prescribed or 
recommended n-3s. Geographical scope, a willingness to set aside sufficient time without 
interruptions, and a private setting defined acceptable participant access criteria. 
For data collection, I conducted personal interviews using a semistructured format 
to facilitate free expression by participants and allow clarifying questions. The data I 
collected was qualitative. Neuman (2011) observed a quantitative research method is 
appropriate for seeking numeric responses to narrow question responses. However, the 
rightness of understanding how physicians make decisions was achieved perhaps to a 
greater degree without quantitative measurement.  
Before data collection, I validated the research interview instrument through one 
pilot test interview and used interviewing-the-investigator technique (Chenail, 2011) to 
determine realistic responses as well as improve interviewing skills. These preparatory 
steps were taken to enhance the trustworthiness of collected data and therefore improve 
the reliability and validity of coding, theme development, analysis, and study outcomes. 
After data collection and theme development, I sent identified themes and transcript 
excerpts to participants for the purposes of member-checking and triangulation. I 
protected the confidentiality of all participants and identified only the initial of the 
subject reviewing the document. The intent of this step was to enrich study validity, 
conformability, and outcomes significance. Approximately one-half of study subjects 





Using the primary study question, I invited situational examination (contextual 
application) and expanded knowledge (Ellis & Levy, 2009). The answer shaped the 
strategy for n-3 marketers regarding how physicians make medical decisions using 
observable, selected data, and how they add personal meanings, assumptions, and 
conclusions to the data resulting in behavioral action. My primary research question was: 
For the purpose of marketing strategy, what is the ladder of inference physicians use to 
recommend n-3 dietary supplements?  
The specific interview questions were: 
1.   Considering the previously explained ladder of inference and reflexive loop 
(Ayers, 2002), what processes do you go through to determine what products 
you will prescribe or what dietary supplements you will recommend? 
2. What credible clinical evidence have you seen regarding fish oil dietary 
supplements? 
3. What made the evidence credible or incredulous?   
4. What are the risks of taking fish oil dietary supplements?  
5. What are the risks regarding specific patient groups or disease states?   
6. What are the important differences between quality fish oil dietary supplements 
and low quality fish oil dietary supplements?  




8. If clinical evidence is credible and convincing regarding fish oil efficacy for 
health prevention for disease amelioration, what education and 
communication methods to physicians are best? 
9. Similarly, what education and communication methods to patients are best? 
10. Within the context of the ladder, please explain your present professional 
opinion regarding the health value of fish oil dietary supplements, specifically 
fish oil containing n-3s, for patients with no contraindications.  
11. What are your prescribing or recommending practices regarding n-3 fatty acid 
dietary supplements and the priority of n-3 dietary supplements as compared 
with other dietary supplements (e.g., multivitamins, chondroitin, niacin)?  
12. How influential are your peers’ prescribing practices to your decisions?  
13. When you speak with your peers, what percentage of them would you say are 
committed to frequently recommending omega-3s? 
14. If all your patients took a high quality omega-3 every day, what would be the 
impact on your whole practice?  
15. If all your patients took a high quality omega-3 every day, what would be the 
positive impact on U.S. healthcare costs?  
Conceptual Framework 
Physicians, in general, lack sufficient knowledge of dietary supplements, and in 
particular n-3s (Ashar, Rice, & Sisson, 2008), to discuss with confidence these substances 




2003). I found no reference more recent than 2003, which supports a gap in the literature 
and the need for this study.  
Ladder of inference theory (Argyris, 1976) provided a conceptual framework for 
deciphering and prioritizing the complex and competing factors influencing physicians’ 
knowledge and willingness to recommend n-3s. Ladder of inference theory includes six 
ladder rungs as requisite steps leading from data to enacted behavior. These progressive, 
logical ladders are as follows: (a) observable data and experiences, (b) selected data from 
observable data, (c) assumptions based upon meanings added to data based upon cultural 
and personal experiences, (d) conclusions drawn from assumptions, (e) adopted beliefs 
about the world, and (f) actions taken based upon beliefs (Argyris, 1976). Using the 
ladder of inference model to guide interview questions added structure and meaning to 
physician subject responses. This structure also facilitated data coding, interpretation, and 
analysis. The ladder of inference theory facilitated physicians’ self-understandings, 
helped identify needs for education and marketing purposes, and fostered efficiency when 
attempting to drive theme clarity and outcomes from the group upon member-checking 
follow-up.  
Definition of Terms 
Allopathic: A system of treating disease by inducing a pathological reaction 
antagonistic to the treated disease (Venes, 2009). 
Atherosclerosis: Arterial disorder characterized by restricted blood flow from 
cholesterol-lipid-calcium deposits in the walls of arteries. Over time, arteries may 




can close, and organs or tissues may infarct. Risk factors for atherosclerosis are tobacco 
abuse, diabetes mellitus, elevated blood lipid concentrations, hypertension, family 
history, male gender, menopause in women, microalbuminemia, chronic kidney disease, 
increased age, sedentary lifestyle, and obesity (Venes, 2009).  
Atherogenesis: The formation of plaques beneath the membrane of artery linings 
(Venes, 2009). 
Auto-ethnography: As the researcher, my experience automatically derives from a 
cultural connection or identification with the subject (Sergi & Hallin, 2011) 
Complementary and alternative medicine (CAM): CAMs are alternative therapies 
to conventional treatments. Conventional treatments demonstrate efficacy and safety to 
achieve FDA approval. Complementary medicine indicates a therapy may be added to a 
conventional treatment. Alternative medicine implies a therapy other than a conventional 
treatment. The Cochrane Collaboration provides a classification of CAM treatments 
(Wieland, Manheimer, & Berman, 2011).  
Chemotaxis: Cellular movement toward or away from chemical stimuli. The term 
chemotaxis primarily refers to phagocytic white blood cells (Venes, 2009). 
Docosahexanoic acid (DHA): Long chain polyunsaturated n-3 (Venes, 2009). 
Docosapentanoic acid (DPA): Long chain polyunsaturated n-3 fatty acid 
metabolized by the body into eicosapentanoic acid (EPA) (Whelan, 2009). 
Eicosapentanoic acid: Long chain polyunsaturated n-3 fatty acid. 
Essential fatty acid (EFA): A polyunsaturated fatty acid necessary in the diet for 




to changes in cell structure and enzyme function, resulting in decreased growth and other 
disorders. Symptoms include nail problems, brittle hair, dandruff, allergic conditions, 
dermatitis, and eczema in infants (Venes, 2009). 
Homeopathic, homeopathy: Based upon the proposal that very dilute doses of 
extracts, medicines, or other substances producing symptoms of disease in healthy people 
will cure those diseases in affected patients (i.e., “like cures like”). Homeopathy differs 
from allopathy because homeopathy emphasizes the body healing itself (Venes, 2009).  
Hypertriglyceridemia: A condition marked by too many triglycerides in the blood 
(Venes, 2009). 
Ladder of inference: A mental model containing decision rungs, all of which are 
confirmable by others, except the bottom rung of observable data and experiences. 
Subsequent ascending rungs include I Select Data (from what a researcher can observe), I 
Add Meanings (cultural and personal), I Make Assumptions (based on the meanings the 
researcher adds), I Draw Conclusions, I Adopt Beliefs (about the world), and I Take 
Actions (based on the researcher’s beliefs). An individual can unconsciously ascend the 
ladder quickly, perhaps too quickly, taking actions based upon established beliefs, 
triggered by observed data. This process is a reflexive loop (Ayers, 2002). 
Momentary salience: the temporal influences of personal mood and environment 
affecting a decision (Weiss, Weiss, & Edwards, 2010) 
Omega-3 fatty acids (n-3s): Essential fatty acids with double bonds at the third 




Physician: An individual who successfully completed the prescribed curriculum 
of studies in a medical school officially recognized by the country of the medical school 
location, and who has acquired the requisite qualifications for licensure in the practice of 
medicine (Venes, 2009).  
Preventive medicine: The branch of medicine to prevent disease and methods to 
increase power of patient and community to resist disease and prolong life (Venes, 2009). 
Qi gong (qigong): The Chinese approach to healing based upon the harnessing of 
inner energy sources. Therapists employ movement, breathing exercises, meditation, and 
relaxation (Venes, 2009). In the medical field sometimes referred to as qi (Wieland et al., 
2011).  
Reflexive loop: Human reactive behavior where an individual interprets observed 
data selectively, biased by personal beliefs and experiences (Ayres, 2002). 
Rigor: The process of identifying gaps between what was actually done versus a  
prescribed or standard method using a measurement approach throughout the analysis  
to assure accuracy and reduce the risk of shallow analysis (Zelik, Patterson, & Woods, 
2010). 
Stearidonic acid (SDA): An n-3 fatty acid with similar biological properties to 
EPA found in plant sources such as soybean oil, hemp seed oil, and black currants 




Assumptions, Limitations, and Delimitations 
Assumptions 
Assumptions are statements about factors not observable or testable (Neuman, 
2011). My first assumption was that physician subjects want to recommend what is in the 
best interest of their patients. The second assumption was most physicians do not 
recommend n-3s and this study confirmed this assumption also supported by the 
literature. The third assumption was the integrity of the physician subjects and the 
substance of physician conversations supported this assumption. My fourth assumption 
was that the conducting of interviews in private settings to limit uncontrollable variables 
(e.g., interruptions) would enhance uniformity, prevent material bias, and ensure 
confidentiality (Alcadipani & Hodgson, 2009).  
Limitations 
Two limitations of this study included purposeful sampling of primary care 
physicians in a limited geography (Kentucky, Indiana, Tennessee). I did not select 
physician subjects from other specialties because of a lack of relevancy and focus upon 
cardiovascular preventive medicine. Physicians in a wider geography, for example, on the 
west coast or east coast of the United States may have different viewpoints of n-3s.   
A third limitation was the sample size (n = 20), although I did not gather 
significant new information after the 15th interview and therefore, believe I reached the 
point of saturation in less than 20 interviews. Saturation is a guiding principle of sample 
size determination in qualitative studies (Carlsen & Glenton, 2011). Mason (2010) 




number of variables such as the aims of the study, homogeneity of participants, and skill 
of the interviewer. The focused aims of this study, similar specialties among physician 
subjects in a limited geography, and richness of data gathered during interviews support 
the possibility of achieved sample saturation for this defined population.  
Kerr (2010) that explained investigators cannot predict saturation before the study 
but for practical purposes, investigators need to plan number of subjects. From a 
literature review, Kerr determined investigators who sought to establish sample size 
guidelines for qualitative methods of inquiry advocated samples sizes of six to 20 
subjects. Similar to Mason (2010), Kerr stated that saturation depended upon 
heterogeneity of subjects and study objectives. These guidelines support the purposeful 
sample size for this focused physician decision-criteria marketing study. 
Delimitations 
Delimitations included the conscious inclusion and exclusion criteria specified in 
this study and Informed Consent. I based purposeful selection upon interest in the study 
subject, an open perspective regarding diverse opinions, and access. Geographical scope 
and a willingness to set aside sufficient time without interruptions in a private setting 
defined acceptable participant access criteria. Considering these delimitations, I could not 
determine if interviews would have elicited different data if the physician participants did 
not have an interest in the topic, practiced in states other than Kentucky, Indiana, and 




Significance of the Study 
Reduction of Gaps 
Marketers of n-3s may benefit from the research findings of this study to improve 
understanding of how physicians think regarding prescribing or recommending decisions. 
The ladder of inference posits individuals do not test self-generating beliefs to validate 
truth (Argyris, 1976). For example, individuals believe own beliefs are the truth, and the 
truths they believe are the obvious truths. Individuals also believe they base beliefs and 
conclusions upon real data (Argyris, 1976). The next ladder is the data individuals select 
to believe to formulate truth is, in fact, real data (Argyris, 1976). In this study, I examined 
the steps in the ladder of inference relevant to prescribing or recommending decisions; 
these important study outcomes may reveal strategic business opportunities for marketers 
of n-3 dietary supplements.  
One unintended, but relevant, theme that emerged from this study was the 
physician participants’ unanimous and unsolicited opinions regarding the inadequacy of 
dietary supplement training in medical schools. This theme reinforces the findings of 
Adams, Kohlmeier, and Zeisel (2010). Based upon ProQuest multiple database searches, 
few studies have been published regarding this subject. 
Implications for Social Change 
Validating prospective business (marketing) and societal benefits were central 
intentions of this study. In a university IRB-approved pilot interview with a physician, J. 
Lach (personal communication, November 17, 2011), Lach confirmed the prevalence of 




upon the possible social benefits of a preventive cardiovascular disease product like 
Lovaza. The data from the pilot interview, therefore, confirmed the prospective social 
change benefits of this study. Contemplating the effects of physicians’ more frequent 
prescribing and recommending n-3s (behavioral change), physicians who participated in 
this study confirmed the possibility of substantial societal benefits resulting from reduced 
cardiovascular disease, providing the positive outcomes of some n-3 studies were true 
and the negative outcomes of other n-3 studies were not true. 
Study Prospects for Improving Society 
Change occurs when a research study affects society. In this case, the marketing 
of n-3 supplements, medicine, and science intersect each other with possibly different 
values (Matheson, 2008). Matheson expounded how business profits motivate 
pharmaceutical marketers, good health motivates physicians, and the truth motivates 
researchers. So determining this study’s prospects for improving society requires 
objectivity with respect to n-3 safety and efficacy as well as a fair appraisal of the impact 
of effective marketing on society. The outcomes from this study may drive improved 
communication and symmetry between physicians and patients regarding accountability 
for preventive health. Physicians may more effectively collaborate with their patients to 
accomplish requisite n-3 dietary changes. All of this may be positive for society, 
providing n-3s deliver the preventive cardiovascular disease benefits claimed in many but 
not all clinical studies. 
The societal implications for this study follow a sequential chain. First, marketers’ 




communication between n-3 marketers and physicians regarding the possible preventive 
cardiovascular disease value of n-3 dietary supplementation. Second, physicians’ 
assumptions and conclusions based upon credible, observable data may lead to a more 
educated cognitive framework regarding n-3s. Third, physicians’ experiences may 
reinforce behavioral change. The change in physician subjects’ attitudes and behaviors 
may expand preventive medicine practice. 
When published, study results may expand societal benefits in a wider, national 
geography. Additionally, study findings may influence the population of primary care 
and specialist physicians to recommend n-3s to their patients as preventive medicine. 
America’s cardiovascular disease epidemiology may decrease along with the concomitant 
health interventional treatment costs. 
A Review of the Professional and Academic Literature 
This section includes six related literature review areas. First, I identify and 
describe CAM as the nondrug classification system including n-3s. Next, a portion of the 
literature review supports the efficacy, safety of the correct n-3s, and n-3 daily dosages as 
dietary supplements although another portion of the literature review raises questions 
regarding the safety and efficacy of n-3s. In the subsequent three sections, I cite literature 
to support the knowledge deficiency and need for physician education as well as a 
framework for understanding physicians’ recommending and prescribing decisions. In the 
final section, I highlight the importance of the role of the patient and the importance of 
the physician’s achievement of patient conviction and compliance. The literature review 




ABI/Inform Complete, Academic Search Complete/Premier, Science Direct, Business 
Source Complete, Google Scholar, and PubMed. Additionally, corporate and trade 
sources provided leads to scholarly journals. I used search words such as “omega-3,” 
“cardiovascular disease,” “eicosopentanoic acid,” “docosahexanoic acid,” “fish oil,” “fish 
oil contaminants,” “dietary supplements,” “physician education of dietary supplements,” 
“omega-3 clinical evidence,” “omega-3 safety,” and “omega-3 efficacy.” 
Complementary and Alternative Medicine 
The Cochrane Collaboration has become an important source of information 
collection and organization of 396 reviews regarding CAM therapies (Wieland et al., 
2011). The Cochrane Collaboration has defined CAM operationally, and Wieland et al. 
(2011) articulated how the standardized definition has provided an objective, 
reproducible, and systematic method for defining, revising, and classifying multiple 
CAM therapies. Wieland et al. described how some medical school officials have 
integrated CAM therapies into medical school curricula, in addition to randomized 
controlled trials (RCTs) and systematic reviews. Despite increased mainstream openness 
to CAM therapies, practitioners, researchers, and consumers concede certain therapies 
remain outside the mainstream medical model such as CAM therapies. For example, 
according to Wieland et al., medical professionals agreed acupuncture is a CAM 
classification but disagreed about other CAM classifications, such as vitamin 
supplements. To reduce ambiguity, enhance understanding of the field, guide research, 




definition of CAM evolved into a more important and pragmatic standardized operational 
CAM definition.  
In this classification process, Wieland et al. (2011) first considered theories of 
disease and whether or not the historic notion of the subject therapy was considered CAM 
or conventional. Second, the researchers excluded CAM classifications from entities 
currently accepted by the medical community, including insurance payers and the FDA. 
Third, the researchers considered who administered the therapies; they were more likely 
to classify therapies as CAM if the patient self-administered the therapy or if non-medical 
practitioners administered the therapy. Interestingly, Wieland et al. did not include 
efficacy evidence because they noted the presence of too many therapies not currently 
accepted as efficacious (e.g., chemotherapy), or noted the lack of convincing evidence of 
efficacy.  
Wieland et al. (2011) considered information obtained from the US National 
Library of Medicine's PubMed database, including the Medical Subject Headings 
definition of complementary therapies and the complementary medicine-subset search 
strategy. From the review and decision process described above, Wieland et al. identified 
51 groups of CAM therapies used for treating or preventing disease. Wieland et al. gave 
preference to CAM therapies in their operational definitions to therapies previously 
subjected to RCTs. Wieland et al. noted they would expand their operational CAM 
definitions over time as additional clinical research is completed. 
The Cochrane CAM field listed more than 200 CAM therapies. Regarding n-3s, 




DHA and EPA as separate classifications. Perhaps the reason for overlap is Wieland et al. 
(2011) described RCT evidence as an important criterion for inclusion. See Appendix A 
for the CAM therapy list.  
To assess physician acceptance of CAM, Johnson, Priestley, Porter, and Petrillo 
(2010) conducted an online survey to members of a professional health educator listserv 
(n = 501). The researchers’ purpose of their study was to examine health educators’ 
attitudes regarding CAM while examining the educators’ use of CAM therapies, 
presumably to confirm expressed attitudes by the educators. The study results indicated 
educators have positive attitudes toward CAM in general.  
Ninety percent of respondents used at least one CAM therapy in the previous 12 
months (Johnson, Priestley, Porter, & Petrillo, 2010). On a 5-point scale, a score of 1 
indicated the respondents strongly agreed, whereas a score of 5 meant the respondents 
strongly disagreed. The response scores of men and women respondents to the statement 
“CAM should be included in professional health education preparation curriculum” were 
2.2 and 1.87, respectively. To the statement “CAM is a threat to public health,” the male 
respondent mean score was 3.93 and the female mean score was 4.23. The researchers  
noted a physician interest in CAM and CAM use by physicians was increasing in the 
United States.  
Omega-3 Cardiovascular Efficacy and Safety  
In this section, I provide evidence to support, as well as refute, the efficacy and 
safety of n-3s. Harvard University and University of Western Australia authors 




collective and complementary cardiovascular benefits for humans. Some studies noted by 
Mozaffarian and Wu suggested favorable cardiac diastolic filling (facilitated cardiac 
blood flow), arterial compliance (arterial wall flexibility), and reduced metrics of 
inflammation and oxidative stress. Combined EPA + DHA or docosapentanoic (DPA) 
acid + DHA levels were associated with a lower risk of fatal cardiac events. The authors 
noted based upon the current evidence, increasing consumption of either DHA or EPA 
would offer cardiovascular advantages versus little or no consumption.  
Reviewing clinical trials including more than 30,000 subjects with cardiovascular 
or hyperlipidemia history—the Diet and Reinfarcation Trial (DART), Japan EPA Liquid 
Intervention Study (JELIS), and Gruppo study Italiano per lo Studio della Sopravivenza 
nell’Infarto Miocardico (GISSI), Vrablik et al. (2009) opined a number of conclusions. 
First, Vlabik et al. determined uncontrolled diets as independent variables in clinical trials 
could influence study outcomes, especially in long-term follow up. The investigators 
opined evidence supported a recommended daily EPA and DHA dietary supplement 
intake of 500 mg to 1,000 mg. 
Vrablik et al. (2009) also opined EPA and DHA could reduce triglyceride levels 
by 25%-35% and in cases of severe hypertriglyceridemia, by 45%. Vrabik et al. also 
observed evidence where only DHA increased the levels of good cholesterol HDL. The 
researchers suggested both EPA and DHA reduce atherosclerosis development, reduce 
blood pressure slightly (5.8 mmHg for systolic and 3.3 mmHg for diastolic), and at 




In another literature review, De Caterina (2011) recapped the history of n-3s, from 
obscurity to substantial researcher interest. In the 1960s, Danish investigators reported 
the Greenland Inuit population showed a low incidence of heart disease. In the first 
epidemiologic observations of Inuits in Greenland (who regularly consumed a diet 
consisting of fish, seal, and whale), scientists suspected a nutritional factor was 
associated with cardiovascular protection. These observations were later confirmed in 
studies of Northern Canada and Alaska natives who consumed traditional diets as well as 
high fish-consuming Japanese, Western, and Chinese (De Caterina, 2011) and rural 
inhabitants Nenet Autonomous Okrug in Russia (Petrenya et al., 2012).  
 In 25 studies involving 280,000 participants, De Caterina (2011) reported an 
inverse association between fish consumption and morbidity or mortality from coronary 
heart disease. De Caterina determined blood levels of n-3 fatty acids correlated inversely 
with death from cardiovascular causes and total mortality. De Caterina also cited clinical 
trials with other cardiovascular outcomes including lowered triglycerides, reduced risk of 
sudden cardiac death, decreased systemic inflammation, slowed buildup of 
atherosclerotic plaque, and reduced risk of thrombosis and stroke. De Caterina stated the 
AHA recommended adults eat fatty fish at least twice a week as well as vegetables 
containing n-3 fatty acids (ALA). De Caterina noted the AHA also recommended 
coronary heart disease patients consume approximately one gram of EPA and DHA 
(combined) per day, from oily fish or fish-oil capsules (with physician consultation and 
advice). The AHA recommended higher daily doses of EPA and DHA (2 - 4 grams) as 




deciliter) to reduce serum triglyceride levels by 20% to 40%. In this paradox, Catarina 
explained how one type of desirable fatty substance lowers another undesirable fat in the 
human body.  
In a blood sample experiment, Holub, Wlodek, Rowe, and Piekarski (2009) 
reported correlative results from living human subjects (n = 2,053). The researchers 
compared fatty acid ratios between anti-inflammatory, healthy n-3 (EPA and DHA) with 
the pro-inflammatory n-6 arachidonic acid using the following ratios: n-6/n-3, AA/EPA, 
AA/DHA, and AA/EPA + DHA. Although correlational analyses indicated inverse 
relationships between the concentration of n-3s in the serum and each of the four ratios in 
phospholipids, the researchers concluded the strongest statistically significant inverse 
relationship was evident between serum n-3s and the n-6/n-3 ratio. These research results 
support a diet high in n-3s will reduce the level of n-6s in serum phospholipids and 
support the theory of preferential cell wall acceptance of n-3s over n-6s, thus reducing 
deleterious health effects of phospholipids too high in n-6 concentrations. In a controlled 
quantitative experiment consisting of 107 hyperlipidemia patients, Krysiak, Gdula-
dymek, and Okopien (2011) also found a diet high in n-3s (EPA 465 mg and DHA 375 
mg twice daily) significantly lowered plasma triglycerides (p < 0.05).  
In another study, Saravanan, Davidson, Schmidt, and Calder (2010) presented 
evidence of n-3 efficacy in reducing triglycerides and reducing the incidences of heart 
failure, atherosclerosis, stroke, and systemic inflammation. Regarding inflammation, 
Saravanan et al. discussed anti-inflammatory mechanisms including n-3 modulating 




certain pro-inflammatory stimuli (e.g., n-6s) these cells release chemical mediators to 
increase the inflammatory response. Systemic inflammation of blood vessel walls can 
lead to cardiovascular disease. 
Saravanan et al. (2010) reviewed clinical trials to assess daily EPA/DHA dosage 
regimens, ranging between 1 gram to 4 grams per day, depending upon triglyceride level 
acuity and patients’ regular dietary consumption of n-3 fatty fish. The authors determined 
a one-gram daily dosage of EPA and DHA dietary supplements equals an intake of 55 
grams of tuna, trout, salmon, or sardines, and 652 grams of cod. To determine adequate 
intake, Saravanan et al. used the n-3 index. The n-3 index is a relatively new approach to 
determine the appropriate quantity of n-3s in the body by measuring the amount of EPA 
and DHA in red blood cells. Saravanan et al. reported an n-3 index of 8% or higher as the 
guideline for the highest cardiovascular protection whereas an n-3 index of 4% or lower 
as the least cardiovascular protection.  
In another study, Soltan and Gibson (2008) provided information regarding 
recommended daily intake recommendations for n-3 ingestion and concentrations of n-3s 
by fish type. The researchers recommended 500 mg/day of DHA/EPA n-3s in healthy 
adults, 1g/day for patients with coronary heart disease, and 2–4g/day for patients with 
hypertriglyceridemia. In general, researchers determined that fatty fish provided potent 
sources of n-3s thereby reducing consumption requirements to achieve daily desired n-3 
intake. Unfortunately, several species of popular dietary fish provide poor quantities of n-
3s. Poor sources include Atlantic cod, whiting, barramundi, and southern Bluefin tuna. 




Soltan and Gibson (2008) determined the most potent sources of fish species for 
n-3s were swordfish and Atlantic salmon. Consumption of only 40g (1.4 ounces) of these 
species provides 1 gram of n-3s. Conversely, an individual would have to consume 
approximately 400g (14 ounces) of barramundi or southern Bluefin tuna to ingest 1g of n-
3s. The researchers noted the impracticality of ingesting enough popular dietary fish 
portions to achieve sufficient n-3 levels and emphasized the need for n-3 dietary 
supplements. Soltan and Gibson also elucidated how some fish contained much 
arachidonic acid, an undesirable n-6 fatty acid. Fish species with high n-6 content include 
northern whiting, shrimp, and barramundi. Popular dietary fish with low n-6 content 
include salmon, red snapper, and southern Bluefin tuna. 
Deckelbaum and Torrejon (2012) reported n-3s promote health and prevent 
disease in a number of human body systems, but the mechanisms of EPA and DHA may 
be the most remarkable in cardiovascular disease. Cardiovascular benefits result from 
progressive chain mechanisms improving chemotaxis and other anti-inflammatory 
responses, reducing oxidative damage and systemic inflammation, reducing 
atherogenesis, reducing vascular resistance, and lowering blood pressure. However, 
Deckelbaum and Torrejon noted the inadequacy of cold water fish and other dietary 
sources to achieve n-3 daily intake recommendations.  
As one partial solution, Deckelbaum and Torrejon (2012) recommended genetic 
modification of soybeans to produce high volumes of stearidonic acid (SDA). In human 
metabolism, the body synthesizes SDA into EPA. In another study including SDA, 




fish sources and SDA because an n-3 precursor found in many vegetable oils, -linolenic 
(ALA), may not provide the same health benefits because of its partial conversion to n-6 
and n-9 fatty acids.  
 Whelan (2009) noted another benefit of investigated fatty acid, SDA, as an 
alternative source of n-3 because of concerns for fish oil purity. According to Whelan, 
researchers have determined SDA may have similar biological properties to EPA. SDA 
sources include soybean oil, black current, and hemp seed oil. In a scientific comparison, 
Whelan concluded SDA shares many of the same biological effects as EPA, and 
therefore, may become an important food additive and contribute a significant supply of 
n-3 dietary supplementation for the Western world.  
Based on a meta-analysis of 25 RCTs, Whelan et al. (2012) concluded EPA and 
DHA dietary intakes, on average, reduced triglyceride levels 27 mmol/L. In their 
literature review, they found EPA and DHA dietary intake had the most pronounced 
effects on circulating triglyceride levels at daily doses > 2g/day, but with smaller effects 
on HDL and LDL cholesterol levels. Dosages ranged from 0.8g to 5.4g/day. Whelan et 
al. highlighted most studies employed dosages in the 2–4g/day, with the most pronounced 
effects on triglycerides at doses greater than or equal to 3g/day. 
Marik and Varon (2009) reviewed 11 randomized, placebo-controlled studies, 
including 39,044 patients with histories of recent myocardial infarction, heart failure, 
implanted cardioverter defibrillator, hypercholesterolemia, and peripheral vascular 
disease. Average doses of n-3 EPA and DHA ranged from 0.6–3.0g/day. Patient follow-




dietary supplementation reduced the risk of cardiovascular deaths (p = 0.002), sudden 
cardiac death (p = 0.04), all-cause mortality (p = 0.02), and nonfatal cardiovascular 
events (p = 0.02). Although multiple regression analyses did not demonstrate a dose-
response relationship, patients in this study ingested higher average doses than 
recommended by the 2008 expert panel (Harris et al. 2009). The authors recommended n-
3 dietary supplements as a practice of secondary cardiovascular event prevention. 
 N-3 fatty acids may reduce blood pressure and pulse rate according to the results 
of a meta-analysis by Hoy and Keating (2009). A mean systolic/diastolic BP reduction of 
2.3/1.5 mm/Hg occurred with a mean n-3 dosage of 4100 mg/day. In subgroups, Hoy and 
Keating reported more meaningful blood pressure reduction in older subjects (age >45 
years) versus younger subjects. Additionally, Hoy and Keating determined hypertensive 
subjects experienced more blood pressure reduction than did normotensive patients. Hoy 
and Keating also determined n-3s reduced pulse rate. Mean heart rate was significantly (p 
= 0.002 vs. placebo) reduced by 1.6 beats/minute in subjects who consumed a median n-3 
dosage of 3500 mg/day. In subgroup analysis, Hoy and Keating discovered a significant 
(p < 0.001) reduction of 2.5 beats/minute in subjects with mean heart rates of 69 
beats/minute at baseline, but no significant change in subjects with mean heart rates of 
<69 beats/minute at baseline.  
 Regarding recommended n-3 dosages, Hoy and Keating (2009) opined n-3 
dosages for the secondary prevention in patients with a history of myocardial infarction is 
1000 mg/day. In patients with hypertriglyceridaemia, Hoy and Keating recommended a 




researchers noted patients might choose to take n-3 supplements with food to avoid 
gastrointestinal disturbances. This analysis demonstrated sufficient n-3 dosages may 
provide clinically significant reductions in serum triglyceride levels, blood pressure 
reduction in patients with untreated high blood pressure, and heart rate reduction, 
irrespective of sex or age.  
Somewhat confirmatory, Cabo, Alonso, and Mata (2012) reported some studies 
indicated n-3 consumption reduces systolic blood pressure. However, Cabo et al. noted 
study results were not consistent. Cabo et al. recommended n-3 supplementation as 
beneficial for mildly hypertensive patients, preferring dietary changes before starting 
drug therapy. 
As a corollary to cardiovascular disease, Grenon, Hughes-Fulford, Rapp, and 
Conte (2011) cited population studies indicating peripheral artery disease (PAD) affects 
more than 12% of people over 65 and 20% over 75. Grenon et al. explained PAD 
treatments cost more annually than coronary artery disease or cerebrovascular disease. 
PAD also includes development of thromboses resulting in possible emboli.  
Explaining the root causes of PAD, Grenon et al. (2011) confirmed U.S. daily 
dietary intake of 1.6g of ALA, but noted ALA’s inferior desirable biological activity to 
EPA and DHA. Grenon et al. also compared the average dietary intake of ALA (1.6g) to 
the average dietary intake of 14.8g/day of n-6 linoleic acid. They listed sources of n-6 
fatty acids as corn oil, soybean oil, safflower oil, and sunflower oil. Sources of n-6 




oil, canola oil, and soybean oil but soybean oil contains more LA than ALA. Grenon et 
al. listed only oily fish and fish oil capsules as viable sources of EPA and DHA.  
Grenon et al. (2011) explained the differences in end-mediators resulting from 
consuming n-3s versus n-6s in the diet. Consuming n-6 produces end-mediators to 
promote systemic inflammation, including lipoxins, thromboxanes, prostacyclins, and 
leukotrienes. Conversely, n-3s produce resolvins and protectins, substances active to turn 
off inflammation. Tartibian, Maleki, and Abbasi (2010) explained how n-3s also alter 
cyclo-oxygenase and lipoxygenase pathways to reduce inflammation. Somewhat 
evidentiary, the Tartibian et al. study demonstrated how n-3 consumption during intense 
wrestling training improved pulmonary function of wrestler athletes. Grenon et al. also 
reported one fish-oil-enriched meal improved flow-mediated brachial artery vasodilation 
(FAD). Improved FAD for PAD patients may lower systemic inflammation and reduce 
progressive atherosclerosis, improving circulation and abating the risk of PAD.  
The circulatory effects resulting from ALA dietary consumption evolve from 
complex chemical mediator synthesis mechanisms. Discussing dietary plant oils as 
sources of ALA and n-3s,Vrablik, Prusikova, Snejdrlova, and Zlatohlavek (2009) 
explained of the essential n-3s, ALA, which is present in plant oils such as walnuts, 
soybeans, and flaxseeds, only 5% of ALA is converted into EPA and DHA in the body. 
Most of the ALA converts to n-6 arachidonic acid, thereby adding to the excessive and 
potentially harmful levels of arachidonic acid already prevalent in the American diet. 
This conversion process adds understanding of another way (in addition to red meat 




As possible contradictory evidence to the dietary effects of ALA, Kris-Etherton, 
Hu, Ros, and Sabaté (2008) advocated the possible health value of ALA in nuts. Kris-
Etherton et al. also discussed how after ingestion, the body converts some ALA to EPA. 
Pooling results from four U.S. epidemiological clinical studies, Kris-Etherton et al. 
evaluated cardiovascular health effects from the consumption of different tree nuts and 
peanuts, dietary sources of ALA and other cardio-protective nutrients. The study 
compilation indicated individuals who consumed nuts five or more times per week 
reduced risk of fatal coronary heart disease by 39% and nonfatal myocardial infarction by 
32%. Additionally, men who consumed nuts two times per week had a 47% reduction in 
sudden cardiac death. Subjects who consumed peanuts twice per week had a lower 
incidence of coronary heart disease by 34%. 
Kris-Etherton et al. (2008) described the ingredients and mechanisms by which 
nuts exert these health benefits. The nut mechanisms reduce oxidation, reduce systemic 
inflammation, and reduce vascular reactivity. Nut ingredients that reduce oxidation 
include tocopherols, phenoloic antioxidants, melatonin from walnuts, mononsaturated 
fats, and PUFAs. Nut ingredients that reduce inflammation (as measured by a reduction 
in circulating C-reactive protein [CRP] levels) include ALA, metabolized in the body to 
PUFA n-3s. Nut ingredients responsible for increased vascular reactivity (vasodilation, 
reduced cellular adhesion to blood vessel walls, reduced atherosclerosis) include l-
arginine, ALA (to n-3), and other antioxidant nutrients.  
Kris-Etherton et al. (2008) noted the predominant study of walnuts as potent 




College of Cardiology prediction by 2050 the American incidence of cardiovascular 
disease will double. They advocated an overall diet high in fruits, vegetables, nuts, whole 
grains, legumes, low-fat dairy products, and lean protein. 
In another study, Tovar et al. (2012) advocated the modulating effects of a healthy 
diet including n-3s in individuals with cardio-metabolic diseases (CMD) and metabolic 
syndrome (MetS). Administering a healthy diet with daily intakes of multiple function 
foods including n-3s (subject daily dosages were 2.4g for women and 3.0g for men), 
Tovar et al. demonstrated statistically significant CMD and MetS risk-reduction health 
benefits. In a crossover design study with treatment and washout periods each lasting 4 
weeks, subjects (n = 44) between the ages 50 to 73 were randomly assigned to either a 
control diet (CD) or active diet (AD). Subjects maintained their habitual diets during the 
CD arm. The AD included a specified menu including (a) items rich in antioxidants; (b) 
n-3s; (c) probiotics (Lactobacillus strain) and prebiotics, including intact barley kernels, 
whole kernel rye flower, and isolated barley fiber; (d) low glycemic foods, such as high 
fiber bread, whey protein, and vinegar; and (e) soybean products and margarine enriched 
in stanol esters and dry almonds.   
Tovar et al. (2012) determined statistically significant CMD and MetS risk-
reducing effects from the AD arm but not the CD arm. The AD arm benefits included: (a) 
8% reduction in systolic BP, (b) reduced high sensitivity C-reactive protein (hs-CRP) 
scores by 29%, indicating reduced vascular inflammation, (c) lower Framingham Study 
algorithm cardiovascular risk scores by 30%, and (d) lower Reynolds cardiovascular risk 




reduction in LDL by 34%, (c) reduction in HDL by 10%, (d) reduction in the LDL/HDL 
ratio by 27%, and (e) reduction in the ApoB/ApoA-1 ratio by 10%. The ApoB/ApoA-1 
ratio measures apolipoproteins, which when combined with LDL/HDL cholesterol ratios 
indicate risk of MetS.  
Tovar et al. (2012) noted the satiating effects of the AD, which allowed ingestion 
of some animal meat and how the AD was more effective than the Mediterranean diet, 
the Nordic diet, and the vegetarian diet in its reduction of systemic inflammation and 
cardiovascular risk. Although not an intended study outcome, the researchers posited the 
weight loss drop in the AD group probably resulted from satiety associated with the diet 
higher in protein content. Tovar et al. stated the drop in systolic BP probably resulted 
from the high dietary supply of long-chain n-3s. Although the researchers in this study 
did not focus singularly upon n-3 efficacy, the Tovar et al. provided some evidence of the 
possible contributory and potentiating effects of n-3s upon good cardiovascular health 
when combined with other healthy dietary initiatives (see Appendix B).  
In another study of n-3s with other dietary supplements, (Radler, et al., 2011) 
demonstrated health benefits of n-3 ingestion combined with polyphenols and L-carnitine 
in MetS subjects (n = 22). After 12 weeks of therapy, subjects experienced a free fatty 
acid serum reduction of - 29% and serum triglyceride reduction of - 24% (each p < 0.05). 
Although the findings were statistically significant, one limitation of this trial was the 
combination therapy. 
From a global perspective, clinical research outcomes have enhanced international 




regarding negative methyl-mercury purity messages and therefore developed a 
risk/benefit summary for consumption by fish species. Farmed salmon, herring, and trout 
species had the highest benefit/risk ratio. Other species had a small net benefit or net risk 
rating (e.g., flounder, canned light or white tuna, halibut) but swordfish and shark rated 
high risk/low benefit. A logical conclusion is concentrated EPA/DHA purified fish oil 
supplements may provide n-3 health benefits while obviating methyl-mercury 
consumption risks associated with commercial fish food species. According to De 
Caterina (2011), the AHA advised caution with respect to fish contaminants but 
acknowledges some species are low in methyl-mercury, noting fish oil supplements are 
free of methyl-mercury. 
The following studies also provide some evidence to question the safety and 
efficacy of n-3s. In a meta-analysis of clinical trials including 33,429 subjects with 
cardiovascular disease, Chen et al. (2011) determined no significant differences in 
lowered epidemiology of sudden cardiac death, cardiac death, and all-cause mortality. 
One limitation of the Chen et al. analysis was trial heterogeneity including n-3 dosage, 
baseline disease severity, and follow-up duration. One important feature to this study is 
46% of subjects were receiving concomitant statin therapy to lower cholesterol and 
triglycerides.  
Regarding SDA as a source of n-3s, Whelan, Gouffon, and Zhao (2012) 
questioned the suitability of genetically altered SDA as a replacement for DHA/EPA 
from fish sources. Whelan et al. (2012) noted the challenge of a sustainable fatty fish 




noted previous researchers who advocated genetically altered soybean oil modified to 
produce SDA concentrations of at least 30%, as a suitable replacement for EPA from fish 
sources at a ratio of 3.7 grams of SDA to one gram of EPA. In a retrospective review of 
three human clinical trials comparing SDA with EPA for clinical effects in lower 
triglycerides as well as LDL and HDL cholesterol levels, Whelan et al. determined SDA 
was not effective in lowering triglycerides, HDL, or LDL levels.  
In a presentation of evidence after evaluating several epidemiological studies 
spanning 15 years, Borghi and Pareo (2012) raised skepticism regarding the efficacy of n-
3s in reducing ventricular arrhythmias. The investigators acknowledged the role of n-3s 
in moderating atrial fibrillation. Borghi and Pareo opined n-3s may not reduce the 
incidence of cardiac mortality and sudden death in ventricular arrhythmic patients.   
Raising skepticism of n-e efficacy in a specific patient group, Bosch et al. (2012)  
studied 12,536 patients who were at high risk for cardiovascular events. Study subjects 
received at least 900 mg ethyl ester n-3s or placebo daily and the investigators followed 
this group for a median period of 6.2 years. This group of high-risk patients included 
those with glucose metabolism impairment: impaired fasting glucose, impaired glucose 
tolerance, or diabetes. Bosch et al. concluded n-3s had no effect on cardiovascular 
outcomes in this group of high-risk patients.  
In a literature review of n-3 clinical trials, Vlablik, Prusikova, Snejdrlova, and 
Zlatohlavek (2009) raised the possibility n-3 dietary supplementation may raise 
undesirable low-density lipoprotein (LDL) cholesterol levels when used in high doses for 




correlated with higher LDL blood levels. Vlabik et al. noted the effects of EPA on LDL 
levels may be mitigated by DHA because investigators have demonstrated DHA 
increases desirable high-density lipoproteins (HDL). Vlabik et al. explained DHA 
changes the sub-fraction distribution of LDL particles so the particles are less sticky and 
therefore less likely to contribute to atherosclerosis. Therefore, for patients taking high 
doses the inclusion of sufficient DHA in n-3 formulas with EPA may prevent a rise in 
LDL or at least prevent deleterious health effects associated with higher LDL. 
In a multicenter, double-blind, randomized, placebo-control trial of 4,837 patients 
with previous myocardial infarction incidents, Kromhout, Giltay, and Geleijnse (2010) 
determined low dose n-3 dietary supplemenation (226 mg EPA and 150 mg DHA) did 
not reduce fatal or nonfatal cardiovascular events. Subjects consumed margarines with 
EPA/DHA, ALA, or placebo identical appearances and investigators monitored cardiac 
events for up to 40 months. A total of 13.9% of all patients experienced major 
cardiovascular events and the rate of events in the EPA/DHA group was 46 per 1,000 
compared to the rate of cardiovascular events for placebo or ALA of 45.7 per 1,000.  
In a study of 834 men with prostate cancer, Brasky et al. (2013) linked high n-3 
blood levels to increased prostate cancer (i.e., 44% increase in low-grade prostate cancer 
risk and 71% increase in high-grade prostate cancer risk). Brasky et al. also correlated 
higher blood levels of linoleic acid (n-6s) to a lower incidence of prostate cancer. The 
authors opined n-3 fatty acids are involved in prostate carcinogenesis. Other investigators 




minerals (Mullins & Loeb, 2012). Unpurified fish oils may contain one or more of these 
toxins including methylmercury (Ginsberg & Toal, 2009). 
In an objective to assess the role of n-3s on major cardiovascular outcomes, 
Rizos, Ntzani, Bika, Kostapanos, and Elisaf (2012) reviewed 20 studies including 68,680 
patients reporting 7,044 deaths, 3,993 cardiac deaths, 1,150 sudden deaths, 1,837 
myocardial infarctions (MI), and 1,490 strokes. Rizos determined no statistically 
significant correlation between n-3 supplementation and lower risk of all-cause mortality, 
cardiac death, sudden death, MI, or stroke. The investigators concluded the published 
randomized evidence does not support universally statistically significant reductions in 
cardiovascular outcomes in different patient populations. The studies in this section may 
inform n-3 marketers of important, contradictory n-3 viewpoints and evidence. 
Applicable Decision Criteria and Theory 
 In the following sections, I describe several decision variables applicable to 
physician prescribing decisions. The multiattribute utility (MAU) decision model is 
appropriate to facilitate understanding complex, prescribing decisions. The MAU model 
constructs utilities and consequences of individual decisions. Weiss et al. (2010) 
proposed a modified MAU decision model including the variable momentary salience to 
explain violations of individual policies. Weiss et al. simplified the MAU decision 
hierarchy for pragmatic purposes to differentiate between every day, little decisions, and 
infrequent, big decisions.  
 Momentary salience is primarily an emotional influencer including the influences 




the context of this ladder of inference study, because physicians evaluate complex 
utilities and consequences expected from prescribing decisions but at the same, can be 
influenced by momentary salience factors. This modified MAU theory provides a 
corollary framework to ladder of inference theory to facilitate the organization and 
understanding of physicians’ logic, beliefs, and desires triggering their n-3 
recommending/prescribing behavior. 
   In business marketing settings, rather than the psychological construct MAU, 
marketing vernacular uses customer needs. Customer needs apply to both physicians and 
patients, because patients are the end-consumers; although the focus of this study is upon 
physician–customer needs. Modified MAU and ladder of inference theories, used 
together when analyzing and interpreting study data may augment trustworthiness to 
study outcomes. Using both theories simultaneously may facilitate the translation of 
empirical, psychological study findings to pragmatic, business purposes of fulfilling 
customer needs. 
Customer Needs and Ladder of Inference  
 A justificatory starting point for inference ladder application and understanding 
defines basic customer needs. Montoya, Netzer, and Jedidi (2010) revealed physicians 
respond to competent pharmaceutical detailing of efficacy and safety features as well as 
receiving drug samples the physicians can trial with patients. Physician detailing and 
drug sampling support physician needs, evidentiary by the 2005 United States 
pharmaceutical industry marketing spending the majority of approximately $18 billion on 




(24 months) following a firm’s launch of a post-menopausal drug, Montoya et al. 
evaluated the effectiveness of sampling and detailing on driving prescriptions and 
discovered company waste through excessive sampling, excessive detailing, and incorrect 
physician targeting. Montoya et al. concluded both detailing and sampling have long-
term influence on physicians’ prescriptions; detailing is particularly effective as an 
acquisition tool whereas sampling is mostly effective as a retention tool. 
  In addition, Montoya et al. (2010) determined sampling had a stronger short-term 
effect than detailing, but detailing had a stronger long-term effect. The researchers also 
demonstrated how ignoring physician buying behavior dynamics and not evaluating 
marketing activity effectiveness could lead to suboptimal resource allocation. Detailing 
and sampling activities fulfill customer needs as Montoya et al. demonstrated by 
physician prescribing behavior frequency (i.e., inactive, infrequent, and frequent 
prescribing). These physician-customer satisfaction elements apply to physician ladder of 
inference analysis. Information from pharmaceutical detailing is intriguing, because 
physician acceptance of information perceived as complete and accurate is a similar 
construct to ladder of inference data observation and selection. Subject relevant, n-3 
dietary supplement cardiovascular efficacy, safety, and differential quality attributes may 
influence physicians to recommend n-3s. 
Montoya et al. (2010) did not differentiate between relational and transactional 
decision influencers from detailing. These influencers may be obvious or hidden. To 
identify hidden influencers, Gofman, Moskowitz, and Mets (2010) presented rule 




systematic approach to random experimentation of product feature or promotional 
messages mixes. Using RDE, researchers determine customer needs and preferences by 
eliciting customer responses to prototypes. Researchers develop silos of varied and 
important product or message elements and present combinations likely to appeal to 
customers. The underlying RDE conceptual framework applied to this doctoral study to 
develop deep inquiry interview questions and drive clear understanding of customer 
needs using follow-up e-mails for member checking of transcript content and theme 
development among the 20-subject physicians. 
Similar to the hidden customer needs discoverable through RDE (Gofman et al., 
2010), Bassi (2007) used latent class (LC) analysis to determine which physicians were 
most receptive to pharmaceutical representative sales calls. Bassi used LC analysis to 
measure the latent importance of seven criteria to 487 Italian practitioners. The seven 
criteria included: (a) attention of industry keeping physicians up-to-date, (b) frequency 
and dependability of pharmaceutical representative visits, (c) helpfulness to physicians 
with diagnostic and therapeutic problems, (d) respect for physician's experience and their 
suggestions, (e) knowledge and professionalism of pharmaceutical representatives, (f) 
industry current events and activities information, and (g) quality of global promotions 
and information provisions. Using LC factor analysis, Bassi identified, post hoc, which 
segments of practitioners were most receptive to sales efforts of pharmaceutical 
representatives. 
In a study that the authors designed to evaluate physicians’ prescribing decision 




(2011) posited elderly patients are at increased risk for adverse drug reactions because of 
physiological changes (e.g., reduced renal or liver function), multiple morbidities, and 
polypharmacy. The researchers listed the following as primary drug criteria that 
physicians typically use in drug selection: effectiveness, safety, clinical experience, and 
convenience. Huisman-Baron et al.’s primary study purpose was to determine the criteria 
set for optimal drug selection in frail, elderly patients. From a list of 31 questionnaire 
criteria presented to a panel of 32 physicians who treat geriatric patients as well as 26 
pharmacists (n = 58), the group consented upon 23 criteria divided among four 
categories: effectiveness, safety, experience, and convenience. A criterion of particular 
relevance to this doctoral study, which included 23 criteria, was the number of doses 
needed to treat, which Huisman-Baron et al. stated was especially important with 
preventive medicine, dosage frequency, and cardiovascular adverse events. Through 
study outcomes, investigators confirmed and explicated prescribing decision criteria and 
added important considerations for elderly patient formularies.  
In a relevant quantitative study (n = 135), Tichelaar et al. (2010) purposed to 
correlate which factors determined drug choices by medical faculty (generalists and 
specialists) and final-year medical students, and specifically the impact of the teachers’ 
favored drugs upon the students’ choices. As a basis for the study, the researchers noted 
practicing physicians reach their prescribing decisions heuristically, and therefore, may 
not be aware of their own drug choice logic or value judgments. Tichelaar et al. noted  




about therapeutic reasoning (i.e., the decision process physicians use to make treatment 
choices).  
Tichelaar et al. (2010) presented the respondents with six case studies and asked 
them to rank 14 factors influencing their prescribing decisions. In general, the medical 
students prescribed similar drugs to general practitioners and ranked examples from 
teachers as higher influencers. Clinical specialists prescribed a broader range and more 
potent drug products than generalists or medical students. Generalists and specialists 
placed more emphasis upon the following practice-related and drug-related factors: own 
clinical experience, patient convenience, and compliance of the patient (practice related), 
drug effectiveness, scientific literature, and information from the pharmaceutical industry 
(drug related). Other decision influencers included easy administration of the drug, side 
effects, drug costs, therapeutic spectrum, standard treatment guidelines, patient case-
studies presented by professors, opinions of colleagues, education, and postgraduate 
education. Tichelaar et al. concluded medical curricula should include more therapeutic 
reasoning and medical school professors should present medical students with more 
clinical problems to add meaning and understanding to the prescribing logic of students. 
In a 7-point, Likert scale mail survey to 201 general practitioners and 513 medical 
students (n = 714), Godin, Beaulieu, Touchette, Lambert, and Dodin (2007) determined 
to identify those factors leading to physicians’ recommending CAM treatments to their 
patients. Godin et al. measured eight variables as behavioral determinants. Intention was 
defined by subcomponents: (a) attitude (advantages and disadvantages of CAM 




perception of control (including knowledge of CAM treatment and reimbursement for 
treatment), and (f) control beliefs. Attitude referred to a person’s overall evaluation of 
behavior, also measured indirectly by behavioral beliefs. Subjective norm measured the 
social pressure from others to perform, whereas normative beliefs measured approval 
perceptions from others resulting from one’s behavior. Perception of control was the 
control extent one perceives to have over self-behavior, and control beliefs pertained to 
the perceived difficulty or barriers to performing the behavior.  
Seventh, variable moral norm measured the intensity of an individual’s personal 
feelings of obligation toward performing the behavior. Eighth and last, descriptive norm 
measured the individual’s perception of the prevalence of behavior among peers. Based 
on the results of the multivariate analysis of variance (MANOVA) analyses performed in 
the study, the requisite to CAM prescribing, investigators prioritized the perceptions of 
the physician and medical students as follows: (a) low risk to health, (b) CAM treatment 
effectiveness, and (c) absence of conventional treatment alternative. Subjects with 
positive intentions to recommend CAM treatments also indicated the importance of 
involving the patient and associations with open-mindedness, contributions to improved 
health, and a strong therapeutic alliance.  
In a relevant retrospective study to determine whether pharmaceutical advertising 
exerted undue influence on physician prescribing behavior, Joyce, Carrera, Goldman, and 
Sood (2011) compared narrow versus broad prescribing of drug products in 10 




tendencies among physicians. They measured patient-level outcomes, including 
medication adherence, therapeutic switching, and out-of-pocket drug costs.  
As a measurement instrument, the researchers used the medical possession ratio 
for medication adherence, defined as the number of days of medication held by the 
patients over the 6-month period following the physician’s initial prescription. Joyce et 
al. (2011) concluded physicians prescribed broadly in 10 therapeutic categories, choosing 
generics and brands. In eight out of 10 therapeutic classes, physicians prescribed at least 
three different drugs. Joyce et al. also noted the physicians regarded pharmaceutical 
representative detailing as an important source of information. The pharmaceutical 
representatives’ drug sampling also provided greater flexibility for low-income patients 
as well as clinical experience for physicians.  
With respect to drug cost as a physician need, in a study to determine the 
influence of managed care about physician prescribing habits, Rice (2009) measured the 
breadth of physician prescribing of 13 drugs during 1997–2000. Also measured was 
whether physicians in HMOs tended to prescribe the same drug for the same medical 
condition. Rice determined physicians in HMOs are less diverse in their prescribing 
choices than choices by other physicians. Rice also determined HMO physicians were 
more price-sensitive and therefore, more likely to use generic substitutes. Rice concluded 
HMOs have a modest influence on physicians’ prescribing of generic drugs.  
Rising healthcare costs drove investigative interest to determine attitudes and 
factors influencing physicians’ prescribing in Greece and Cyprus (Theodorou et al., 




similar to the FDA in the United States, as the most important source of information 
regarding adverse drug reactions and scientific journals the most important source 
regarding new drugs. Physicians ranked efficacy as the number one criterion for drug 
selection justified by publications in medical journals. Regarding adverse drug reactions 
and new drug information, physicians ranked pharmaceutical representatives as the third 
most important source of information. Even though Theodorou et al. (2009) reported 
physician attitudes toward drug therapy, these findings may also define the influences 
placed upon physicians in their decision-making processes for CAM and n-3 therapies.   
Computer-assisted prescribing is another potential influencer of physician 
prescribing and fulfills a need for information organization and instantaneous access to 
information. Noting the high volume of prescriptions written and resultant inevitability of 
some poor outcomes, in a review of two research articles covering 29 trials, Maxwell 
(2010) presented modest evidence for computer-assisted prescribing. Maxwell noted 
benefits of computer-assistance to aid physicians with treatment standards, drug 
interactions, side effects, dosages, lifestyle change recommendations, and even restrictive 
formularies. In one trial of dyslipidemia patients, the collaborative system improved 
cholesterol levels slightly over a 1-year period, but the regimen did not include n-3 
dietary supplements. The findings in this section provide important background for 
planning discovery of n-3 recommendation criteria by physicians. Study outcomes may 




Dietary Supplement Physician Education 
In a survey, investigators explored physicians’ beliefs, attitudes, intentions, 
knowledge, and behaviors regarding CAM. Milden and Stokols (2004) presented results 
from 196 board-certified physicians of varying specialties who practiced medicine in 
California. The findings revealed only 20% of surveyed physicians received some sort of 
CAM training in medical school. Sixty-one percent of physicians did not regard personal 
CAM efficacy and safety knowledge as adequate, and 81% of surveyed physicians stated 
they wanted more CAM education. Milden et al. asserted physicians are crucial in 
influencing patients' use and beliefs about CAM. These findings raise important issues 
with respect to physicians’ medical education and patient care.  
Kemper et al. (2003) assessed knowledge in herbs and dietary supplements 
(H/DS) in a survey (n = 537) of 111 medical doctors, advanced practice nurses, 
pharmacists, and dieticians. The e-mailed survey was distributed to in-training (16%) and 
practicing clinicians (84%) at Harvard Medical School, Children’s Hospital, Dana Farber 
Cancer Institute, Boston Combined Pediatric Residency Program, Massachusetts College 
of Pharmacy and Health Sciences, Brigham and Women’s Hospital, Massachusetts 
General Hospital, and the Veterans Administration. An important subject inclusion 
criterion was previous H/DS training. Of the specialists, registered dieticians scored the 
most correct (60%) on the 10-question survey.  
Two important findings of the Kemper et al. (2003) survey were physicians’ 
average score was 9.2 (out of 20) on the H/DS knowledge test and physicians scored 3.0 




The researchers noted the risks of H/DS and the importance for clinicians to discuss 
H/DS with patients as routine healthcare practice. Kemper et al. expressed the concern 
consumers/patients would turn to unqualified store clerks, websites, or popular magazines 
or books for clinical advice if healthcare professionals were silent.  
Physician-authors Ashar and Rowland-Seymour (2008) provided evidence of 
prevalent consumer use of dietary supplements (20% of the population) to maintain or 
promote health, spending more than $23 billion annually. Notwithstanding this abundant 
use, the authors posited that patients and physicians are often unaware of limited 
government dietary supplement regulation as well as potential risks. Ashar and Rowland-
Seymour observed the lack of physician knowledge about dietary supplements potentially 
strains the doctor–patient relationship. They presented a 6-step approach for physicians to 
use for competent patient advising. The six steps include (a) inquiring about supplement 
use, (b) evaluation of the supplement, (c) discussion of DS regulatory issues, (d) 
discussion of available safety and efficacy data, (e) comparison of the risks and benefits 
of optional conventional therapies, and (f) monitoring for adverse events and therapeutic 
responses. Ashar and Rowland-Seymour recommended physicians should enhance their 
own DS knowledge, a theme consistent with this research project.  
In a quantitative study consisting of data from 165 completed physician surveys, 
Silverstein and Spiegel (2001) posed three primary research questions. The researchers 
first determined most physicians asked their patients about the use of CAM treatments. 
Second, physicians did not routinely check references to determine safe usage. Third, 




treatments, correctly answering an average of 1.39 out of 10 CAM safety questions. 
Despite these results, the researchers opined the medical community is increasing its 
awareness of CAM treatments—benefits and risks. 
In a multicenter, online educational intervention program to 335 physicians in 15 
internal medicine residency programs, Ashar et al. (2008) conducted an objective 
assessment of physician DS knowledge. In a pretest, the researchers measured baseline 
knowledge of commonly used dietary supplements. Despite medical school education 
and training curricula, baseline knowledge of dietary supplements was low (pretest score 
 = 59.7%). Ashar et al. reported low scores in response to questions regarding safety and 
drug-supplement interactions. Regarding efficacy, only 36% knew fish oil lowered 
triglyceride blood levels. They concluded the residents' knowledge of dietary 
supplements was poor, but an online didactic education module could improve 
physicians’ knowledge and potentially enhance patient–physician communication 
regarding DS usage.  
Legare et al. (2011) noted the role of continuing professional development (CPD) 
is the primary process physician generalists and specialists use to stay current and 
improve knowledge and skills requisite for patient care optimization. They developed a 
global instrument to assess the value of CPD activities on clinical practice. Legare et al. 
verified the acceptability and value of CPD instruments, what features needed revision, 
and what CPD instrument content needed deletion or addition. Immediately following 
completion of CPD and 2 weeks later, session participants completed the assessment tool 




of the knowledge to action process (KTA) for healthcare professionals guided 
determination of program success: the knowledge creation cycle and the action cycle.  
In another study assessing doctor–patient communication of DS, Young, Faurot, 
and Gaylord (2009) explored the use of DS among hospital patients, and noted DS usage 
is common in the United States. Young et al. raised the possibility of DS usage concern 
among hospital patients, and therefore, determined to assess the degree of patient–
physician communication regarding patients’ DS usage. The cross-sectional, 
observational study of 60 hospitalized patients at the University of North Carolina 
Medical Center revealed although nearly 80% of patients used some form of DS, 
physicians documented inquiring about patients’ usage only 20% of the time. 
 Twenty-five percent of patients used multivitamins (the DS most used), and 4% 
of patients used some kind of fish oil. Young et al. (2009) concluded the use of DS in 
hospitalized patients is common, but patient–physician communication regarding DS 
usage is limited. Noteworthy observations from this study are the small percentage of 
physicians who seriously considered DS usage among hospital patients as well as the 
small percentage of patients who took fish oil (unspecified with respect to the fish oil’s 
DHA and EPA potency). 
Underscoring the importance of physician–patient communication, in an 
interesting Swiss study of 6,133 patients who completed a written survey, researchers 
Busato and Künzi (2010) determined higher general patient satisfaction, higher 
expectations of healing, and better physician–patient communication among CAM 




CAM therapy patients. Busato and Künzi asserted effective communication between 
physician and CAM patients played an important role in patients’ expectations of positive 
outcomes. This research supports the importance of physician–patient communication 
perhaps relevant to positive long-term outcomes from n-3 dietary supplementation 
compliance. 
Results from another study support how physicians can provide important role 
models for their patients. Weiner, Swain, Wolf, and Gottlieb (2001) provided an eight-
page survey of all 614 internal medicine specialists of the Wisconsin Research Network 
with an MD or DO degree. The researchers collected survey data from categories of 
stress associated with medical practice, including self-awareness, sharing of feelings and 
responsibilities, self-care, developing a personal philosophy, and setting limits. Weiner et 
al. grouped data into wellness promotion categories, including relationships, religion, 
self-care, and approaches to life. Regarding relationships, physicians advocated such 
wellness-promotion practices as being involved in and spending time with family, 
friends, colleagues, or the community. The religion or spirituality theme included prayer, 
Bible reading, attending church services, and involvement in church activities.  
Self-care activities included reading, good nutrition, avoiding drugs or alcohol, 
getting treatment for depression, professional counseling, leaving unhealthy relationships, 
taking vacations, aerobic exercise, hobbies, and meditation. Work activities promoting 
wellness included medical practice specialty choice, limiting practice size, and deriving 
meaning from one's vocation. The final wellness category was approaches to life and 




balance in life, and specific strategies for accomplishing these approaches. Interestingly, 
according to Weiner et al. (2001), physicians demonstrated increased psychological 
wellbeing (SPWB) scores when using any of the five wellness-promotion practices when 
compared with nonusers.  
The approach to life practice was associated with statistically significantly higher 
SPWB scores (P<0.01) than the use of any other category of wellness-promotion practice. 
Weiner et al. (2001) stated the use of wellness-promotion practices by physicians was 
more consistent with patients' definition of health than with physicians' typical absence-
of-disease model. They exhorted physicians to incorporate a broader model of health 
behavior practices into their own lives to interact more functionally with their patients. 
Weiner et al. reasoned healthy role models make better healers, because they tend to give 
advice and interact with patients with more impact and identification. 
Also with respect to physician modeling, in a study sponsored by dietary 
supplement companies, the Council for Responsible Nutrition conducted market research 
to determine how many physicians took dietary supplements personally and whether or 
not those physicians recommended the same supplements to their patients (Dickinson et 
al., 2011). The researchers conducted a survey among 900 physicians and determined 
72% of physicians took a multivitamin, but that only 27% took a supplement for heart 
health including n-3s, vitamins B6, B12, or E. Although one study outcome was 79% of 
physicians recommended dietary supplements to their patients, Dickinson et al. (2011) 





Other studies demonstrated most physicians do not believe they are themselves 
adequately educated regarding dietary supplements (Adams, Kohlmeier, & Zeisel, 2010; 
Dickinson et al., 2009) and some may be reticent to recommend dietary supplements to 
their patients. In this qualitative research study, I gathered information to facilitate 
understanding why physicians do or do not recommend dietary supplements, what 
information physicians need, and how physicians make rational decisions to recommend 
supplements. An educated audience may regard this qualitative study on its own more 
than a scientific survey because of more value-based, scientific logic (i.e., the medical 
reasoning or ladders of inference used by medical practitioners). Conclusions from this 
qualitative study may spawn follow-up, confirmatory quantitative studies.  
Factors Affecting Patient Compliance 
N-3 marketers should not underestimate the importance of patience compliance as 
a major physician decision criterion. Patient compliance demographics may also 
influence n-3 marketers regarding targeted market segments. Olafiranye, Jean-Louis, 
Zizi, Nunes, and Vincent (2011), affiliated with the State University of New York, 
Brooklyn Research Foundation on Minority Health, Kingsbrook Jewish Medical Center, 
and Sophie Davis School of Biomedical Education, concluded a substantive body of 
evidence suggests patient anxiety independently predicts adverse cardiovascular events. 
These events include coronary heart disease, stroke, sudden cardiac death, fatal 
ventricular arrhythmias, and congestive heart failure. Olafiranye et al. cited studies 




unhealthy diets. Individuals with anxiety disorders may be less likely to comply with 
physician recommendations to change unhealthy diets or take dietary supplements. 
Perhaps more troubling, Olafiranye et al. (2011) noted individuals with recent 
coronary hospital experiences were not inclined to make dietary changes, thereby 
increasing future cardiac risks. The implication here is physicians’ recommendations may 
not make a difference in health outcomes. N-3 marketers should regard patients in this 
category as less likely to comply with physician recommendations.  
Motivation and understanding also affect patients’ engagement in taking 
responsibility for positive, healthy behaviors. Epstein, Aaron, Baicker, Hacker, and Pauly 
(2009) discussed the changing landscape of healthcare including the difficulty in 
understanding the implications of healthcare reform, skyrocketing costs, a physician 
shortage, patients’ habits, engagements, and responsibilities for their own health. Rao et 
al. (2010) stressed the importance of patients understanding accountability for their own 
health and underscored the importance of physician-patient communication. Physicians 
may have work harder to convince unmotivated patients, an important factor for n-3 
marketers to consider regarding physician prescribing decisions. 
Marketers of n-3s should also consider patient literacy and numeracy as 
compliance variables possibly affecting physician decisions. Martin et al. (2010) assessed 
the 10-year risk of coronary heart disease correlated with four literacy skills of 409 
subjects. Martin et al. assessed reading, numeracy, oral language, and aural language 
skills. They found a statistically significant (p = .001) inverse relationship between 




study sample bias may have contributed to this gender inequity. Martin et al. noted only 
12% of the population has proficient health literacy and rates of cardiovascular death are 
substantially higher (19.3%) among individuals with inadequate literacy versus 
individuals with adequate health literacy (7.9%).  
Brooks and Pui (2010) suggested numeracy scores were better predictors of 
patients’ abilities to understand health information sometimes vital for life or death 
decisions. The researchers studied the relationship in numeracy test scores and general 
mental ability (GMA) test scores because medical practitioners rely upon GMA scores as 
predictors of patients’ understanding of health-related information. Brooks and Pui 
provided the rational basis and administered the Wonderlic Personnel Test, the Numeracy 
Scale, the Rational-Experiential Inventory Test, and the Mini-International Personality 
Item Pool to 200 undergraduates.  
Regarding other compliance factors possibly effecting physicians’ decisions, 
Brooks and Pui (2010) found the strongest positive correlations between numeracy and 
GMA, and between numeracy and rational cognitive style. Numeracy positively 
correlated with rational decision making, whereas GMA did not. Interestingly, Brooks 
and Pui reported negative correlations between numeracy and two personality traits: 
extraversion and neuroticism. They posited introverted, emotionally stable individuals 
might make better health-related decisions. Brooks and Pui also correlated numeracy and 
GMA and recommended practitioners consider patients’ numeracy scores.  
Underscoring the importance of correlating patient conviction to compliance, 




numeracy inhibits patient decisions regarding preventive medicine choices, reduces 
medication compliance, impairs risk communication, and affects medical outcomes. 
Additionally, Nelson et al. reported patients with low numeracy scores are less likely to 
engage in preventive medicine behaviors and inferior disease management. Finally, they 
reported low-numerate individuals tend to base medical decisions on short-term benefits 
and costs rather than long-term outcomes. The implications of this article for marketers of 
n-3 products are patient consumers with higher literacy scores may be more likely to 
welcome preventive medicine concepts and comply with preventive regimens. In 
addition, market segments consisting of patients with higher education levels may be 
more profitable for n-3 marketers. The implication for physicians’ decision criteria is 
patients with deficient numeracy and literacy skills may require additional effort and 
monitoring to secure DS regimen compliance.  
Patient interest in CAM therapies is another compliance factor. In one study to 
determine how patient interest in self-care with CAM influenced them to take CAM 
therapies, researchers Bradley et al. (2011) telephone surveyed 321 patients with Type 2 
diabetes. They determined patient interest in trying CAM therapies did not correlate with 
patient insurance coverage, demographics, clinical status, health history, or self-care 
behaviors. Bradley et al. also determined patients were more likely to try CAM therapy if 
they were not satisfied with their current medical treatments for controlling blood sugar. 
Additionally, Bradley et al. (2011) determined patients were more likely to try 
new CAM therapies if they previously used CAM. Bradley et al. determined public 




al. study for patient compliance with n-3 dietary supplements is physicians may find 
more success recommending n-3s to patients positively inclined to CAM therapy or 
dissatisfied with conventional medicine overall. 
In a similar study, Gaul, Schmidt, Czaja, Eismann, and Zierz (2011) explored 
patient attitudes toward CAM with two questionnaire surveys completed by 432 primary 
headache patients and 194 low back pain patients in Austria and Germany. Gaul et al. 
discovered no correlation between patient demographics and CAM use. They determined 
patients were more likely to use CAM therapies if they had previous CAM experience. 
Additionally, lack of effectiveness of conventional treatment was another statistically 
significant CAM use motivation. 
Interestingly, Gaul et al. (2011) noted patient concerns about drugs were four 
times higher among patients inclined toward CAM therapy. In contrast to the Bradley et 
al. (2011) study where the condition was diabetes with less symptomatic manifestations, 
the Gaul et al. study consisted of highly symptomatic pain patients. Consistent findings 
regarding previous CAM use and lack of conventional therapy efficacy drove CAM 
interest and usage among patients. These factors are important relevant to n-3 treatment 
compliance.  
Another potential factor relates to the study of symptoms. In a Canadian-based 
study of population patterns in patients who use CAM therapies, researchers Metcalfe, 
Williams, McChesney, Patten, and Jetté (2010) concluded Canadians appear to use CAM 
therapies in conjunction with conventional therapies. From a cross-sectional survey 




asthma (15.1%) and migraine headaches (19.0%) than diabetes (8.0%). Metcalfe et al. 
also reported literature review findings of CAM therapy use varying between 6% and 
84%. From a literature review, the researchers also reported higher CAM use among 
individuals with higher income or education levels, women, certain ethnic groups, and 
those with chronic conditions.  
These study results support the hypothesis asymptomatic patients may be less 
compliant overall, or less compliant with CAM therapies. If generalizable, the relevant 
decision criterion for physicians relates to compliance. For n-3 marketers, the best 
candidates for n-3 therapies may be patients with higher income or education levels, 
women, and those who suffer from chronic, symptomatic cardiac conditions. 
Drug and CAM Marketers’ Methods to Physicians 
To facilitate application and integration of these constructs, provided in this 
section is an historic and present-day backdrop of marketing methods used by 
pharmaceutical and CAM marketers. Controversy has surrounded the issue of direct-to-
consumer (DTC) drug advertising, especially prescription drugs. Although most n-3 
brands are nonprescription, the concerns raised by physicians regarding prescription drug 
advertising to patients apply to over-the-counter supplements as well.  
Historical marketing. In a precedential case of pharmaceutical promotion 
deception, Landefield and Steinman (2009) discussed misinformation and manipulative 
practices of Parke-Davis. In 1996, a young, newly employed biologist discovered and 
reported illegal off-label promotion of Neurontin by Parke-Davis management and sales 




settlement in 2004 to resolve the criminal charges and civil liabilities. The 
whistleblowing action highlighted subtle, clandestine approaches to promote off-label 
use, including dinner programs, continuing medical education courses, consultant 
arrangements, and personal conversations between sales representatives and physicians. 
Landefield and Steinman concluded the methods and programs used by Parke-Davis were 
legal, but noted the prospects for abuse.  
To determine DTC benefits and risks, Frosch, Grande, Tarn, and Kravitz (2010) 
examined proponent and opponent studies from peer-reviewed literature and determined 
some ads contained accurate and balanced information although some ads were deficient 
or misleading. Ads frequently did not disclose alternative treatments, risks, or costs, and 
prompted patients, many with insufficient education or understanding, to request 
physicians to prescribe an advertised drug. Physicians may not have seen the 
advertisements for drugs patients requested or were not fully educated regarding new 
drugs at the time of patients’ requests. These situations predispose conflict and Frosch et 
al. reported results from national surveys where 39% of physicians and 30% of patients 
regarded DTC as interfering with the physician-patient relationship. Frosch et al. 
enlightened the potential magnitude of this problem because drug advertisers spent $4.9 
billion on DTC in 2007. The authors cited additional survey evidence 89% of physicians 
claiming DTC increased prescriptions for advertised drugs, some of which are 
unnecessary.  
Frosch et al. (2010) also disputed DTC proponents’ claims DTC improves patient 




patient adherence. Perhaps more pertinent, no evidence existed to support DTC results in 
favorable health outcomes. Considering these factors, Frosch et al. constructed measures 
to improved outcomes with balanced evidence and regulatory policy. They proposed 
content guidelines for drug ads including questions regarding candidacy, drug benefits, 
and drug risks. Frosch et al. provided a detailed questionnaire advertisers should answer 
with communication understandable by eighth-grade level education listeners.  
Nurse practitioners and advanced practice nurses (APNs) can also prescribe and 
recommend medications and supplements to patients so their opinions regarding DTC 
pharmaceutical advertising are relevant. In an online survey, 961 Texas APNs responded 
to two research questions about the impact of DTC prescription drug advertising on 
patient behavior and quality of care (Mackert, Eastin, & Ball, 2010). Researchers 
Mackert et al. (2010) reported 49% of APNs believed DTC did not help nor harm the 
physician–patient relationship. Of the remaining 51%, 31% believed DTC hurt, and 20% 
believed DTC helped.  
 Importantly, 69.6% of APNs believed DTCs led patients to request specific drug 
brands and 57.8% said patients requested switching to the advertised brand. APNs 
(63.8%) reported DTC drove patient involvement in his or her healthcare, but 57.7% 
stated the patients demanded inappropriate therapies. APNs (63.5%) acknowledged DTC 
informed patients to ask intelligent questions but 66.1% of APNs stated DTC caused 
patient misperceptions and questions (46.2%) about health care advice. Marketers of n-3s 
may find DTC advertising methods beneficial but should follow the Frosch et al. (2010) 




Present-day marketing. Approaching DTC prescription pharmaceutical 
advertising from a constructive educational viewpoint, physician researchers Kaphingst 
and DeJong (2004) proposed seven recommendations to improve the educational value of 
DTC advertising. The researchers posed the central question regarding whether average 
consumers could understand the brief risk messages, often unconsciously diluted by 
neutral or positive images. Kaphingst and DeJong’s recommendations focused upon 
improving communication and reducing biased, prospectively harmful promotional 
messages. Specific recommendations included: (a) balance risk and benefit information, 
(b) use consumer-friendly language, (c) provide additional sources of information, (d) 
provide text materials geared to the eighth-grade reader, (e) explain more educational 
information about symptoms and disease, (f) conduct follow-up research to determine 
consumer ad comprehension, and (g) require prior approval of ads. These points add 
insight for n-3 marketers.  
Using DTC in another channel, marketers of n-3 dietary supplement may employ 
DTC advertising using the Internet as a promotional strategy. Khosla and Khosla (2011) 
noted how marketers have replaced traditional forms of drug-product advertising with 
Internet advertising. They identified OTC medical products as Internet candidates 
because consumers can purchase these products without a prescription. Khosla and 
Khosla advocated marketers should employ Internet marketing to educate consumers and 
advise them when to see their doctors. They noted the importance of balanced, truthful 




Resulting from a comprehensive review of published and archived literature, 
physician researchers Greene and Herzberg (2010) evaluated the practices of drug 
marketers during the 20th century and the effects of these practices upon public health. 
They reviewed ghostwriting of popular articles, DT drug advertising, public relations 
events, continuing medical education content, and implicit consumer advertising 
methods. Greene and Herzberg listed broad social networks used in drug promotion, 
including artists, journalists, gossip columnists, physicians, filmmakers, medical 
educators, researchers, science writers, and medical educators.  
Greene and Herzberg (2010) explained the difficulty in the century-long 
consistent flow of complex information to consumers through multiple media and big 
spending. Although they advocated more regulatory scrutiny, Greene and Herzberg cited 
the reality of disproportionate drug advertising spending, more than twice the budget of 
the entire FDA, dwarfing the budget of the FDA office responsible for consumer 
advertising oversight. Greene et al. advocated ethical transparency among drug marketers 
and increased regulation of informal and non-advertising forms of drug promotion.  
In an article regarding Pfizer’s market segmentation methods, Kiron, Shockley, 
Kruschwitz, Finch, and Haydock (2012) discussed Pfizer’s use of analytics and tablet 
personal computers (PCs) to retrieve field-marketing data daily. A team of 40-50 analysts 
used this daily information to determine if field representatives were detailing the right 
physicians, if they were presenting the company’s message tailored for the specific 
physician market segment, and if the presentations resulted in prescriptions. In an 




promotional message designed for physicians who treat elderly patients in Florida. 
Because drug-to-drug interactions are a primary concern among physicians in this market 
segment, the pharmaceutical representative must deliver the company’s promotional 
message as directed. Immediately after sales calls to physicians, Pfizer representatives 
must enter conversation details and transmit this information to company analysts the 
same day. From other data sources (e.g., IMS), Kiron et al. reported analysts can track 
promotional effectiveness by measuring post-sales-call physician prescribing then using 
the database information to refine physician customer segments based upon customer 
preferences and responses to promotional messages.  
Relevant to this study, n-3 marketers may use similar practices to Pfizer to define 
physician customers most favorably inclined to recommend dietary supplements. These 
physicians may be price conscious, appreciate differentiating efficacy and safety features 
of cardiovascular preventive health supplements, treat patients with cardiovascular 
disease, or those physicians who already recommend preventive supplements more 
frequently than average. N-3 marketers could use databases to develop a holistic 
marketing approach with historical product-type utilization behavior, reactions to product 
profile, competitive product use, attitudes toward preventive treatment protocols, and 
personality traits.   
Marketers of n-3s should consider cultural influences when defining customer 
segments. In an interesting study of cultural influences on a healthy diet, Sun, Horn, and 
Merritt (2009) analyzed previously surveyed subjects from 25 nations (n = 21,974). The 




members, peer groups, health professionals, and mass media; other factors also 
influenced healthy diet choices, such as living alone, food preference, understanding the 
diet–health link, high-income residence, and concern for personal appearance. After 
explicating how elemental personality traits combine with cultural environment to form 
compound traits (e.g., competitiveness, playfulness, self-reliance, or task orientation), the 
researchers articulated four emerging cultural dimensions: (a) individualism/collectivism, 
(b) power distance, (c) masculinity/femininity, and (d) uncertainty avoidance.  
Collectivist cultures value group membership. Power-distance cultures advocate 
social inequality. Cultures favoring masculinity roles include assertiveness, competition, 
and toughness, whereas femininity roles are oriented toward family, children, tenderness, 
and home. Uncertainty-avoidance cultures value stability, low stress, and predictability 
versus change and new experiences.  
Sun et al. (2009) determined how public self-consciousness mediated the four 
cultural dimensions. Public self-consciousness includes physical attributes and concern 
with impressing others. The researchers determined cultures valuing collectivism (e.g., 
Japan or Saudi Arabia) are higher in public self-consciousness and concern for goals of 
group members than cultures who advocate individualism (e.g., Americans). Sun et al. 
tested the validity of their 4-point Likert scale surveys and determined Cronbach alpha 
values of 0.81 and 0.76. Their primary conclusion was public self-consciousness 
positively and statistically significantly correlated with a healthy diet intention (p = 0.00). 
Secondarily, Sun et al. concluded a negative relationship between individualism and 




0.00), masculinity and public self-consciousness (p = 0.00), and a negative relationship 
between uncertainty avoidance and public self-consciousness. The researchers noted 
cultural differences drove 12% of the variance in public self-consciousness and 26% of 
the variance in a healthy diet intention. Sun et al. also noted power distance was the 
highest predictor of public self-consciousness. Marketers of n-3s may use these cultural 
findings to develop market segments. 
Weighing cultural influencers against personality trait influencers may facilitate 
n-3 marketers to define n-3 segments with effective marketing plans. Laura (2011) 
compared Hofstede’s cultural framework to the five-factor model (FFM) to investigate 
thoughts, feelings, behavior patterns, and preferences among individuals. Hofstede’s five 
cultural differentiating criteria included: (a) uncertainty-avoidance index, (b) 
individualism index, (c) power-distance index, (d), masculinity index, and (e) long-term 
orientation index. FFM differentiates among five personality traits: (a) extraversion, (b) 
agreeableness, (c) conscientiousness, (d) neuroticism, and (e) openness to experience 
(Laura, 2011). In some circumstances, culture may exert more behavioral influence than 
personality trait. The relevance of these models here relates to distinct cultural 
influencers as well as personality tendencies. Marketers should consider cultural and 
personality trait influencers when defining targeted market segments.  
Method and Design  
Golafshani (2003) prescribed specific methods for qualitative researchers to 
establish reliability and validity. Conversely, Holt (1991) rejected the application of 




traditional approaches by others. Golafshani proposed researchers should use methods to 
substantiate the reliability and validity of qualitative research and researchers should 
replace traditional reliability and validity vernacular by quality, rigor, credibility, 
transferability, and trustworthiness. Golafshani acknowledged the researcher should 
protect the constructivist and naturalistic tenets of qualitative research.  
Even so, Golafshani (2003) insisted triangulation and other methods could 
enhance the rigor of the research without compromising its inherent value. An objectivist 
approach to qualitative research was possible without altering the reality description 
expressed by the respondent and interpreted by the researcher. Researchers should 
employ triangulation for both data collection and analysis and should strive to make their 
research findings generalizable. A true test of validity is replication by wider groups in 
similar, if not identical circumstances.  
Holt (1991) refuted mainstream qualitative study validity and reliability 
techniques on the basis such techniques “contradict the nature of the interpretive task, and 
pose insurmountable problems in application” (p. 59). Holt argued a subject or 
researcher’s individual, contextual interpretation of any event is not verifiable as accurate 
or truthful. Another individual might relate the same experience differently because of a 
separate, unique frame of reference and context. Individuals construct whole 
interpretations from parts, and in addition to contextual interpretation, an individual 
interpretation of parts emanates from that individual’s use of rhetorical words, traditions, 
political views, and history (i.e., events change as time passes). Holt argued reviewers 




and the power to convince (Thompson’s gestalt experience, as cited in Holt, 1991). Holt 
posited if enough peer experts agreed, the consensus would define the predominant 
interpretation. 
Holt (1991) and Golafshani (2003) both emphasized the importance of preserving 
the naturalistic benefits of qualitative research. Both drove convincing arguments the 
reliability and validity criteria used for quantitative research are not applicable for 
qualitative research, although Golafshani embraced the concepts, but used different 
labels. Both authors cited other reputable sources who advocated reliability and validity 
testing for qualitative research.  
For example, Holt (1991) discussed traditional methods of testing naturalistic 
inquiry including credibility, transferability, dependability of measure, and 
conformability. Holt added a fifth criterion, integrity, citing Belk, Sherry, and Wallendorf 
(1988). Holt explicated the 10 recommended techniques of Belk et al.: (a) prolonged 
engagement and persistent observations, (b) use of triangulation with different 
researchers for data collection and interpretation, (c) frequent on-site team interaction, (d) 
negative case analysis, (e) peer debriefing, (f) member checking, (g) limiting exceptions, 
(h) purposeful sampling, (i) reflexive journals, and (j) independent audits. Golafshani 
(2003) cited additional authors who advocated validity techniques by different names that 
enveloped reliability at the same time. Neuman (2011) advocated applying similar criteria 
to those recommended by Belk et al.  
Other authors advocated similar methods to add validity to naturalistic and 




observational techniques and four manipulative techniques for unbiased theme 
development. Shepherd and Rentz (1990) provided steps “to minimize the subjectivity of 
coders” (p. 62). Scott-Jackson, Druck, Mortimer, and Viney (2011) discussed 
interviewing techniques to guard against bias and reactivity, threats to validity. Brent and 
Slusarz (2003) recommended computer assistance “to assess and improve the reliability 
of coding by the researcher” (p. 299). Last, Zelik, Patterson, and Woods (2010) proposed 
a model with eight specific components to establish rigor and prevent shallow analysis in 
qualitative research. Zelik et al. observed just because researchers employ the word rigor 
as a justificatory warrant for their studies, does not necessarily provide assurance.  
The preponderance of evidence and opinions of experts drive the need for 
doctoral students to employ robust methods in qualitative research to establish and 
maintain research project validity. At the same time, researchers should appreciate and 
maintain the naturalistic benefits intended by qualitative methodology. The five criteria, 
10 methods, and the rigor scale are useful elements to ensure trustworthiness and 
credibility in qualitative research studies.  
Shepherd and Rentz (1990) presented the critical incident technique. With respect 
to content analysis, they presented specific techniques regarding coding schemes and 
code processing. Shepherd and Rentz emphasized the coding scheme should reflect the 
purpose of the research and the scheme should emerge gradually as the researcher 
becomes familiar with all the accumulated data. They also discussed minimized coder 




employing mutually exclusive response categories (e.g., black or white, not both) and 
maintaining the independence of the codes so the codes are not linked.  
Shepherd and Rentz (1990) presented a compelling argument the word rigor is 
often platitudinous rhetoric as applied to qualitative data. They provided eight examples 
of shallow analysis and presented an alternative chart with eight attributes as criteria to 
determine low, moderate, and high rigor. The eight attributes included hypothesis 
exploration, information search, information validation, stance analysis, sensitivity 
analysis, information synthesis, specialist collaboration, and explanation critique. 
Shepherd and Rentz indicated researchers can use the eight attributes as measures to 
prevent shallow analysis but 10 or more contextual factors influence the judging of rigor 
sufficiency.  
Bernard and Ryan (2003) asserted theme development is a mysterious process and 
researchers typically lack instruction and skills for discovery and consistency. They 
identified four important tasks in theme development: (a) discovering the themes and the 
subthemes, (b) limiting themes for practicality, (c) building theme hierarchies, and (d) 
linking themes to theories or models. Bernard and Ryan noted themes must be visible in 
data, may be symbolic, culturally dependent (contextual), and derived from codes. They 
outlined 12 techniques, eight observational and four manipulative, to facilitate competent 
theme processing. 
Themes emerge from coding. Brent and Slusarz (2003) advocated the use of 
qualitative analysis programs to facilitate coding of typically voluminous transcribed 




enhance reliability, limit missed codes, and reduce researcher time and workload. Brent 
and Slusarz analyzed the coding process and disclosed computational strategies as case-
based reasoning, natural-language generation, semantic networks, and production rules. 
Brent and Slusarz stated programs learn and become more valuable to the researcher as 
the program amasses transcribed information garnered from observations or interviews.  
Qu and Dumay (2011) differentiated interviewing perspectives, and therefore, 
data interpretation and thematic development, based upon the interviewer’s worldview. 
They defined the neo-positivist, romanticist, and localist perspectives. With some overlap 
among categories, Qu and Dumay argued neo-positivists use structured interview 
technique and study facts, romanticists use unstructured interviews and focus upon 
meaning, and localists use semistructured interviews to focus upon context and the 
interviewee’s account of events. Interviewer worldview and technique therefore 
influences data interpretation and thematic development. 
Considering different worldviews and interview approaches used by qualitative 
researchers, Qu and Dumay (2011) reported how quantitative researchers regard 
qualitative interviews as unreliable and subject to bias. Qu and Dumay emphasized how 
careful interview preparation, use of competent interviewing skills (e.g., questioning, 
listening, dyadic conversational skills, etc.), and protecting against asymmetrical control 
can produce a rich data set. Qu and Dumay stated no one interview approach is right, no 
single format is appropriate for each interview, and the same questions will not always 
work. The unique compositional experience of each interview can affect data collection: 




setting (Qu & Dumay, 2011). The collection of data, its coding, thematic development, 
analysis, and interpretation, together present a complex task to optimize desired 
meaningful study outcomes. Those desired outcomes include a clear understanding from 
study subjects to formulate effective communication for educating physicians and 
influencing n-3 prescribing behavior.  
Regarding educating physicians, Legare et al. (2011) noted the role of continuing 
professional development (CPD) as a primary process physician generalists and specialist 
use to stay current and improve knowledge and skills requisite for patient care 
optimization. Legare et al. developed a global instrument to assess the value of CPD 
activities on clinical practice. Legare et al. verified the acceptability and value of CPD 
instruments, what features needed revision, and what CPD instrument content needed 
deletion or addition. Both immediately following completion of CPD and two weeks 
later, session participants completed the assessment tool to rate aspects of the CPD 
program. Two overriding principles promulgated by promoters of the KTA process for 
healthcare professionals guided program success determination: the knowledge creation 
cycle and the action cycle.  
Adding credibility to the action cycle concept in KTA, Rodriguez, Marquett, 
Hinton, McBride, and Gallagher-Thompson (2010) studied action plans as a follow-up 
tool to assess changes in clinical practices after training. One study objective included the 
assessment to change barriers. Three months after clinical training, 73% of respondents 
acknowledged action plans stimulated specific behavioral changes in clinical practice. 




design of the present doctoral study. In the present study, therefore, I included a specific 
follow-up question to determine if respondents increased their recommending of n-3s as a 
study outcome to drive real, effective, behavioral, and clinical practice change. 
Psychological cognition mechanisms precede behavioral change and Cova, 
Dupoux, and Jacob (2010) explained pure scientific models consisting of desire and 
intentions as psychological states cannot explain human behaviors. Cova et al. (2010) 
reasoned behavioral models are also deficient because these models do not include a 
moral causal variable and therefore cannot correctly predict human intuitions or actions. 
Depending upon context, cognition, and the decision-maker’s moral compass, an 
individual may decide consciously to take action (or refrain from taking an action), which 
baffles the logic of observers. This explains how individuals can initiate behaviors others 
regard as illogical, but to the individual, the behavior is irrefutably and morally right. 
Important for n-3 marketers, supported by data collected from interviews in this study, 
physicians consider moral rightness when making decisions. 
Transition and Summary 
Section 1 was an introduction to possible n-3 health benefits, the business 
problem of marketing n-3s, the research questions, and qualitative study design and 
methods I used to drive study outcomes and answers to research questions. The outcomes 
of this study may fill gaps in understanding physician prescribing decision processes. If 
120,000 Americans die each year prematurely from cardiovascular disease (CDC, 2011) 
and if the daily ingestion of the proper ratios of n-3 can reduce cardiovascular disease by 




Study outcomes may facilitate n-3 marketers’ sustainability and profitability 
because an improved understanding of physician prescribing decisions may improve 
effective communication with physicians resulting in physician prescribing behavior 
change. Increasing preventative medicine behavior among physicians in this capacity will 
enhance public awareness and society’s cardiovascular health. These study outcomes are 
consistent with the Walden University DBA Doctoral Study rubric. Section 2 includes 



















Section 2: The Project 
Purpose Statement 
In this qualitative, phenomenological research study, the purpose was to improve 
n-3 marketers’ understanding of how physicians reach decisions to prescribe or 
recommend products, including omega-3 (n-3) dietary supplements and which product 
characteristics may be the most important to physicians. I explored physicians’n-3 dietary 
supplement knowledge and decision criteria (ladder of inference; Argyris, 1976) and 
found physicians’ inference ladders for prescription drugs are similar to physicians’ 
inference ladders for n-3s. The education of physicians and the ladders of inference 
physicians cognitively ascend determined their n-3 prescribing/recommending choices. 
By understanding these complexities, n-3 marketers will be able to develop effective 
learning instruments and promotional tools (predictors) to influence physicians to 
recommend patients comply with a daily dosage regimen of quality n-3s containing 
adequate DHA and EPA concentrations (criteria).  
In Kentucky, Indiana, and Tennessee, I interviewed 20 primary care physicians. 
According to Ashar and Rowland-Seymour (2008) physicians are opinion leaders 
because of their primary influences over patient health thereby justifying the selection of 
physicians as participants in this study. The study objective was to answer the primary 
research question regarding what ladder of inference physicians use to recommend 
dietary supplements, especially n-3s. Another study purpose was to gather useful 
physician marketing strategy information regarding n-3s and cardiovascular disease 




physician customer thinking and needs. An increase in physician education may 
culminate in more preventive medicine behaviors by physicians, augmented marketing 
effectiveness of n-3s, increased n-3 use among the general population resulting in 
improved health, reduced cardiac disease, and reduced U.S. healthcare spending.  
Role of the Researcher 
The role of the researcher, in this data collection process, was to interview the 
study participants. Using a digital recorder, I recorded the interviews and a qualified 
assistant transcribed the interviews verbatim. I enlisted coding services from a second 
coder to code the transcripts and develop themes to increase internal validity (Bertolotti 
& Tagliaventi, 2007). Transcriber and coder assistants signed Confidentiality Agreements 
and an IRB approved their participation. 
Chenail (2011) emphasized the important central role of the researcher who 
serves as the research instrument, primary collector of data, driver of investigator-subject 
contextual interactions, facilitator of communication flow, and conveyor of interview 
atmosphere and communication ease. In this role, if a study subject is reticent to talk 
openly, the researcher should ask open-ended questions and prevent open-ended 
questions from turning into closed-ended questions. As the primary data collection 
instrument, the researcher is also the primary threat to study trustworthiness and source of 
bias. Interviewer/researcher bias may occur with the researcher’s abnormal psychological 





The process of qualitative research requires a fully immersed investigator. Sergi 
and Hallin (2011) noted the application of ontology to qualitative approaches, where the 
researcher’s experience is deeply emotional and personal, necessary to reveal the richness 
of the situation. Sergi and Hallin posited although some may describe qualitative research 
as a linear, step-by-step procedure, the qualitative approach is inherently a lived 
researcher’s whole-self experience whereby the researcher feels the emotions and 
perspectives of the study subjects. Through this lived experience including its affective 
facets, the researcher gains a richer image of the subject matter and goes closer to the 
real-life experience.  
Sergi and Hallin (2011) emphasized that the researcher’s experience is an 
inevitable part of the research study and is therefore a thick performance. This framing is 
fundamental to understand and address bias. This understanding also accentuates change 
and practice as fluid elements in qualitative research: change because study subjects 
continually evolve and practice because, by definition, practice involves the researcher’s 
thinking, skills, and rationality, but also the researcher’s emotion, body, power, intuition, 
and a contextual interpretation. Sergi and Hallin differentiated their emphasis of the 
researcher’s performance from autoethnography. Autoethnography assumes the 
researcher’s experience automatically derives from a cultural connection with the subject. 
Rather, acknowledging the importance of the researcher’s role with personal emotions 





I obtained access to research participants through published physician list records. 
The purposeful sample consisted of physician subjects interested in the study subject, 
acknowledged an open perspective regarding diverse opinions specified in the signed 
Informed Consent document, and who were accessible. I selected participants in three 
targeted states with whom I did not develop personal relationships previously.  
I protected participants through informed consent (see Appendix C) and protocol 
implementation approved by an institutional review board (IRB). Before commencing 
any data collection, subjects understood, signed, and returned Informed Consent 
documents to the interviewer. This group of medical professionals understood principles 
of ethical research.  
Research Method and Design 
In the sections below, I describe the research method and design as follows: (a) 
description of research method and design, (b) justification of method and design, and (c) 
relevancy to the business problem statement. The method and design were appropriate 
with respect to the problem statement. This subsection is an expansion of Nature of the 
Study in Section 1. 
Method 
This qualitative method was appropriate for this marketing topic. Smith, Bekkar, 
and Cheater (2011) discussed the difficulties of choosing qualitative research methods in 
topics involving health care because most researchers use quantitative methodology. 




complexities affecting health, including economic, social, environmental, and political 
factors. Bekkar et al. also advocated qualitative methods as adjunctive to quantitative 
methods. They reasoned qualitative methods can expand the investigator understanding. 
After discussing the problems of fit with ethnographic, phenomenological, and 
grounded theory designs, Smith et al. (2011) recommended a generic approach to 
researcher using qualitative methods in health care. Smith et al. reasoned investigators 
who maintained an open, holistic perspective rather than pursue evidence to support a 
predetermined theory would enhance credibility among readers in the medical 
community. Although I intended n-3 marketers as the primary audience of this marketing 
study, some in the medical community may find the outcomes of this study relevant and 
useful (e.g., physician impressions of their own knowledge of dietary supplements).   
Research Design and Method Justification 
In this study, I followed important guidelines that were recommended by 
Malterud (2001), who observed some members in the health care community are 
skeptical regarding qualitative research, citing the perceptions of subjectivity and absence 
of facts with qualitative research methods. Malterud posited qualitative research findings 
could be important in health care and outlined important processes for qualitative 
researchers to enhance acceptance by members of the health care community. Malterud 
noted the difference in procedure for data interpretation but underscored similar research 
principles, including relevance, validity, and reflexivity as overall standards for 
qualitative inquiry. Malterud also warned of the challenges presented with reflexivity, 




health care community. Malterud that noted researchers must be prepared to answer 
questions regarding their findings and interpretations, internal and external validity, 
context and bias (explaining the value of contextual interpretation), and data analysis 
processes. 
Regarding interpretation and analysis, Malterud (2001) advocated a thorough 
analysis, including a discussion of valid, alternative interpretations. Proper data analysis 
includes decontextualization and recontextualization. Decontextualization extracts 
portions of data for scrutiny and compares these units within the holistic context of the 
rest of the data. Recontextualization confirms the consistency of patterns within the study 
context (Malterud, 2001).  
The researcher-emphasized knowledge does not emerge from data only, and 
researchers must include empirical substance and theoretical bases to form valid 
conclusions. Malterud (2001) emphasized researchers who fail to acknowledge theory 
and claim an inductive approach reduce credibility because theory influences all 
researchers. Last, to enhance qualitative study trustworthiness, Malterud advocated a 
transparent path description from data collection to findings in the research report to 
facilitate readers’ understanding of research procedures.  
Accentuating the lower opinion of some health care community members 
regarding qualitative research, researcher Beck (2009) emphasized evidence-based 
practice, including critical appraisal of evidence. Beck ranked highest the quantitative 
systematic reviews of RCTs. Beck posited critics rate qualitative studies lower than 




who employ quantitative methods use data collection instruments validated to strict 
standards whereas qualitative method researchers use perceived subjective instruments. 
Beck advocated qualitative studies as useful to enhance understanding of patients’ lived 
experiences and described five trustworthiness criteria to use when evaluating qualitative 
studies. Consistent with Beck’s thinking, the outcomes from this phenomenological 
research study can enhance n-3 marketers’ understanding of physician prescribing and 
recommending decisions. 
Al-Hamdan and Anthony (2010) provided a useful contrast between positivism 
and post-positivism research approaches. Positivism is the foundation for quantitative 
methods, whereas post-positivism is the foundation for qualitative methods. Al-Hamdan 
and Anthony described positivists as committed to transferring the precepts of naturalism 
and natural sciences to the social study objectives as a conceptual unification of methods. 
Positivists approach social science data as undeniable facts and attempt to apply scientific 
laws to establish truth. Al-Hamdan and Anthony positioned positivists as those who study 
the social world with a hypothetic-deductive method to find objective data through 
natural-world observations. Critics of the positivist approach state the approach does not 
allow the researcher to examine human behavior in depth.  
Conversely, Al-Hamdan, and Anthony (2010) described postpositivist researchers 
as interpretive sociologists focused upon studying the individual who are active and 
mindful of contextual surroundings, able to make independent choices. Although 
postpositivists consider observed and real lived experiences of subjects, they do 




Postpositivists engage in rich, holistic analysis not in positivist research approaches. Al-
Hamdan and Anthony identified reality influencers such as culture, gender, and beliefs.  
Al-Hamdan and Anthony (2010) cited postpositivist research critics who 
described qualitative researchers as those who present interesting stories with isolated, 
potentially biased findings not advancing the discipline, because they do not spur further 
reproductive research to establish external validity. In this study, the qualitative design 
and interview methodology were relevant to finding important information to solve the 
stated business problem. Learning how physicians make prescribing decisions constituted 
more than presenting interesting stories. Employing the methodological techniques 
described above facilitated the objectivity and unbiased findings of the study. Open-
ended exploratory interview questions with follow-up clarifying questions yielded 
information specific enough and relevant enough to enable significant meaning to study 
outcomes regarding the articulated business problem.  
Population and Sampling 
The study population included physicians who practice primary care and 
cardiovascular medicine worldwide. The purposeful sample in this study included 
primary care physicians in a limited geography (Kentucky, Indiana, Tennessee). The 
sample size was sufficient (n = 20) because I did not gather significant new information 
after the 15th interview, evidential I reached saturation in less than 20 interviews. 
Saturation is a guiding principle of sample size determination in qualitative studies 
(Carlsen & Glenton, 2011). Mason (2010) argued saturation is elastic and true saturation 




participants, and skill of the interviewer. Consistent with Mason’s factors affecting 
saturation, the focused aims of this study, similar specialties among physician subjects in 
a limited geography, and richness of data gathered during interviews support the 
possibility of achieved sample saturation for this defined population.  
Kerr (2010) stated investigators cannot predict saturation but for practical 
purposes, investigators need to plan number of subjects. From past studies, Kerr 
determined investigators who sought to establish sample size guidelines for qualitative 
methods of inquiry advocated samples sizes of six to 20 subjects. Similar to Mason 
(2010), Kerr stated saturation depended upon heterogeneity of subjects and study 
objectives. These guidelines supported the purposeful sample size for this focused 
physician decision-criteria marketing study. Further justifying the sample size and intent 
of this study, Bloomberg and Volpe (2012) advocated studying a small number of 
subjects for phenomenological study investigators to conduct deep inquiry and collect 
thick, rich data thus reducing the need for a larger sample.   
Data Collection 
Instruments 
With respect to data collection, I followed the advice of scholarly investigators. 
Rubin and Rubin (2012) advocated responsive interviewing to uncover and examine 
complex, hidden phenomena. Responsive interviewing emphasizes the mutual 
involvement of both the interviewee and the interviewer essential to derive meaning. To 
derive reliable and valid meaning, the interviewer must build a reciprocal relationship 




Similarly, Denzin and Lincoln (2008) underscored the importance of an intimate 
relationship and resultant participatory engagement between the interviewer and 
interviewee.  
The interviewer must remain cognizant of emotional effects of the interview on 
both parties and prevent biases by acknowledging potential areas of vulnerability and 
data contamination. By using main questions, probes, and follow-up questions, the 
interviewer can drive in-depth interviews to facilitate understanding of the obvious and 
unobvious aspects of complex human behavior and collect rich, thick, data. The 
interviewer should employ main questions to structure the interview, probes to elicit 
more specifics and maintain conversation flow, and follow-up questions to explore 
comments and ideas emerging during partnership conversations (Denzin & Lincoln, 
2008).   
In a relevant study in which investigators used subjects’ words to develop themes 
related to CAM therapies, Ritenbaugh et al. (2011) developed outcome instruments 
derived from patients’ words instead of preexisting theory. The researchers produced a 
final questionnaire consisting of 18 items. These items included assessments of positive 
and negative self-perceptions in the following outcome domains associated with CAM 
therapy compliance: physical, social, psychological-cognitive, psychological-affective, 
spiritual, and whole person. In this study of physician decision criteria, physicians used 
words indicative of similar domains. Therefore, the Ritenbaugh et al. study outcomes 




To test the quality of the interview protocol and as a safeguard against researcher 
bias, Chenail (2011) proposed a pilot study to test planned interview questions and 
procedures as well as interviewing-the-investigator technique. I used both tests in before 
conducting this study. Chenail specified the qualifying criteria for interviewing the 
investigator as the investigator must be part of the study subject population or have a 
strong understanding of the study subjects. A pilot study requires IRB approval with 
human subjects, achieved in this study. Interviewing-the-investigator method does not 
require IRB approval.  
The benefits of pilot studies include finding weaknesses or possible failures and 
determining if the interview questions are vague, irrelevant, unproductive, or too 
complicated. Pilot studies also provide the interviewer an opportunity for practice, obtain 
feedback from subjects regarding the questions, determine interview duration, and revise 
or edit questions. Chenail (2011) noted data collected during the pilot study is typically 
not included in the main research study. The pilot study included an in-depth interview 
using planned study interview questions (see questions listed below in Data Collection 
Technique section). The pilot study subject answered questions regarding the 
effectiveness of planned interview questions.  
Subject answers to interview questions and interview procedure informed planned 
field research (Chenail, 2011). During the pilot study, I practiced interview and follow-up 
question administration, test audio recording procedures and function, and received 




background, consent form including risks, benefits, and privacy, study methods, and 
study procedures to the participant. 
To test the instrument in this doctoral study, I also used interviewing-the-
investigator technique and tape-recorded the process. Regarding practical steps for 
interviewing the investigator technique, Chenail (2011) explained the investigator can 
play the role of the interviewed subject only, or play both roles (interviewer and 
interviewee). Chenail advised the investigator may enlist the help of a colleague or 
faculty chair to accomplish this process. Chenail recommended a cyclical process to 
incorporate ideas emerging during the trial interviews until no further changes evolve 
during the process.  
A unique benefit of interviewing-the-investigator technique is the investigator 
experiences the thoughts and feelings of the interviewee (study subject). The investigator 
should document any feelings or discoveries of potential biases with corrective actions 
because the IRB will analyze the investigator’s pre-study steps to determine instrument 
rigor. Finally, the interviewer should identify and document pretextual, subtextual, and 
contextual factors to control response divergence (Csordas et al., 2010). These two 
instrument tests increased my awareness of voice intonation, placement of audio 
recording device, revised question sequence, and improved my skill in using impromptu 




Data Collection Technique 
Study subjects heard interview questions for the first time during live interviews. I 
audio recorded each interview. In addition to audio recordings, I made written notes to 
document subjects’ main responses to questions.  
To determine interview format for this study, I considered Turner’s (2010) 
interview design descriptions: (a) informal conversational interview, (b) general 
interview guide, and (c) standardized, open-ended interview design. According to Turner, 
most critics regard the informal conversational interview as unstable and unreliable. The 
general interview guide approach allows an interviewer freedom to ask questions using 
personal style or paraphrase. To minimize inconsistent responses from study subjects, I 
did not use the general interview guide approach. According to Turner, the best format is 
the standardized open-ended interview, because the interviewer asks participants identical 
questions with additional probing questions for clarification. This procedure reduces 
researcher bias and is the interview protocol I used for this study. 
Turner (2010) provided suggestions for conducting qualitative interviews, 
including preparation, participant selection, pilot testing, effective research construction, 
follow-up questions, and interview implementation. Turner’s other ideas include 
selecting participants who will be willing to share their story honestly, avoiding evocative 
or judgmental wording in open-ended questions and not asking why questions or asking 
them with care. Turner advised flexibility by the researcher if a subject does not answer a 
question (i.e., come back to the question later in the interview) or if the subject answers a 




prepared and ready to ask immediately follow-up questions, consistent with the interview 
protocol planned for this study.  
Demonstrating a model for interviewing physicians and other clinical staff, 
Curran et al. (2012) conducted qualitative research using interview data collection 
methods to test the effectiveness of an intervention for anxiety: Coordinated anxiety 
learning and management (CALM) in 17 U.S. primary care clinics (n = 47). The 
investigators trained the interviewers prior to study inception. The interviewers employed 
a core group of nine questions included in the interview guides. Prior to the study, a 
group of investigators decided upon the questions after revising the questions several 
times, including question revision after interviews had begun. The interviewers asked 
open-ended core questions to determine facilitators and barriers to implementing CALM.  
The interviewers also used open-ended questions to find the facilitators/barriers to 
sustaining CALM after study completion. Interviewers recorded the conversations, 
subsequently transcribed verbatim. Curran et al. (2012) reported in two instances, the 
transcriber used the interviewer’s notes because the audio tape-recorder malfunctioned, 
which highlights the importance of interview note taking I used in this study.  
Curran et al. (2012) designed the interview protocol to support conventional 
(inductive) and directed (a priori) content analyses. In this respect, the protocol included 
a mixture of overview questions (e.g., “Tell me about your role and involvement in the 
CALM project”) and specific follow-up probes designed to facilitate contextual 
understanding, procedures, peer influences, and attitudes. Curran et al. (2012) explained 




approach subsequently enables data analysts to focus upon describing phenomena freely 
without constriction to a specific theory or behavioral model. Interview questions also 
elicited data later subjected to directed content analysis whereby investigators explored 
predetermined themes and concepts leading to predetermined codes. Curran et al. noted 
their emphasis on inductive data collection, applicable and used in this study.  
I followed the suggestions of Skirbekk and Nortvedt (2011), who demonstrated 
relevant qualitative study interviewing methodology in a medical setting. The purpose of 
their study was to understand medical professionals’ conflict between care and concern 
for particular patients versus impartial considerations of justice, which become central to 
moral deliberations. From interview results conducted with physician and nurses in 
Norwegian hospitals (n = 21), Shirbekk and Nortvedt discovered the dominant value 
norm: making differences for patients. Nurses, more than physicians, based their care 
decisions upon patients’ subjective needs.  
In vacant hospital offices assisted by audio recording technology and a notebook, 
Shirbekk and Nortvedt (2011) conducted interviews. Subsequently, transcribers 
converted taped interview content verbatim. In this study, too, interviewers followed a 
specific interview guide. In a consistent theme, they designed the interview questions to 
facilitate open discussion and reflection upon phenomena of common interest.  
Shirbekk and Nortvedt (2011) described their technique as active interviewing, 
with both the interviewers and interviewees epistemologically active, participating in the 
process of making meanings. The trained interviewers encouraged nurses and physicians 




regarding the subject phenomena. Shirbekk and Nortvedt explained the roles of the 
interviewers as more than reporting subjects’ responses. They emphasized the 
interviewers’ active interview participation. 
To document the process of active interviewing, Shirbekk and Nortved listed 
specific questions asked during the interview process. Most questions were open-ended. 
For example, interviewers asked subjects what they considered just treatment, what were 
just priorities, how they set priorities, and how they dealt with patient priority conflicts. 
Additionally, the researchers developed interview questions to explore how often they 
discussed such priorities with colleagues, expectations from colleagues and hospital 
executives, and their sense of responsibility for their patients. These questions and 
interview methodology are relevant models for the present n-3 study.  
 Scheermesser, Bachmann, Schämann, Oesch, and Kool (2012) provided a 
valuable schematic to depict the circular process and long-time requirements for 
competent data collection and analysis. Scheermesser et al. described the process to 
encompass six quality criteria of qualitative research. These criteria included: a) 
documentation of the data collection procedure, b) validating interpretation by 
argumentation, c) systematic, dyadic procedure, d) closeness to research object, e) 
validation by coder and author communication, and f) triangulation of methods. 
Interestingly, Scheermesser et al. portrayed a circular, dynamic process to accomplish 
triangulation after collecting data from a purposive sample through interviews, in-depth 
interviews, and focus groups. The authors reviewed collected data repeatedly to define 




 The Scheermesset et al. (2012) study example demonstrates how qualitative 
research methodology is inductive rather than deductive because the nature of the 
research seeks descriptions of people and their particular situations, meanings, and 
experiences. The qualitative research process is antithetical to quantitative research in the 
respects qualitative research is nonlinear and nonsequential. The findings of the 
aforementioned investigators influenced my selection of the qualitative method and 
guided interview-question design in this study.  
The specific interview questions were: 
1. Considering the previously explained ladder of inference and reflexive loop 
(Ayers, 2002), what processes do you go through to determine what products 
you will prescribe or what dietary supplements you will recommend? 
2. What credible clinical evidence have you seen regarding fish oil dietary 
supplements? 
3. What made the evidence credible or incredulous?   
4. What are the risks of taking fish oil dietary supplements?  
5. What are the risks regarding specific patient groups or disease states?   
6. What are the important differences between quality fish oil dietary supplements 
and low quality fish oil dietary supplements?  
7. What are right daily amounts of DHA and EPA? 
8. If clinical evidence is credible and convincing regarding fish oil efficacy for 
health prevention for disease amelioration, what education and communication methods 




9. Similarly, what education and communication methods to patients are best? 
10. Within the context of the ladder, please explain your present professional 
opinion regarding the health value of fish oil dietary supplements, specifically fish oil 
containing n-3s, for patients with no contraindications.  
11. What are your prescribing or recommending practices regarding n-3 fatty acid 
dietary supplements and the priority of n-3 dietary supplements as compared with other 
dietary supplements (e.g., multivitamins, chondroitin, niacin)?  
12. How influential are your peers’ prescribing practices to your decisions?  
13. When you speak with your peers, what percentage of them would you say are 
committed to frequently recommending omega-3s? 
14. If all your patients took a high quality omega-3 every day, what would be the 
impact on your whole practice?  
15. If all your patients took a high quality omega-3 every day, what would be the 
positive impact on U.S. healthcare costs?  
Data Organization Techniques 
After data collection, I organized subject responses and audio recordings by 
individual study subject files. I stored the raw and transcribed data in a locked office with 
limited access controlled only by me. I plan to dispose of subject data using a shredder 





Data Analysis Technique 
Data analysis links to the conceptual framework of the study. I analyzed data in 
the context of ladder of inference theory. Data analysis facilitated physician self-
understanding and helped identify physician and patient needs for education and 
marketing purposes. I identified themes from recurring subject statements coded and 
checked by another coder. Data complexity and diversity did not warrant 
hyperRESEARCH software to facilitate code development.  
Relevant to coding, thematic development, and data analysis, unconscious mental 
processing of data—reflective processing—was a vital, necessary part of this qualitative 
research because of the discovery of important but unobvious underlying psychological 
constructs (Meek, 2003). I experienced this phenomenon often overlooked by other 
researchers, according to Meek. The reflective process includes both intellectual and 
emotional components, where often the gut feeling and intuition catalyze the researcher’s 
conclusions or decision to proceed to the next step (e.g., not adding more codes but 
proceeding to thematic development and analysis). Reflective process has its roots in 
psychoanalysis, wherein Freud differentiated among the conscious, preconscious, and 
unconscious minds (Modell, 2011).  
According to the psychotherapist Meek (2003), understanding the workings of the 
unconscious mind of subjects provides opportunities to deepen understanding and 
discover unobvious mechanisms of motivation and reasoning. The psychotherapist 
describes the workings of the unconscious mind as highly complex, forming associations 




assembling ideas not logically related. Meek provided instances of the unconscious mind 
at work: Working on an unrelated jigsaw puzzle sometimes triggers a solution or an idea 
relevant to a different dilemma or how awaking from a night’s sleep provides new 
insights and revelations.  
Meek (2003) outlined pragmatic steps for reflective processing for researchers to 
follow. Researchers should break complex material into stages, make repeated passes at 
the data to find new revelations, and translate material using own words to articulate new 
ideas. When the researcher is stuck, one should understand any relationship between 
personal conflict and the research topic and identify those links to facilitate 
understanding. Second, Meek advised researchers to take breaks. Because the 
unconscious mind requires time to finish combinatory play, the researcher should not 
always regard a time of perceived unproductivity as wasted time. Meek exemplified how 
fallow fields regenerate during the time microorganisms regenerate themselves, which 
prepares them for the new season.  
Third, Meek (2003) advised the researcher should gain differing perspectives 
about the data by looking at data from a distance. Sometimes researchers become too 
engrossed in data detail. Fourth, the decision to integrate versus deconstruct data is an 
intuitive one. Meek posited researchers realize this point when their curiosity is satisfied. 
Discoveries of the unconscious mind can be valuable, but reflective processing requires a 
conscious stepped approach, and the steps are not necessarily sequential. This advice 




could organize subject responses cognitively into themes and developed a hierarchical 
order of presentation (consistent with ladder of inference theory) for the study report. 
Regarding specific coding methods, Li and Yeo (2011) provided specific coding 
steps as a useful model. They initially established categorical cues grouping research 
questions as broad categories and the follow-up probes as root categories. Li and Yeo 
employed key word searches (e.g., quality, commitment, team, reward, etc.) to garner an 
overall view of the data. Their next step was to identify clusters of information relevant to 
the study purpose of inquiry.  
Following the formation of information clusters, Li and Yeo (2011) engaged in a 
rigorous and systematic patterning process until they observed recurring themes. They 
also grouped examples provided by subjects with the recurring themes. By using 
categorical cues and classification tables, Li and Yeo developed units of analysis and 
thematic patterns. Evolving to analysis, they adopted an integrative purpose to reduce 
responses to clear collective sets. Li and Yeo matched the collective theme sets to their 
research questions and themes identified in literature. They emphasized three 
comparative analysis steps to enhance the trustworthiness of the data: (a) derivation of 
research questions and issues from related literature, (b) rigorous coding adherence to 
established coding system, and (c) inter-coder involvement and verification to ensure 




Reliability and Validity 
Reliability 
Beck (2009) proposed five trustworthiness criteria appropriate for qualitative 
studies including credibility, dependability, conformability, transferability, and 
authenticity. I described all these criteria in previous document sections, except 
authenticity. According to Beck, authenticity is the degree the researchers fairly and 
truthfully described study subjects’ experiences. I increased authenticity and credibility 
by validating transcribed data with participants through e-mail follow-up as a method of 
member checking. 
Beck (2009) also provided a list of 57 valuable questions a medical professional 
should employ to assess study trustworthiness. The questions pertain to study-report 
sections, including the title, abstract, introduction, methods (sample and setting, data 
collection, procedures, enhancement of rigor, etc.), results (data analysis and findings), 
discussion, and global issues (presentation, researcher credibility, and summary 
assessment). These questions guided my development of this doctoral research study. 
Parenthetically, to enhance understanding of the medical professional’s foundational 
ideology for evidence-based practice, Beck advocated (a) asking the burning question, (b) 
collecting the most relevant evidence, (c) critical appraising clinical evidence, (d) 
integrating evidence with personal experience, expertise, and patient preferences and 
values, and (e) continuing evaluation of the medical decision and change in health status. 




questions relating to the cost of drug or dietary supplement therapies and the personal 
experiences of physicians. 
Validity 
Regarding qualitative research, Golafshani (2003) proposed researchers should 
replace traditional validity vernacular by quality, rigor, credibility, transferability, and 
trustworthiness. Golafshani insisted triangulation for both data collection and analysis 
could enhance the rigor of the research without compromising its inherent, naturalistic 
value. Golafshani also advocated qualitative researchers to make their research findings 
generalizable, and a true test of validity is the reproducibility of study findings in wider 
groups and similar, if not identical, circumstances.  
Holt (1991) essentially refuted mainstream qualitative study validity and 
reliability techniques on the basis that such techniques “contradict the nature of the 
interpretive task, and pose insurmountable problems in application” (p. 59). Holt argued a 
subject or researcher’s individual, contextual interpretation of any event is not verifiable 
as accurate or truthful because another individual would relate the same experience 
differently because of a separate, unique frame of reference and context (e.g., the 
Roshomon parable). Holt argued reviewers should employ an interpretive technique and 
judge interpretations by the insight provided and the power to convince (Thompson’s 
gestalt experience, as cited in Holt, 1991). Holt posited if enough peer experts agreed, the 
consensus would define the predominant interpretation. 
Holt (1991) added integrity as a test to the traditional methods of testing 




measure, and conformability. Holt explicated the 10 techniques recommended by Belk et 
al.: (a) prolonged engagement and persistent observations, (b) use of triangulation with 
different researchers for data collection and interpretation, (c) frequent on-site team 
interaction, (d) negative case analysis, (e) peer debriefing, (f) member checking, (g) 
limiting exceptions, (h) purposeful sampling, (i) reflexive journals, and (j) independent 
audits. Neuman (2011) advocated applying similar criteria to those recommended by 
Belk et al.  
Bernard and Ryan (2003) outlined eight observational techniques and four 
manipulative techniques for unbiased theme development. Shepherd and Rentz (1990) 
provided steps “to minimize the subjectivity of coders” (p. 62). Brent and Slusarz (2003) 
recommended computer assistance “to assess and improve the reliability of coding by the 
researcher” (p. 299). Last, Zelik, Patterson, and Woods (2010) proposed a rigor analysis 
model with eight specific components to establish rigor and prevent shallow analysis in 
qualitative research. In this study, I considered the discussion and advice of investigators 
cited above. These elements might also enhance the external validity of subsequent 
similar, but not necessarily identical studies.  
Transition and Summary 
The objectives of Section 2 were to justify and explicate design and methods of 
this research study. Critical to the success of this study was the careful and excellent 
execution of this plan. As a result, I can report meaningful, reliable, and valid results 
important to the general and specific business problems articulated in this study. In the 




Section 3: Application to Professional Practice and Implications for Change 
In this section, I provide a review, examples, analysis of information, and 
outcomes from gathered data to research questions elicited during semistructured, face-
to-face interviews with 20 physicians in Kentucky (16), Indiana (2), and Tennessee (2). 
The physician subjects included 16 males, four females, 18 of whom were medical 
doctors (MDs) and two of whom were doctors of osteopathy (DOs). Physician practice 
experience ranged from one to 38 years. 
Overview of Study 
The purpose of this phenomenological research study was to improve n-3 
marketers’ understanding of how physicians reach decisions to prescribe or recommend 
products including omega-3 (n-3) dietary supplements and which product characteristics 
may be the most important to physicians. I explored physicians’n-3 dietary supplement 
knowledge and decision criteria (ladder of inference; Argyris, 1976), and found 
physicians’ inference ladders for prescription drugs are similar to physicians’ inference 
ladders for n-3s. Argyris’s ladder of inference model facilitates constructing a 
hierarchical schema to facilitate understanding physicians’ decisions, ideal for the 
physician context because higher ladder rungs are not accessible in the absence of bottom 
ladder rungs. With physicians, as expected, the bottom ladder rungs are drug or dietary 
supplement safety and efficacy. After establishing efficacy and safety, physicians 
consider a number of other important factors (i.e., ascending ladder rungs) such as cost 
and reimbursement, their own patient experiences and outcomes, peers (especially 




supply of samples, direct-to-consumer advertising, and personal experiences of patients 
or themselves taking the products.   
I interviewed the 20 physicians in private settings conducive to few interruptions. 
After concise introductions and Informed Consent completion, I outlined the interview 
plan, asked questions, and closed the interviews by thanking the physicians and asking 
for their follow-up response to an e-mail containing confidential transcript and them 
information. Following interview transcript review and study, I developed codes and 
themes in accordance with the code and theme development methods advocated by Meek 
(2003) and Li and Yeo (2011). Meek recommended reading and rereading transcripts, 
and then taking time away from transcribed manuscripts to contemplate coding and 
thematic development. I also enlisted the help of a second coder (IRB approved) to fulfill 
the intercoding verification process advocated by Li and Yeo and further validate the 
triangulation process advocated by Golafshani (2003).   
Bertolotti and Tagliaventi (2007) emphasized the importance of data analysis 
objectification, a critical element to support study validity. Following the 
recommendations of Berolotti and Tagliaventi, I used intercoder agreement, peer review, 
and member checking to triangulate and confirm data accuracy and theme development.  
I e-mailed physician subjects their own confidential transcript content to ensure accuracy 
of transcribed content and thematic confirmation. One-half of physician subjects 
responded and of those who responded, all confirmed content accuracy without 
recommending revisions. I also engaged the help of a colleague in peer review. To ensure 




By rereading and contemplating content, I developed groups of data using codes, 
developed themes from codes, and reduced too many themes into fewer pragmatic 
themes and synthesized my analysis and conclusions. I evaluated my conclusions for 
prospective limitations and delimitations, identified implications for social change, made 
recommendations for follow-up study, and revealed introspective growth perceptions 
from the experience. This process was holistic and my research and evaluation methods 
integrated the problem statement, purpose statement, research question, conceptual 
framework, nature of the study, qualitative design, literature review content, validity and 
reliability controls originally presented in Sections 1 and 2.    
The study outcomes enabled me to answer the primary research question: For the 
purpose of marketing strategy, what is the ladder of inference physicians use to 
recommend n-3 dietary supplements? To answer this primary research question, I first 
established context. Context included how physicians determine what drugs they will 
prescribe and what supplements they recommend because these decisions follow the 
same hierarchy of decision logic: patient safety, product efficacy, experience, cost, and 
other influencers. Physician decision logic fits ladder of inference theory (Argyris, 1976) 
with respect to specific decision influence components including the following key rungs 
in the ladder of inference: data selection (determining clinical trial credibility), data 
interpretation (how the data fit personal experience), practical and ethical factors to 
determine if assimilated data will change behavior (the action of prescribing or 




Presentation of the Findings 
 Through a process of repeated and prolonged data analysis, I determined eight 
prevalent themes from this study. The first three themes were Theme 1: Clinical Trial 
Rigor, Practice Relevancy, Degree of Influence, Theme 2: Physicians’ Experience and 
the Test of Time  Determine Prescribing Habits, and Theme 3: Cost is an Important 
Influencer, Providing Competitive Products Have Similar Efficacy and Safety. Themes 4-
6 included Theme 4: Peer Opinions Influence Prescribing Decisions If Peers are 
Specialists, Theme 5: Competent and Incompetent Pharmaceutical Representatives Have 
Antithetical Effects Influencing Physicians’ Prescribing Decisions, and Theme 6: 
Samples Are a Valuable Influencer to Some Physicians.  
 The final two themes were Theme 7:  Most Physicians Have Negative Opinions 
Regarding the Influence of Direct-to-Consumer (DTC) Advertising but DTC Increases 
Product Awareness, and Theme 8: Lost Influencer Opportunities: Physicians Need More 
Dietary Supplement Education and  Lack of  Dietary Supplement Curricula in Medical 
Schools. All themes are relevant to the core research question. Themes 1, 2, and 3 
seemed essential as influencers and more important than Themes 4, 5, 6, 7, and 8. In the 
following subsection, I explain these themes in more detail and support themes with 
transcript excerpts. I also discuss the pragmatic applications of these themes to 
pharmaceutical and n-3 marketers. 
Theme 1: Clinical Trial Rigor, Practice Relevancy, Degree of Influence  
 The following excerpts support clinical trial validity and reliability criteria 




blind, randomized, placebo-controlled, and number of subjects (sample size). Other 
important factors to determine rigor include investigator credentials and the reputation of 
the publication journal. Physicians also evaluate the relevancy of clinical trials including 
study venue, study subjects, and outcomes. In the transcript excerpts below, I protect 
physician anonymity by using an initial (e.g., Dr. H) not necessarily representing any part 
of the physician’s real name. 
 First, Dr. H commented, “Very simple, number of people in the study. If it’s 150 
people doesn’t tell me anything, if it’s 5,000 people for 5 years, that’s the first thing I 
look at,” while Dr. T stated that, “Well how many people are in those studies? Is it a good 
one, is the finding statistically significant. I look for p values and study rigor.”  Other 
doctors commented: 
Is it effective, how many people, what are the risks, that’s big for me because we 
cause a lot of problems maybe more than we solve, and I am very in tuned to that. 
Generally where I get my information, they are only putting in their stuff that is 
credible, statistically significant. I use  Prescriber’s Letter, I love Prescriber’s 
Letter. I read The Medical Letter. I read something called Core Content Review, 
which is basically Cochran-based, that is where I get all my information, 
basically. (Dr. O) 
   If I am looking, I want to know it’s a large enough study, well done study, 
 placebo-controlled, double-blind, that kind of thing. I want to make sure the 
 conclusions drawn are what I shown in the study. You know a lot of times people 




 include that as part of your study so you can’t say that, you know… a lot of the 
 information the drug companies put out, it’s not real hard data. In fact I’d rather 
 get the data from an academic environment. (Dr. R) 
Well, it’s the number of patients for example if you are looking at a study with 10 
people versus 10,000 people, the one with 10,000 will be more meaningful, 
number one. Number two it’s gonna be how long has the product been on the 
market, do we have any bad reports, any recalls, FDA have any black box 
warnings. (Dr. I) 
I look for the size of the study, how many subjects are involved, what kind of 
study is it, is it observational, is it placebo-controlled, who did the study, whether 
it is university based, Institute of Health based, or pharmaceutical based study, 
um, that’s what I look for when I read articles. (Dr. N) 
Dr. S stated: “OK, Is it a large enough sample? Are they measuring 
something important? Is it something definitive or is it something we are hopeful 
will work and we are not quite sure? Either the data is soft or we don’t know the 
side effects” while Dr. G remarked, “Population size is critical. 20 patients vs. 
400? Primary care docs don’t necessarily look at raw data. At least they don’t 
have the time to do that and don’t have the time to do it. Look at how long drug 
has been on the market and credibility of company and investigator.” 
Dr. C stated: “Well basically, the ones who have a significant endpoint -- 
whatever they are testing for…reduce triglycerides or whatever…and that it works, and 




disclosed: “I look at how they chose the study participants and whether or not it would 
apply broadly.”Dr. B added: “Oh right, well obviously the source of the information has a 
lot to do with it, how big the study is also has a lot to do with it.” Another physician 
added: 
Double-blinded studies, multi-center, the source has a lot to do with it…What 
drives me crazy with some of these studies...they come up with these crazy 
scales…so the study show X was better than Y on some allergy retro scale…on 
some crazy scale and you say ours was .8 and theirs was .6 and okay here’s the 
difference between those two. A 30% difference on a scale does not mean a 30% 
difference on what I see on my patients. And on some of these depression scales it 
does not give you a point of relevance and so you say I don’t know how sick a .6 
is and I don’t know how much better a .8 is, does it apply, does it make my 
patients better. So I think a lot of these studies give you information you cannot 
use. If you are treating shingles, I want to know how fast my patients will get 
better. I am not interested I splitting minutia that doesn’t matter in real life, or 
when p values are such borderline and they give you scores, those drive me crazy.  
(Dr. W) 
Dr. A stated: “If the drug was tried on a few or hundreds of patients. Also if drug 
versus another drug with better results this is important to assess… The main thing is to 
read good journals, New England Journal of Medicine, JAMA…” while Dr. L advised: 




remarked: “I know what the efficacy of the drug is. I want to know what kind of patients 
they are and I want to know how they compare to their peers.”  Other physicians stated:  
 Usually I look at several things, I look at, well the younger guys are much more 
analytical about studies but I am going to look at whether or not it is a blinded 
study. I look at the total number of people in the trial, so often we forget about 
even though a New England Journal of Medicine study, it has a total of 36 
participants. I like a study that probably has more people. Is it 13 patients or 
13,000? Who did it? Which centers? And then, applicability is a big thing for us, 
meaning did they do the study on 5,000 people from Tazmania? Really doesn’t 
have anything to do with my patient population. And so they can have great 
studies with great things but really doesn’t apply to me. So I think it’s important 
to look at all of it and see if it’s applicable…You can rely more on a study that 
came out of New England Journal and you expect studies to be credible...doesn’t 
always have to be that way but usually is. (Dr. J) 
 I like a multisite study, I like more investigators than one investigator’s bias. And 
I like double-blinded because neither the investigator nor the patient knows what 
they are getting, or what they are giving. Those are the kinds of things I look at in 
clinical trials, multi-site, double-blind, big numbers. Sometimes the journals that 
are peer-reviewed will only allow certain studies. You’re going to have the top ten 
journals, or the top five journals and then the next 10. The studies are going to be 




The top five journals have their pick and they are going to make you revise and 
re-submit. And I am going to go towards a more sophisticated study.  With throw-
away journals, I might not consider the study. And then I guess the one thing I 
really look at, in our academy, is the Cochran library, where they take all of the 
studies of a particular thing, and group them together. So there are positive 
studies, negative studies, and neutral studies and somehow they combine the 
numbers and make a recommendation based upon all the studies they could find 
in the literature. (Dr. J) 
Theme 2: Physicians’ Experience and the Test of Time Determine Prescribing 
Habits 
In a relevant quantitative study (n = 135), Tichelaar et al. (2010) noted practicing 
physicians reach their prescribing decisions heuristically and may not be conscious of 
their own drug choice logic or value judgments. Tichelaar et al. noted unlike diagnostic 
reasoning, which is well documented in the literature, little is known about therapeutic 
reasoning (i.e., the decision process physicians use to make treatment choices). The 
findings in this study add understanding of the heuristic physician decision process of 
data selection, interpretation, assimilation, and action. 
 The selection and assimilation of data by physicians is a perpetual process. 
Clinical trial outcomes are important but in long-term effects on prescribing habits, only 
if physicians’ personal experiences support those outcomes. All 20 physicians expressed 
reservations about prescribing unfamiliar products or new products on the market and 




positive feedback and experience, physicians gradually increased product use. Clearly, 
regardless of physician decision influencers, the long-term trump criterion is their 
personal and patient-specific experiences. The following evidentiary excerpts provide 
more insight regarding these findings: 
No, I think it has to do with experience of practicing 34 years. You get somewhat 
in a routine. If you have a patient who you know a drug will work, you throw in 
tolerance and cost, you develop a comfort zone and you may add a new drug from 
time to time. But you kinda know with Miss Jones, these other products worked, 
so will this one. But you get into a routine using drugs that work and really don’t 
try many new things. (Dr. G) 
 If you ask me, and this is just me, we are all a little different, the single biggest 
thing to impact me has got to be familiarity. I’m not one that, as soon as a product 
comes out on the market I’m on it. I tend to take my time, use samples, evaluate 
closely. If they need an antibiotic for a certain indication, I tend to go with the one 
I know works. I know these are the downsides, these are the upsides, can’t use it 
with that…familiarity is probably the biggest factor for me. And if something new 
on the market comes out and does not have that downside, I will start trying it 
slowly and carefully. But for me the biggest part is familiarity. (Dr. V) 
The physicians expressed strong opinions regarding their direct experiences with 
drugs and supplements, especially new products. Dr. I stated: “Everybody has their own 
experiences and own opinions. I would get more influence by the patient themselves. 




much experience”  Dr. H added: “Now with new drugs I got burned so many times, a 
new drug comes out, any kind of total new drug, I sit around and let somebody else use it 
for 4-6 months.” Dr. N stated: “Yeah, have been burned before about drugs that have 
come out, even for 5 or 10 years, and then we found out, so we’ve all been burned.”  Dr. 
M admitted: “I tend to trust old friends who are not going to mislead me.” 
Adding to the importance of product experience, Dr. S stated: “With some new 
products I don’t feel secure enough that it’s been out long enough and that there is 
enough people that have been on it.” Dr. K revealed: “I want to be familiar with the drug 
and I want to know it’s mechanism of action.” Adding a comment regarding proof of 
product efficacy Dr. C advised: “Something like omega-3 I can draw blood and show 
someone cholesterol levels and the test the same later, maybe 3 months or 6 months later 
to see/show results. Those are the kind of results that open eyeballs.” Other important 
physician comments: 
I am very influenced by the big trials, like the nurses trial on breast cancer, and 
the big trials on hypertension, what drug over the long haul always comes out on 
top. Like you can’t beat ACE inhibitors. You cannot beat hydrochlorothiazide. It 
prevents more heart failure than anything else and it has been out for 30 years. I 
guess that’s the big one for me. (Dr. O) 
Something that is very new, I might be a little skeptical before I use it. Um, and 
the thing is, most medications are not new. If you go and look they are in Europe 
10 years before they are here. In Europe they are much faster. They give the OK 




that has been on the market for 10 years in Europe but now it is here, I will go for 
it. Something very new, experimental, maybe I will wait a bit to see what’s going 
down the pike. (Dr. I) 
 Theme 3: Cost is an Important Influencer, Providing Competitive Products 
Have Similar Efficacy and Safety 
 One surprise in this study was the emphasis and importance of cost as an 
influencer of physicians’ decisions to prescribe drugs or recommend dietary supplements. 
Without exception, physicians expressed frustration with inordinate product costs and 
provided compelling patient experience examples where patients did not comply with 
physician directions because costs were too high, even if patients knew health 
consequences would result from noncompliance. Based upon physician explanations, in 
the physician ladder schema of influencers cost elevated to a primary decision influencer 
as perhaps the third most important ladder rung after credible clinical data and physician 
personal experience. The following transcript excerpts enhance the prominence of cost in 
the overall physician decision-criteria hierarchy: 
That is the top priority. You know if you have patients who are Medicare or who 
cannot afford the drug you are not going to use it. So that is a major issue. And 
sometimes you have to acquiesce and choose a less expensive drug even when 
you prefer the brand or they won’t be able to afford it and flat out won’t take it. 
(Dr. G) 
[Cost] Big, big. Not for me, but for the patient. Even if the clinical trial outcome 




in systolic and diastolic blood pressure – the results may be amazing – but if that 
medicine costs the patient a hundred dollars a month, the patient is not going to 
take it. You have to be practical. (Dr. D) 
I think from a patient’s standpoint, the economy of the drug plays a far bigger part 
than you guys realize. I have reps in here all the time and I say really, if you 
would have priced this at $40, I would have 2,000 patients on it. At $140, three. 
And you can’t tell me it costs $120 to make this stuff because it has been out 
forever. And they say well we evaluated it and if it saves one hospitalization a 
year it saves this much and I say don’t give me that crap my patients aren’t paying 
it. These new diabetic drugs are now $300/month versus the old sulfonamides for 
$20 that work just as well…But I think patients are more cost conscious than 
ever. When formularies were $5, $10 and $15, who cares. When $5, $50, and 
$100, wait a minute what is all this formulary stuff. Well you had it all the time 
they just jumped it. (Dr. W) 
Physician expressed strong opinions regarding costs. Dr. M stated: “Yes, it’s a big 
factor. More than it used to be because things weren’t as expensive back then. They’re all 
expensive now…People are really concerned about cost…as long as quality is good then 
you’re going to look at cost.” Dr. F prioritized decision criteria: “Safe, effective, 
available, and cost… Cost is way up there, very important.” Dr. V added: “But we want 
everything covered by our health insurance and then don’t understand why it goes up 
every year…is criminal in what they charge people and keep raising prices higher and 




And I’d go down to the Braves game and the box down there and when I finished 
my talk, I’d say after all this stuff, be honest with me, what is the single factor that 
will get you to write a drug, and every stinkin’ time it was cost… Yes sir, that’s 
the single most important factor… and they came to me and I said I know what I 
am supposed to say, I’m supposed to say efficacy and safety and all that, I said, 
it’s cost. I’ll just tell you it’s cost. And the guy next to me, he started, and he said, 
he’s right. And the guy before me said, an internist from Mississippi, said I want 
to change mine, he’s right, it’s cost. Every one of them said cost…But 
pharmaceutical companies don’t get that. They say well if we cut the price then 
they’ll cut the price and we’ll get into a price war. But if you make a good product 
at a good price, doctors will use it. They’ll lie to you and tell you it’s something 
else but I’ll tell you, it’s cost. (Dr. H) 
It’s pretty high for me, unfortunately, but cost is very important. Regarding brand 
names they are more expensive but if there is a tried-and-proven generic, I usually 
go with that one first. And if they don’t do well on the medication then I will go 
to the brand name. Unless it’s something that is not good enough in my mind in 
that class of generic drugs, then I will go to a brand name. (Dr. P) 
All these things play a role although sometimes you still feel even though it has a 
black box warning, you have used this product for so long, so good to the patients, 
so you pretty much put that aside and go with your gut feeling. Um, insurance, if 
it’s covered or not, it’s significant. People these days they don’t want to pay a 




you know, it doesn’t work that way. So I should tell them now it’s gonna be $200 
co-pay, going up and up and they say, forget it, I don’t want it. Doesn’t matter if 
it’s a life- saving medication, doesn’t matter, they won’t go for it… I think it’s 
also the fact…20 years ago, only one or two medications were expensive out of 
the whole realm of drugs. Today, some medications are 400 or 500 bucks. They 
are routine, so that has made people skeptical about anything not covered by 
insurance. (Dr. I) 
Nowadays pretty huge cause patients are pretty savvy about that. They call you 
back and say, “Isn’t there a $4 choice or generic for this? This costs too much.” 
So you have to factor in cost a lot because if you keep writing people $70 
medications they quit seeing you. It is that world now and they won’t come 
back…in my parents day their copay was $5 bucks. Now a third-tier copay is $50 
or $60 dollar copay and somebody tells you there is a $4 cholesterol medication 
on the list at Wal-Mart. So people are savvy enough to be looking at that and 
saying isn’t there a cheaper alternative I could be taking.  (Dr. T) 
Around here we see a lot of people who do not have insurance or who have very 
poor insurance. Ah, we see a lot of people who are cash pay, people who have a 
very high deductible and it won’t pay anything until they hit say $5,000 in 
medical bills. So in those cases cost is a huge factor. I can give them something 
but if they won’t go fill it, it doesn’t work. Or they just get mad at you, one of the 
two. But more of the time they just don’t get it. I saw a patient yesterday and she 




her an antibiotic. She didn’t get it filled. Now it’s a big, nasty infected wound. 
This was something she needed but she couldn’t afford it. So cost is a big issue 
especially, if well if you take something like an antibiotic and you are on it once 
that is one issue. But if you are taking something for the rest of your life, cost is a 
big, big issue. (Dr. B) 
Huge! I am a generic user, a big, big, generic user. With drugs, if it hasn’t  been in 
our magic sample closet for at least a year, I am not going to use it. Sometimes 
with cardiac drugs I will use it if I know a lot of cardiologists have  used it and I 
have spoken with one I know who is conservative and they say yeah I am having 
a lot of good luck with this drug. Antidepressants, no way. Cholesterol medicine 
there really isn’t that much that comes out. And diabetic medicine, I may be more 
apt to try that. (Dr. O) 
Well, when I prescribe things, I am simultaneously thinking of several different 
things. Efficacy and how the drug will work, cost and their co-pay status, how it 
fits, ease to take it, side effect profile, I am thinking of all these things at the same 
time. (Dr. R) 
It’s important to me because 50% of my patients are cash pay. They don’t have 
Medicaid, Medicare, or private insurance. So it’s important because what they 
have to pay is going to determine whether they are compliant whether they are 
going to take it, whether they are going to take it past what I give them. I may 
give them a sample. But if they can’t afford and they are not going to buy it, it’s 




Um, I don’t have to know it’s going to work on that individual but I have to know 
it fits the individual’s lifestyle. Is this person going to be able to afford what I 
choose? Is this person one who will feel comfortable taking something that is not 
a prescription? Is this an expensive prescription? A lot of it is financial state. Of 
course, if I believe it can help them, and they really need the more expensive 
medicine, I will encourage them to really make a sacrifice for it. If I am uncertain 
about it, I am going to have a lot of trouble trying to convince them to take 
something I don’t necessarily believe in. [If I prescribe something too expensive] 
They don’t take anything or you get a callback in a day or so saying we can’t 
afford this. Is there something else we can take? It is a terrible feeling in a day 
that you gave someone something that was impossible to do, was a failure, and 
you shouldn’t have done it. [Pharmaceutical companies] Yes, they really don’t 
factor that in very well. And they don’t think about how much these people are 
taking. And if they are Medicare, they are even more vulnerable to those 
problems. If they have insurance there is a hope. If they don’t have insurance they 
are dead in the water.  
Medicare, maybe will cover, maybe it won’t. Insurance,  maybe will cover and 
maybe it won’t. Uninsured people, forget it. And then they hit the donut hole and 
they come in and say, “I can’t afford this for the next 3-4 months” so then we 
gotta figure out what to do to get them through the donut hole. So there we have 
double work.  All of sudden we had a medicine I wanted to count on for a year 




input that data into our computer system and then the patient has to bring the 
bottles in so we can confirm what they are taking and make they are right. And 
this just doubles our work in a year’s time with a prescription list. (Dr. R) 
Yes that is the other one I was going to get to. Interestingly they pulled quinine 
off the market which is the old standby that was used for ever, and it costs 
pennies, and as soon as they pulled quinine suddenly we are putting people on 
anti-epileptic medicine costing three figures, hundreds of dollars to put them on 
this stuff, you gotta titrate it, you gotta be careful. And all of a sudden what we 
used to use and treat for pennies, now we are treating for hundreds. Well, older 
people, a lot on Medicare, and that donut hole becomes huge to many people. It’s 
just half a year and I already have patients hitting their donut hole. And now they 
have to float the whole cost of medication because even if you have an over the 
counter it’s better than Lovaza...that pushes you towards your donut hole. So by 
the 6th month, you’ve spent $500 towards your donut hole whereas if you bought 
the over the counter version which is about the same as your copay, you’ve spent 
the same but don’t have it going towards your donut hole. That’s a critical 
factor.…I’ve gotta have the price and the efficacy to match. If it’s something 
that’s very expensive like a cancer drug, then it’s something you can’t do without. 
When you’re talking about BP medicine, I can give you a $4 medicine that is 
going to work great, why would I write a $200 medicine because a drug rep told 
me to? By the same token if I am using, for instance I believe in Synthroid, versus 




balanced. So cost enters into it, but then there are some drugs worth it. And I 
think that is probably what does it for me. I‘ve gotta look at cost and sometimes I 
don’t have a choice. Well you’ve made me think about why I use the things I do. I 
don’t know, ease of use, cost, what the patient will use. Because I always tell my 
students, you can write any damn thing you want, but if the patient doesn’t take it, 
you’ve done no good. You gotta read your patient. I have patients all the time call 
back I can’t afford it I can’t afford it. You stay at this long enough and you learn 
what works. I don’t want those callbacks and I want to know it’s going to work 
right up front. (Dr. J) 
Theme 4: Peer Opinions Influence Prescribing Decisions If Peers are 
Specialists 
I classify credible clinical proof, personal experience, and cost as essential 
influencers. Other influencers may be important as well but may vary in their degree of 
impact, depending upon physician individuality and preferences. The influences of peers, 
pharmaceutical reps, DTC advertising, samples, and dietary supplement education (or 
lack thereof) may all have some influence, but to varying degrees depending upon the 
physician person. Not surprising, younger physicians seemed more receptive to peer 
influence than did more experienced physicians. The following transcript excerpts 
provide insight regarding the variability of physician peer influence:  
Peer influence may be most important with new medicines. Dr. L stated: “Peer 
experience is important especially with new medicines.” Dr. F was positive regarding 




They give me specific instruction on how they have used it. If they say it works better, it 
gives me a motive to try it.” Dr. O disclosed: “Yes and you get information when you 
send a consult to someone and they send you back a report. I like to read my consults all 
the time.” Dr. K clarified: “More if a peer feels comfortable using a medicine as opposed 
to the horror stories of medicines.”  
Younger physicians may be more receptive to peer influence. For example, Dr. M 
stated: “Certainly influenced me in residency when I was learning things. Don’t have that 
contact now. But we share with each other so yeah, we have some contact. I still listen.” 
Dr. P remarked: “Peer influence…residency yes. We get into the habit of using meds and 
then it’s hard to break me of the habit. “Conversely, a physician in practice for many 
years, Dr. I remarked: “Not really, everybody has their own experiences and own 
opinions. I would get more influence by the patients themselves…But not what other 
doctors say or think. “Physicians added other insights regarding peer influence:  
If there is somebody in my immediate circle like in this group here…for example 
if Dr. R has been using a medication and I see his patients get good response, if I 
have not been using it, I might start picking that up. Usually I am one of the 
slower first adopters of new medications and if others want to try it first that is 
fine with me. I will wait and if there are no problems, I might start picking it up. 
I’m a fairly slow adopter when it comes to that. (Dr. N) 
I find that medicine has become the complete opposite of what we ascribe to here 
. . . we try to communicate, we make calls, we send complete records, we try to 




most part medicine is pulling apart so we don’t have as much collaboration as we 
used to. Having said that, If I talk to somebody and my pulmonologist tells me 
this is the best metered-dose inhaler because of this, that, and the other, sure I will 
use that information…he sees the troubled cases. Subspecialists, now when you 
are talking about that kind of collaboration I love to learn from those guys. They 
see the trouble cases. While we see a boatload of them, we send them the ones we 
can’t fix. (Dr. V) 
Probably for certain specialty drugs I am certainly more influenced or more apt to 
use something if the allergist I use all the time prescribes it…I probably do get 
some comfort with a med when the patient comes in and the cardiologist has them 
on it and I get a little more knowledge about what it is because patients are 
already on it. (Dr. T)  
Yes I look at what the specialists prescribe. For example if I send patients to a 
cardiologist and they always come back on a particular drug, I get familiar with 
that because I know if I am going to use a different drug the consultant is 
probably going to change it. So a consultant has an influence on me. (Dr. J) 
[Peer influence]…me particularly, not too much. ‘Cause I don’t have a lot of 
interaction with peers anymore, other than the partners in my own office. I did 
more of that when I did hospital rounds. We’d sit around with specialists in the 
doctors’ lounge and discuss drugs. We no longer have that opportunity. Non-
hospital doctors no longer have the kinds of meetings except when a 




Yes we used to have roundtable sponsored by drug companies…we used  to do 
it. But we haven’t done one it 10 years . . . $50 for a dinner . . . takes time. But I 
think it’s a good idea, you get the doctors together, buy them dinner, pay them for 
their time, and let them discuss the drug and the best way to use it. I think that is a 
good idea. That was when we got the most useful information because we shared 
with each other our experiences and did not rely on research conducted by the 
industry. This is a good idea. It’s not that we are coming for the dinner, we are 
coming for the information. But when you look at it, all the drug companies have 
gone to marketing nurse practitioners, not the doctors or taking them out to 
roundtable dinner. That was the best system we had. (Dr. A) 
Theme 5: Competent and Incompetent Pharmaceutical Representatives Have 
Antithetical Effects Influencing Physicians’ Prescribing Decisions 
In a relevant retrospective study Joyce, Carrera, Goldman, and Sood (2011) noted 
physicians regarded pharmaceutical representative detailing as an important source of 
information. This study’s results support the findings of Joyce et al. but add 
understanding regarding the type and degree of influence – positive or negative – 
depending upon the skills of the pharmaceutical representative and resultant physician’s 
receptivity to individual representatives. Regardless of company or product, physicians 
expressed strong and consistent opinions, the most vehement of all responses to interview 
questions in this study regarding the behaviors and skills of pharmaceutical 
representatives. Perhaps one reason for this stems from the dynamics of interpersonal 




physicians’ time, lack of discernment, poor judgments in physician offices, deficiency in 
identifying customer needs or embracing a customer service orientation, poor product 
knowledge, high pressure tactics, and failure to deliver concise, valuable information 
physicians can use to augment quality care.  
Physicians also commented consistently regarding the counter-productivity of 
company managers when accompanying pharmaceutical representatives. Physicians 
noted the inappropriateness, redundancy, and superfluity of representatives’ comments 
when accompanied by managers, almost as if they must follow a predetermined script 
written by corporate or field management authors seemingly out of touch with the real-
world needs of their physician customers. The following excerpts depict physician 
subjects’ passion and may enlighten understanding of these findings: 
People who are so bought-in to their data they are not going to even look at the 
other alternatives as viable options. That just completely turns me off. If someone 
says “our medicine is good and we understand there are other good ones out there, 
here is what sets us apart. These are the side effects to watch for.” But when they 
start saying “you shouldn’t use this or that because you should be using mine, 
then I think they drank the Kool-Aid.” (Dr. L) 
Ahh, the people I abhor are the ones who are so doggone aggressive. And no 
matter if they see you sweating and people screaming, they gotta tell you every 
study and the outcomes and just my pet peeve. And most of the time I just let 
them finish but there have been a few times when I have not. But for the most 




to say but the ones who come around regularly, and say the same thing, I told this 
one guy you just can’t be that pushy, go push someone else.   
And I want to be treated the same way I treat them. Let someone come in and tell 
me about their product, leave samples, see how I am doing…that’s what I want. 
Most of the reps have made that adjustment. Unless they bring their supervisors 
with them and they have to make the points and I have to sit there and listen to 
them. It’s a game. And they ask me what if I bring my supervisor with me and 
that’s what they do. (Dr. C) 
Well I am pretty opinionated on this and I don’t want to step on anybody’s toes 
and the only representative I have ever met from your company is ideal. OK, I 
will tell you what turns me off, don’t ask me about my kids, don’t tell me I have 
cute shoes on. I despise that. Don’t try to kiss up. At all. Hate that. But give me 
real information, and I don’t want studies with 365 people, give me the down and 
dirty and I will listen. But if you’ve already stood there and talked to me for three 
minutes, which is three minutes I am supposed to be with patients, I am not going 
to be able to ask questions about what I really want to know. And I want to know 
the difference between the competing drugs, say, “Well the biggest difference 
between these two drugs…what my drug does versus what their drug 
does”…Now this may not be possible because they may not know what the 
AstraZeneca drug does or what the rep is saying. But it would be nice. The facts. 




But if you have to turn 4-5 pages, no, my eyes are glassed over and I’m thinking 
about my next patient. (Dr. O) 
Drug reps are good resources but the information is about their product but the 
information is biased and not objective… The one thing is the good reps are 
concerned about patient care. The worst ones are the reps that disregard the cost 
of their drug and whether or not people can afford it. (Dr. F) 
The best drug rep I will tell you, he is the best rep, he knows everything about his 
drug. He will bring in a clinical trial with highlights and quickly point out all the 
things I need to know. He knows everything. He knows what his competitors are 
doing and what the benefits of each drug are, he is so into it. But some reps I will 
ask them even the basic information and they don’t know. (Dr. D) 
I think pharmaceutical reps that have new drugs, that is one thing they can really 
do, they can hone in and give you clinical information about the drug to help you 
decide . . . I haven’t run across many who I would consider “bad reps.” You 
know,  most of them respect your time, are concise in their delivery of 
information, and I like the reps who are knowledgeable about their products and if 
you ask them a question and they don’t know the answer, they will get back to 
you. (Dr. G) 
The biggest thing for me is when you have a new product, I want to hear from 
you. I want to hear clinical data. I want to see studies. You know after you’ve 
seen them five times and you keep hearing the same stuff over and over again, at 




something new and I ask questions on it, I’ll expect a longer answer. If it’s a drug 
that’s been out for five years, you don’t expect a lot of new information on it and 
you don’t want to sit there and listen to the whole thing.  
I am much more receptive and I think they do a better job when the manager is 
not with them. They are trying to hit bullet points and I understand and I’ll sit 
there and listen to it and I know they are doing it for their boss and I’ll sit there 
and listen to it. But honestly, they are not as effective as when they are alone and 
they can relate to me on a personal level and give me the information I am 
looking for. The best drug reps know you and how you work and know the kinds 
of things you want to hear from. You know they’ll talk to you on a personal level 
and they will make their bullet points they need to make. When they hammer on 
you, it gets the opposite effect of what they want because they are pushing on 
you. (Dr. B) 
To me, they are a good informational source, biased of course, but  for me, I 
temper that. And If I am speaking with someone who is unfairly biased, I can also 
speak my mind as to why I don’t like the drug. Some of these reps coming 
through and I tell them this is a horrible product. I have actually told some reps 
they need to look for another job. I have told them this is a drug that is going 
nowhere and you better go somewhere where you are going to be employed for 
awhile. I would think the most important thing is to establish a relationship, has 
nothing to do with their product, has to do with the relationship. Say, “I know you 




time.” Then don’t take much of their time. Say, “Is there anything you are 
uncertain about with this product I can help you with?”  And say, “I can come 
back later if you don’t have much time.” Any offer to make the doctor’s day go 
better. (Dr. S) 
And usually the best drug reps are the ones you become friendly with and know 
them. I had one rep who I finally refused to see her…she would quote me the 
same slogan every time I saw her. It became a real waste of my time to walk 
down the hall. She wouldn’t say hi, I didn’t know anything about her. I didn’t 
know anything about her family and she knew nothing about me. I got the same 
words all the time. I think it’s important they not be pushy, that turns a lot of 
doctors off. Also, don’t like when they suggest why are you using that drug over 
another or gosh, why would you use that when you could use this one, that turns 
me off. I do remember one girl in the sample closet saying where are all these 
drugs going, we are not getting any scripts, what’s happening here? Well we 
ended up kicking here out of the office; she was obnoxious. I don’t understand all 
of the ins and outs of the pharmaceutical industry but these folks are professionals 
and I am sure they have quotas and have to sell so much of their drugs. So they 
have the tedious job of hitting their numbers and keeping the doctors happy at the 
same time. The best reps are the ones you can get to know a little bit, who are 
confident to me it shows they are confident in their product. That ok, I don’t have 
to give you the same slogan all the time it speaks for itself. There’s a lot to be said 




like crazy and when the reps walk in the patients get ticked. And they really don’t 
want me in the hallway spending a lot of time with reps. You know, a few of the 
better reps we invite back to the office. Back in the day which dates me how old I 
am, every company had one rep. And the rep came in and talked about all his 
products and he knew your family and you knew his family. But now face time 
became important and you have five reps for one product and the competitor has 
five reps and really, it’s, it’s a waste of our time. With so many reps coming in 
any more, I don’t think you have to have 20 reps/day. We’re either going  to 
write the product or we are not. You just see where we are with it… The one girl, 
it got so bad, I told her, every time you give me your sales spiel, I will write your 
competitor’s product three times. (Dr. J) 
Well the ones that turn us off are the people who walk in and say will you commit 
to writing this many prescriptions in the next week? And the people that think 
their drug should be the first line drug and I just look at them and say well the 
generic drug out there is the first line and they look at me and say well you should 
make my drug first line. I say there is a good $4 generic equivalent out there that 
is a good drug. I am never going to use your drug as first line so continuing to use 
that as your sales pitch is not going to make me very happy. I think it more of, 
you know, the high pressure, and they say, “When I come back in here you will 
have written at least three prescriptions for this right?” No. (Laughing) You know 
this is a small office and it is just me and the ones who just want to come in and 




look it up. The guys that say, “I see you are busy. I will check back with you”… 
they think of themselves more as a resource to me than someone that is trying to 
sell something to me. And I use them as a resource occasionally. “Have you been 
hearing of this side effect?” And they will tell me “yes” or “no” and what they 
have been hearing from other doctors. Well then they are useful and then there are 
days I am running around like a chicken without a head and its useful when the 
rep walks in and says, “It looks like you are busy and I will check back with you 
next week.” (Dr. T) 
Don’t try to push too hard. Be subtle, give information, be educated. If the 
doctor wants to know more about the drug find out about it. I am finding a lot of 
drug reps do not know about their drug. I don’t care how good they are dressed 
up. They need to know their drug…Drug reps have a role to play but doctors 
don’t have a lot of time. I know they bring lunch and so forth but just because you 
spent $10 for something to eat doesn’t buy me anything. I think if the drug 
companies just spend money on drug reps to educate the doctors and not 
consumer advertising this is much better and will save money, instead of drug 
companies spending $500M on consumer advertising. The advertising costs much 
more than the drug. And the thing is it doesn’t matter, all of these drugs are the 
same. If the FDA wants to help, they should stop approving drugs that cost so 
much. I can prescribe prednisone for $4 but instead patients want drugs that cost 
$250 and don’t work any better. Supreme Court in India ruled on lowest cost 




And it’s more the big pharma reps who recite just like they were trained. Doctor, 
let me show you this brochure and they want to go through all 12 pages of studies 
which is great if it’s new and a revolutionary product and if I have the time. But 
they are not going to vary from their presentation because that is what their boss 
told them to do and they finish with, Can I count on you for the next patient and I 
think really, we don’t do this. I like the guy who comes in and says hey doc we 
just finished a study on X and if you are not too busy, let me show you the 
highlights. Not right now I don’t have time. Great next time or may I leave it with 
you?...It’s those reps who can vary their patterns who know if I am busy and they 
just need a signature and leave me alone until next time. That goes much farther 
than the person who says well I will wait, you go and see another patient and then 
we can talk.  The ones that don’t read the physicians, you get tired of them. You 
know we started in the old days when we had one Merck rep, one Lilly rep, one 
Boehringer rep, and you could count on that rep to take care of all of those 
products. And then they went through the phase when you’d have six Merck 
Reps, 5 Pfizer reps, 6 Lilly reps and you’d have six Merck reps in one day and 
you wouldn’t know which product they were carrying.  Gosh guys I don’t have 
time for this. It’s let me remind you about my product, here are the side effects, 
what can I do to help you, I would love to leave you samples, or what data can I 
get you, what can I do to help that’s what you need. What’s the cost of your drug 
for my patients who don’t have insurance may be all I need to know. Yes and 




true education on it from the rep. And it’s almost a façade and I have to say are 
you really trying to help me here or not. Because I gotta figure out how to use this 
drug. Tell me how to use this product because it’s not working for me this way 
and I need some true education about this product. (Dr. V) 
Dr. L: “…[sometimes need them to] answer a formulary question.”  
Yes. The best rep is the one who will come here and talk to me, not just about 
what he sells, I want him to come and educate me. This is my product and it has 
this and this and this and this. And then there are other drugs on the market, 
similar to ours, but this is what ours does better. But if someone comes here and 
says all these other drugs are crap, don’t even waste your time, this is the best you 
can prescribe, well, I would say this is the worst rep. (Dr. I) 
Best rep, friendly, easy to talk to, has a drug that is actually helpful, I do feel sorry 
for reps who have drugs that are not very good – there are other drugs in the 
therapeutic category that are actually better. Usually one or two points are all I 
can really tolerate, one to remember but if it gets into 3 or 4 points I really don’t 
have that much time, quick to the point, friendly, samples, one who have discount 
cards as well. Worst, ones who take too long or those who ask for a specific 
number of patients: “Maybe could you start one or two patients on this drug this 
month?” You know, the hard sell, that is really a big turn off for me. Just lay out 
the points, this is how many points this lowered cholesterol, this can really help 




The only drug reps that are going to bother me are the ones who insist upon 
pushing the envelope. In other words, they know what the rules are, they know 
what they can do and what they can’t. You don’t have to be the brightest person 
in the world to understand that. If they interrupt me when I am in between patients 
and they see I am busy then I am going to be upset. So walk in the door and get it 
done whether you have samples or not. I don’t particularly like it when people 
hold up brochures and go through them page by page. If they have one sheet and 
they want to make a point then make the point. In my opinion, what you need to 
do is be aware you are providing a service, not an advertisement. If you want to 
provide a service no one is going to give you a problem. If you walk in and say I 
have a new drug that may be of use to you and you give us the stats and be on 
your way, no one is going to have a problem with that. If you try to sell me on the 
same product and say the same thing over and over again, that is going to insult 
me. I got it three times ago. I like it when they come in and describe their product 
and tell what patients to use it on but not ask now what or how many patients are 
you going to prescribe. (Dr. E) 
The best rep is knowledgeable about the disease process to begin with, and then 
knowledgeable about their product, has to be knowledgeable about their 
competitors. You know I lean more towards the one who has a scientific 
background, who can answer my questions on a scientific basis. And then give me 
the information when I want it and not try to give me all the information when I 




give me the full detail, when every room is full and they have no respect for my 
time. And I am just really not going to listen to anything they say. Whether they 
give the whole spiel or not. (Dr. R) 
I like it when they come in and describe their product and tell what patients to use 
it on but not ask now what or how many patients are you going to prescribe. Right 
now if they say will you write this for the next 10 or 15 patients that will be the 
last time I talk to them. (Dr. M) 
I like it when it appears they have some honesty about them and they are going to 
tell me what is in the clinical studies and so forth and they are not going to hide 
studies from me. I mean I know they all do it to some degree but I like to feel that 
if I answer a question I am going to get an honest answer. Usually I’ll ask a 
question I know the answer to just to see what they say and if they are lying to me 
I won’t listen to anything else they have to say. (Dr. K) 
Theme 6: Samples Are a Valuable Influencer to Some Physicians 
Drug sampling as an influencer was supported by Joyce, Carrera, Goldman, and 
Sood (2011), who noted pharmaceutical representatives’ drug sampling provided greater 
flexibility for low-income patients as well as clinical experience for physicians. The 
findings of this study may complement the main tenets in the Joyce et al. (2011) study by 
providing information relevant to the changing health environment physicians are 
witnessing and will witness in coming years, catalyzed by new health care trends and 




by samples, but at the same time, acknowledge private and government payer pressures 
to prescribe more generics have resulted lower sample supplies.  
Transcript excerpts provide more specificity regarding samples as a decision 
influencer. For example, Dr. L stated: “I prefer samples to coupons. Most of the time I 
don’t think patients take the coupons.” Dr. M advised: “To give good service, bring 
samples.” Other physicians explained their positions regarding samples thoroughly:   
[Samples are] Big, big. You see, I’ve been a physician 30 years, and in private 
practice 24-25 of those. And samples have always been huge. They can try the 
product and see what the toleration is before we start spending money. It has been 
an unfortunate lack in recent days. Everything seems to be generic. (Dr. R) 
And I think that’s where samples help a ton. Give somebody two or three days 
and let them take it. Cause we’ve all seen it. You write them a script for $100 and 
they take one pill and they have a side effect and can’t do it. If I had given them 
that pill and they had the side effect I would have saved them $100. Or they could 
say gosh I love that stuff and can take it forever…A lot of times it depends how 
long they are going to be on it. An antibiotic, don’t give me two when I have to 
write a prescription for five more, that doesn’t do any of us any good. So at least 
give me a whole pack so I can give it to one patient today and then if it works I 
can write scripts for other patients because I got good feedback. Now with a 
longer term product give them a week’s worth of samples and usually they will 
fall in love with it. If it’s something like a statin drug where they are going to be it 




it for a long time. And you don’t need three of these, you need two months’ 
worth.  So it varies. With acute type stuff it’s different. And that’s where the 
samples come in to make sure they are not going to turn green on the stuff after 
spending $50 for pills. Oh sure, the other problem with coupons…I think patients 
sometimes get pushed back from the pharmacists. I don’t know how coupons 
work on that end but I get the impression from other physicians pharmacists get 
tired and don’t want to fool with them. In some cases they turn the coupon into 
pharmacists and then pharmacists have to get the coupon to you and in some cases 
they say the pharmacist would not honor that. That’s the only problem when the 
patient must present the coupon to the pharmacist. (Dr. W) 
Practically speaking, there’s not a lot of difference between those medications but 
what is the patient going to get? The one that is on my shelf. Because I can give it 
to them, they can try it, and they can see how they do. So that is the one thing that 
is out there that I think is the elephant in the room out there that pharmaceutical 
companies and drug reps do not see. The government says ahh you are making 
people spend more money. No I am not, I am helping people spend less money. 
I tell you what, you may not want to know this but what does affect what I use is 
what I have on my shelf. You know if I am looking at a diabetic medicine because 
I am dealing with a lot of people who pay cash money I will look at what I have 




Theme 7:  Most Physicians Have Negative Opinions Regarding Direct-to-Consumer 
(DTC) Advertising but DTC Increases Product Awareness 
 The results of this study confirmed and expanded the findings of Frosch, Grande, 
Tarn, and  Kravitz (2010), who examined proponent and opponent studies from peer-
reviewed literature. Frosch et al. (2010) determined ads frequently did not disclose 
alternative treatments, risks, or costs, and prompted patients, many with insufficient 
education or understanding, to request physicians to prescribe an advertised drug, the 
same complaints voiced by physicians in this study. Frosch et al. also determined 
physicians may not have seen the advertisements for drugs patients requested or were not 
fully educated regarding new drugs at the time of patients’ requests, ads increased 
requests for advertised drugs, and these situations predisposed conflict with the 
physician-patient relationship. This study differed from the Frosch et al. study with 
respect to approximately one-third of physician subjects who offered positive or neutral 
responses. 
Categorically, physicians acknowledged DTC increased patient and physician 
awareness. One physician observed most DTC advertisers promote expensive products 
and therefore, demand for those products is tempered by patients’ unaffordability. One 
physician opined DTC may increase patient visits and a few physicians stated DTC made 
his job easier because patients already accepted the prescribed product. Second to the 
physician emotion voiced over pharmaceutical representatives, physicians who opposed 




 I generally don’t like it [DTC] especially TV commercials, and it’s usually for 
conditions that are not life threatening, they are more lifestyle based…things like 
testosterone and bladder control agents things like that…Viagra…things that are 
not really important to the long-term health of the patient. Things like that irritate 
me. (Dr. N)  
You know. I don’t think it has as big of an impact now as it did when I first 
started. Because now all the stuff that is going direct to the consumer is more 
expensive. Cause the patients come to me and say I saw this commercial on TV 
and I should try Cymbalta and I say yeah you could try that and then they come 
back and say maybe I could find something cheaper. (Dr. T) 
[DTC] has had its place, at times to bring a topic to people’s awareness. And you 
could use testosterone as one of those issues but it has probably been for a greater 
percentage of the time, a detriment. Where people come in and they say I want 
that purple pill and they don’t even have reflux, and what makes you think you 
need the purple pill? (Dr. R) 
That is a big turnoff. Myself, we don’t have TV, so I don’t know what’s on TV, 
so I don’t see a lot of that stuff. But it’s a turnoff when a patient comes in tells me 
they want it. But that doesn’t mean I won’t write it for them but it is annoying. 
(Dr. O) 
To tell you the truth, I don’t like it. I don’t like it because the patient doesn’t 
know the whole picture. They just see what the pharmaceutical company wants to 




be treated with no major side effects by taking this medication, because let’s face 
it, part of the treatment is placebo. On everything, no matter what, people taking 
Echinacea or something like it, it helps with the flu. Well maybe, but a big 
percentage of people get better on their own, but the idea of taking something 
helps them get better. So if someone wants to take something and I don’t see any 
major problems with side effects or interactions then I say take it, try it, and let’s 
see what happens… Like osteoporosis, I took Evista for a few days and I feel 
stronger. Well you’re not going to feel anything for at least a week (laughing) but 
I know the difference. It won’t help you for at least a week but the patient says 
well I took Evista yesterday and I feel it in my bones, stronger. So I say if you 
want to take something for osteoporosis you might as well take Evista because 
you say it works. In that case I would go for it. (Dr. I) 
Umm (sigh)…I think most physicians initially felt it was a bit insulting 
thinking they were taking power away from us but you have to be able to deal 
with it. You have to know patients are going to find out things on line. Normally 
the people come in and ask, and half of them are candidates and half of them 
aren’t even close. So uh, the big one now is Low-T, the low testosterone. Number 
one, was that created by drug companies? Is that a real issue or one created by 
drug companies? Low testosterone, there are still physicians who believe the issue 
was created by drug companies to sell their drug. So I think most physicians are a 
little leery of the big pharma anymore. They are more leery and they don’t believe 




go, but you know what it generates patient visits. Maybe it isn’t all that bad, 
maybe we are all in this together. But they stuff they direct market to patients I 
would say about ½ really need what they come in and ask for. (Dr. J) 
It changed things so dramatically in our world from the standpoint…you have to 
ready to deal with it. Both the good and the bad of it. You now that they are a 
little more informed. If it’s not I saw it on TV then it’s one of their friends, so we 
have to deal with this stuff all the time. And everybody in our practice knows 
somebody, and that person told them they oughtta talk about this…I think it 
impacts us…I don’t think it sways me enough to say oh yes, you definitely need 
to be on that, now, if it’s a toss-up between two or three things I will say, I don’t 
have a problem with that. I won’t put somebody on it just because they say they 
want to be on it…So you are trying to stay as much as you can off the radar with 
the news so you know they are not reading 8 million things about it every day. If 
they hear a negative story they are going to want to stop it immediately and if they 
hear about side effects they will be pre-programmed to experience those side 
effects. (Dr. V) 
Um, it has its place. Certain things are good like getting the name out. 
Unfortunately, the legality of things, they also hear the bad things 15 or 30. Take 
this drug and it is great but the side effects could be death, loss of bowel control, 
or something. So in some cases it makes my job actually harder. Sometimes they 
come in and ask for a drug and it is absolutely the wrong one for them. There are 




Cymbalta first came out as an antidepressant well, some patients did want to take 
it because they knew it was an antidepressant. Now recently they got it approved 
for what is pain control. Now they know it is for pain and they will take it but you 
can actually get by and use it as an antidepressant. (Dr. B) 
Now I love, let me say, I love consumer advertising. I love it because it makes my 
job easier. Like Abilify. People are ready to accept it. They are ready to take it. 
On the other hand if it is like that bladder control medicine, that is something you 
are supposed to report. People sue for taking it, they can make money on it. So 
there is that part, the part that is negative, but the positive part is really helpful. 
(Dr. S) 
You know, if it’s a drug I am familiar with I don’t have a particular problem with 
it. You know some of the pharmaceutical companies have done very well with 
their consumer advertising. In the old days we didn’t have drugs advertised on TV 
just in journal ads. The bigger problem I see is for drugs I don’t know OTC that 
may be advertised online, supposed to cure this that or the other, you know, 
herbal remedies or something they think is God’s greatest gift to medicine. I say I 
don’t think it will work and try to downplay those but if they are insist, I tell them 
to go ahead and try it. I suppose a lot of people make a lot of money with these 
kinds of non-prescription drugs. And I don’t get a lot of patients who come in and 
ask me for advertised prescription drugs. Of course drugs like Viagra, guys use 
the ad as a way to introduce a problem. Overall, I don’t oppose consumer 




learned a long time ago if a patient doesn’t feel they are getting what they need, 
they will go to another doctor. Now if it’s a reasonable thing we will talk about it, 
but overall, I am not opposed. (Dr. G) 
I would say it affects in you in that it brings disease states to the front normally 
patients would not talk about. So, for erectile dysfunction people weren’t coming 
in and saying I have erectile dysfunction. With seven minutes to say what’s 
important to them about their heart you don’t have a list where you get down to 
say is everything working all right for you. So direct-to-consumer advertising 
there made people feel comfortable enough to come to the doctor and talk about 
it. (Dr. L) 
I hate it…I look at the patient and wonder why they want it, if they are short-
focused. They are the consumer. Direct to consumer advertising, this should have 
never happened. The reason is you bring the company between the patient and 
me. I may not have a problem with the drug, but the patient asks for it, I have to 
get prior authorization, and then the patient finds out how much it costs and does 
not want to pay and I have to deal with it. Take testosterone, Androgel, putting 
these ads all over, testing testosterone has gone up by 1,000%. My prescriptions 
have gone up by 1,000 %. Whether the patients need it, probably not, many of 
them are border line and want it.  
Now they are talking about how many side effects they have. Nexium, 99% of 
people does not need Nexium. I am told Prilosec will do the same as Nexium but 




direct to consumer advertising. The government should let drug companies and 
their sales people give information to the doctors and let the doctor decide and not 
advertise to the consumer. (Dr. A) 
Theme 8: Lost Influencer Opportunities: Physicians Need More Dietary 
Supplement Education (Including N-3 Education) and Lack of Dietary Supplement 
Curricula in Medical Schools 
 Physicians who knew the benefits of certain dietary supplements including n-3s, 
those physicians were more enthusiastic about recommending these products and stated 
they took a more active role advising their patients to take these products. If physicians 
were unfamiliar or uncertain about the efficacy, safety, quality, or cost of certain dietary 
supplements including n-3s, they expressed skepticism and would not recommend such 
products to their patients. Several physicians explained deficient medical school curricula 
regarding dietary supplement education.   
 Physician subjects, in general, desired credible, evidentiary information and 
education regarding n-3 efficacy, safety, quality assurance of products, and costs. Most 
physicians expressed more concern about dietary supplement quality assurance than 
FDA-approved and monitored drug quality. The transcript excerpts below support these 
findings and accentuate the importance of physician personal experience with dietary 
supplements and specifically, n-3s:  
It is hard, really hard. Patients come in and tell me they are taking supplements 
but they have no idea about the quality of these supplements and neither do I…I 




products anywhere. You just don’t know about the quality of these products. I 
look at supplements and try to determine if a supplement is going to hurt them. 
You know I’ve had several people come back to me and say, whether this is a 
placebo effect or not, “you know I feel better when I take my supplements. I sleep 
better, my energy is better, I don’t know.” But I am more confident in a 
prescription medicine because I feel more confident in what they are getting… 
There is a lot of evidence and I think more should be taught in medical school, 
having just gotten out of medical school. I think maybe it might not get 
recommended or advised. (Dr. F) 
[Quality of supplements] Now that…now that…you’ve got me there. That is 
something you could definitely put…that I would not be aware of. You 
know…eh…this one is better than this one because we do this…I don’t know that 
about this particular product…if it’s a prescription for a patient I have prescribed 
then I know that but for this kind of product…if you come in and tell me hey we 
don’t have mercury we go the extra mile then that’s darn right I’m going to use 
your product. That highly influences me. (Dr. H) 
It’s difficult. I don’t know who’s doing the studies and how can I judge one 
manufacturer of omega-3 versus another manufacturer of omega-3? It’s a tough 
thing and usually I am trying to determine if I have heard anything bad about this 
product and you won’t hear me recommend a product unless I know the 




Right that’s tough, and those [dietary supplements] aren’t FDA controlled. We 
don’t learn about those in medical school. And if I don’t have a personal interest 
in it, I don’t even know about it so, well some of it I do know something about 
and some of it comes up in Prescriber’s Letter. They will provide some 
information about some of them from time to time. For example, if you have a lot 
of patients on coral you should know coral can cause deterioration of coronary 
arteries. And sometimes a patient will come in and say I am on ribo-something or 
other and I just say, You know I don’t know anything about that. I’m not saying 
you should or shouldn’t be on it but I don’t know anything about it. So, I don’t 
have to know anything about that. (Dr. O) 
If it’s an over-the-counter product, I am not sure. I guess the information is 
available somewhere but if it is, I don’t really see it much. I am hoping what they 
say is in the product is really in there and I am hoping the FDA or somebody is 
looking over these products to make sure they are OK. That’s really about it. For 
me it’s a pretty murky area…for some patients if I do recommend a supplement I 
tell them to stick with a name brand people know. There’s lots of them out there, 
calcium, vitamin D supplements, but I tend to have them stick with a name brand, 
a few names that I know of…kinda stick with those. (Dr. N) 
Well, a lot of times I don’t know what it is and I tell them I don’t know and can’t 
give them any advice on it. Yeah, I know there is a big variance on them and I 
don’t have enough information to evaluate them. Quite frankly that is something 




so I think the biggest problem you are going to have is getting the information out 
there…like I said we don’t get a lot of this information in school so it depends 
upon how interested the physician is in the subject and how much time he will 
spend on it.  If you have something the physician can give out to the patient and 
he knows [the n-3] is a good product, then it is going to go a long ways. And if I 
know it’s a good brand I will recommend the brand  and this goes a long way…as 
long as I know it’s affordable. (Dr. B) 
Yeah I see patients who say, “I am taking this red yeast rice”. I haven’t seen that 
work. (Laughing) But you have fun with that. I have not seen one patient where it 
worked but they say yeah taking this red yeast rice. I am not going to tell you not 
to take it but I think you might be wasting your money. I go look I up or Google 
it. I have an over the counter PDR as well. What is it, what is in it and try to find a 
reputable source. Try to compare something with what the patient is taking. 
Attempt to tell people not to take supplements very often especially if they are 
taking something with ephedrine. And if they are borderline high blood pressure 
and I tell them their problem is this pill. (Dr. T) 
When you go out and start buying stuff over the counter, you can’t guarantee 
what patients are going to get. I was talking to a patient the other day and she said 
I got a bottle of those fish oil pills and they were terrible. I smelled the product 
and it was fishy nasty. I like pure products with labels that tell what you are 
getting the DHA and EPA. We know one pill a day meets requirements and if I 




the other thing is they go to Sam’s and you look at some of their omegas, and they 
got 6s and 9s combined with 3s. Well that’s counterproductive because we are 
trying to change the ratio between the 3s and the 6s and they’re just defeating the 
purpose…You take the amount of 3’s in the puzzle and in fact you’re left with 
very little 3s. In fact it might be detrimental…We want the ratio of n6 to n3 to 3:1 
or 4:1, but in our diet it’s become 10:1 or 12:1. So you want to get rid of that, and 
the purity. There was a study done with the athletic trainers, and I think the 
[Consumer Reports] study was done in 2008. And the amount of impurities in the 
product, it was about a 30% impurity rate. They found traces of arsenic, mercury, 
PCBs. Our oceans are polluted. (Dr. J) 
To tell you the truth those supplements are anything patients can get without 
prescriptions and without asking the doctors, the majority of them they come to 
me and they have already been on supplements. And they have been influenced 
by friends, relatives, TV, magazines, whatever…what I recommend to people if 
they don’t take anything, I recommend a well-balanced diet with a lot of fruits 
and vegetables, give you the majority of vitamins, nutrients, anti-oxidants that you 
need. If you want a supplement, a one-a-day multi-vitamin is adequate. If you are 
a man, I recommend saw palmetto just because of the prostate protection. And 
men and women, I recommend they take one baby aspirin... unless they have a 
problem. And women, menopausal, should be on some type of calcium 




Well I am a big statin user. I have used n-3 along with statin, probably would use 
n-3 alone. Now a lot of people talk about being on fish oil. I am not sure I always 
appreciate the kind of fish oil they take, basically if the numbers are where they 
need to be OK, if not we need to make adjustments. With supplements, the 
evidence is not quite the same the FDA requires to approve drugs.  Not the 
scrutiny of production, someone could say they have an n-3 but it doesn’t have 
what it says in it. So I caution patients and tell them let’s be careful take this stuff 
and let’s see what it does.  If it’s working, I wouldn’t pay an arm and a leg for this 
stuff. So I guess my approach is cautionary. Except I do see the value of n-3s, a 
multivitamin, saw palmetto for prostate…when I write a drug I know the dosage, 
the quality, the side effects. When my patients take an omega-3 I don’t know the 
quality and if they are going to have side effects. A big discrepancy. They 
probably think they are harmless. (Dr. G)   
I had a lady come in the office the other day, showed me a supplement, 
and the label, because she wanted me to know how wonderful it was and I looked 
at the label and there were 23 different ingredients. Twenty-three different 
medications. And I said to her, “You realize there are 23 different medications in 
this supplement,” and she said, “yeah.” And I said, “I don’t want you to think I 
am poo-pooing it because I am not, I am telling you there is 23 different 
homeopathic ingredients here that are medicines, of course they are not natural, 
they didn’t fall off a tree, they went out and filled up the bottle with whatever, so 




had a headache and I gave you 23 prescriptions, would you come back to see 
me?” “Well, no.” That is my feeling, there are some very good, n-3s probably 
serve a purpose but there are people who abuse supplements because they don’t 
understand what they are doing. That is my personal opinion. (Dr. E) 
And with n-3s sometimes I will add to drug regimen. But it’s results and that’s for 
all medicines. I don’t like a lot of supplements because I don’t know what they 
are putting into them. With drugs, yes but supplements not so much so I allow 
them to take cinnamon and fish oil and that’s it. Way too many brands but if they 
bring me the bottle I will look at it and I will tell them I don’t know what that 
ingredient is or that one and therefore you should take it…except cinnamon and 
fish oil. (Dr. D) 
I think there is definitely a place for them. I wish they were better studies. Not all 
of them. Some of them have good studies. Generally speaking, they are not held 
to the same [quality standards]…And when I am recommending a supplement 
knowing there are such differences, I am not sure which brand to recommend so 
that puts a lot back on my shoulders. Or if I recommend the wrong brand a) they 
are not going to get what they need or b) they are going to get something 
deleterious. So I feel there is a burden there and I’m not sure it should be my 
burden. Or at least I am not adequately trained to know. And that’s a little bit 
frustrating. I’ll tell you when I have someone who really likes to be on a lot of 
different supplements and avoid any kind of pharmaceuticals, prescription 




the research. You know there are certain sites where they can evaluate the 
different brands and the different compounds. So I put it back on their shoulders 
as much as I can. They like to be on a lot of different things. Otherwise I just try 
to stick to the few things I can trust. (Dr. K) 
I hate like hell to tell them to buy fish oil because I have no idea what they are 
going to end up with…I like the idea of knowing. I like the idea of knowing it’s 
going to be effective, easy for the patient to get, and affordable. So effective, 
affordable, and compliance. (Dr. S) 
It does come up a lot. I tend to get a little more excited about it for healthy people, 
for prevention. If somebody comes in and they’ve already had CABG, diabetes, 
and other problems I am not sure how much this is going to help. But if someone 
comes in and is healthier, maybe with a family history of heart disease but not 
eating right, but is overall healthy, this I think is where omega-3s come in and can 
be pretty beneficial. (Dr. N) 
I tried myself to take it, a few months ago. I had such a bad odor in my mouth, 
fish odor, when I would burp, so I don’t know if there is another way to take it to 
eliminate this kind of side effect, so people more willing to try it…My wife went 
and got some because I told her we both should try taking n-3 so I don’t know 
what she bought. But man we both had the side effect and then said the hell with 
it, you know burping fish everyday (laughing)…But when I tell people to put 




When I was writing Lovaza from time to time, and they say to me can’t just take 
fish oil over the counter and my answer to them, remember those Total 
commercials they use to have, you know you could eat those corn flakes but you 
would have to eat 14 bowls to get the nutrients in one bowl of Total. So I tell 
people you have to look at what is equivalent and you would have to take like 16 
tablets of your fish oil to get the same fish oil that is in the 4 tablets of Lovaza so 
you have to decide is it worth it to you to take 14 tablets of fish oil a day. (Dr. T) 
You know it’s [n-3] been of interest for its anti-oxidant effects for a long time. 
You know I can’t review all the literature and I’ll go to lectures and let’s say half 
a day we are going to do cardiology type of stuff. And they present articles which 
may be inconclusive regarding omega-3. But I have used Lovaza and I’ve see 
triglycerides drop 50%. I’ve seen HDL raise, they’ll tell you 20% but I’ll tell you 
maybe 10%. And I haven’t see it do much of anything with LDL. (Dr. T) 
But you know that’s a pervasive one. Almost everybody knows about n-3s. And 
n-3s have positive effects on inflammatory properties, and cholesterol, I know 
something about that and I am going to recommend n-3s. But you come in and tell 
me about something well gingko I know about, but some others I’ve never heard 
of, no. Now n-3s, that’s easy. (Dr. O) 
 
 




Physician subject comments regarding influencers of their decisions to prescribe 
or recommend products have broad implications for industry and society. These 
implications apply to professional practices of health care regulators, physicians, medical 
school educators, and marketers of drugs and dietary supplements. For regulators, the 
abundance of conversation and prioritization of cost as an influencer reinforces the 
effectiveness of insurance company and government policies to drive down health care 
costs. Also, physician responses supported the need for FDA regulation of DTC 
advertising and manufacturing quality of drugs and dietary supplement manufacturing 
quality provide valuable safeguards for society.   
N-3 marketers should consider medical school students and residents may benefit 
from reading the findings of this study regarding dietary supplement education. All 20 
physicians interviewed expressed inadequate dietary supplement training in medical 
school. By providing useful prescribing information, n-3 marketers may facilitate 
physician-to-patient communication and result in safer and more effective dietary 
supplement intake among members of American society.   
Pharmaceutical marketers may also benefit from other findings in this study.  
Credible clinical proof, personal experience, and cost are certainly essential influencers 
of physician decisions to prescribe or recommend products. Other important influencers 
vary in importance depending upon the physician, but include the influences of peers, 
pharmaceutical reps, DTC advertising, samples, and dietary supplement education. 




respected journals by credible investigators. Studies with optimal design should be 
double-blind, randomized, and placebo-controlled with a large number of subjects.  
Considering the importance of personal experience as an influencer, marketers 
may increase the emphasis of personal use by physicians or third-party testimonials. 
During interviews, physicians repeatedly emphasized drug and dietary supplement 
marketers underestimate the importance of cost. Marketers should disclose clearly costs 
of medications and supplements to physicians and should make cost disclosure a sales 
and marketing message priority. Worthy of emphasis, in the physician ladder schema of 
influencers cost elevated to a primary decision influencer as perhaps the third most 
important ladder rung after credible clinical data and physician personal experience. 
Marketers should remember to serve physicians as customers rather than 
aggressively attempt to sell them products. Physician subjects provided strong negative 
responses to deficient pharmaceutical representative skills and lack of tact and 
consideration of physicians’ time. Pharmaceutical marketers may be better off without 
pharmaceutical representatives than to deploy pharmaceutical representatives without 
adequate training or with inappropriate service philosophies regarding physician needs. 
Physicians essentially regarded pharmaceutical representatives with these deficiencies as 
incompetent.  As an extension of pharmaceutical representatives’ services, most 
physicians viewed samples as useful when practical for marketers (i.e., brand name 
products with no generic substitutes) and samples serve as a potent short-term brand 




Marketers should heed the opinions of subject physicians in this study, who 
commented consistently regarding the counterproductivity of company managers when 
accompanying pharmaceutical representatives. Physicians noted the redundancy and 
inappropriateness of representatives’ comments when accompanied by managers. 
Marketers should ensure field managers understand the needs of their customers and not 
impose inappropriate or irrelevant sales points during representatives’ conversations with 
physician customers.  
 N-3 marketers should present credible information and education regarding n-3 
efficacy and safety. Because subject physicians expressed more concern about dietary 
supplement quality and lack of knowledge regarding quality than FDA-approved drugs, 
n-3 marketers should provide more evidence of quality assurance and purity of n-3 
products. Marketers should design easy-to-understand handouts physicians can use to 
describe and explain the value and differences of quality n-3 products to their patients. 
Patients’ understanding of quality n-3s may be more difficult for lower educated patients 
less inclined to engage in preventive medicine behaviors (Nelson, Reyna, Fagerlin, 
Lipkus, & Peters, 2008). A number of physician comments support the positioning and 
marketing of n-3 products.  
For example, Dr. H stated: “For men and women over 40, n-3s would be 
excellent.” Dr. D advised n-3 marketers: “The key may be to let the doctors know and if 





Now as far as something like an omega-3, we already know it is a benefit. Now I 
am going to be looking at is this product as good as something else. Is it cheaper? 
Are there going to be side effects from it, like a fish burp…my own personal 
experience is going to bias me a lot…those are the things I am going to be 
throwing into my head all at one time. Let me respond back on something. You 
were talking to me about quality. It is really important for me to know, to be able 
to say, here is an over the counter product that is high quality. Like Lovaza, I have 
no doubt this is a supreme product, goes through a lot of testing. They take out the 
impurities and crap and doesn’t have fish oil burp problem the other do and so 
you know you are getting a uniform product, but if I know there is an over the 
counter product that is as good or can do as good a job and save the patients 
$100/month I am happy and my patients are happy…I will be pretty excited about 
saving patients money and I feel like I am doing the right thing for the right 
reasons. (Dr. S) 
I would love to see a large study that shows the clinical benefit. N-3 arm, no n-3 
arm, costs a lot of money to do this, takes it out for a long period of time. And 
what’s your end point, could be heart attacks, strokes, fatal heart attacks, fatal 
strokes, peripheral arterial disease. (Dr. R) 
I have a handout from Mayo in Cleveland and it tells them what to look for in fish 
oil and I print it out and give it to them. They say the same things as you: the 3:2, 
you don’t want n-6s because you have plenty in the diet already, does not go into 




aware of the patients who have had heart attacks and there are many cardiologists 
who have all their patients on n-3s and then there are some who say they don’t 
need n-3s because their patients are on statins. And I am not sure who is right and 
who is wrong depends upon the literature you read. I think the thing is if you have 
a well-designed marketing piece I can give my patients because if it takes me 30 
minutes to explain, forget it. Let me tell you about omega-3s and here is 
something to read…the 3:2 ratio, the purity, and they can go home and digest it. 
Now whether it has your branding on it or not. Some give these blatant, retarded 
pieces and obviously we don’t hand them out. They go in the garbage. Well-done 
handouts help us educate patients and save us time. (Dr. W) 
If someone has and LDL of 130 I am probably not going to see if go any lower 
than 120 but I can get a triglyceride of 250 down to somewhere in the real world, 
somewhere it should be. And usually we are dealing with a patient who is taking a 
statin already and I say we got your LDL down to 60 but your triglycerides are 
still 410 are you eating every carbohydrate you can find? And those are the folks 
where I say let’s try the omega 3’s and see what happens.  (Dr. T) 
You know in medicine we talk about the four A’s of success. Ability, Affability, 
Affordability, and Availability. Those are the four A’s of success, there may be 
fifth one is some schemas. So affability is it packaged well does it look good like 
it will do the job, ability does it meet the needs of the patient, will it do what it is 
supposed to do, affordability can the patient pay for it. And then availability and 




probably a subset of people who would like one of those the most better than any 
other, some would work all 3 ways, some only at the store, some hardly ever go to 
the store vs. online. (Dr. S) 
You pretty much touched all bases. Everything we learn today is from our peers, 
in print or the Internet, and the third one is our reps. So if you want a successful 
product you have to attack those three areas: you have to have doctors talking 
among themselves, print and Internet, and pharmaceutical reps. (Dr. I) 
Implications for Social Change 
From the outcomes of this qualitative phenomenological study, I filled a gap in 
related literature by providing marketers of drugs and dietary supplements insight 
regarding how physicians make prescribing decisions. A better understanding can 
facilitate communication effectiveness between drug and dietary supplement marketers 
and physicians. Physicians who increase their understanding of drug and dietary 
supplement usage may improve prescribing efficacy and safety for patients. Physicians’ 
understanding of n-3 preventive cardiovascular disease benefits may result in more 
frequent physician recommendations of n-3s to their patients, resulting in more n-3 intake 
in the American population. Nearly all physicians that I interviewed (18 out of 20) opined 
if our society consumed more purified quality n-3 supplements, our societal risk of 
cardiovascular disease would decline, especially if members of our society would 




Recommendations for Further Study 
Action defines the top ladder of inference rung, a change in behavior. N-3 
marketers may find useful a follow-up study with the same physician subjects to 
determine if the mere interview and discussion of n-3s resulted in behavioral change (i.e., 
increased contemplation and prescribing of n-3s). N-3 marketers may devote more study 
to the optimal design of teaching materials for physicians and for patients. Follow up 
study with medical schools regarding dietary supplement education is yet another 
opportunity for further study. Considering the outcomes of this study, a follow-up 
quantitative study investigators may further substantiate, confirm, and advance the 
findings of this study. Last, more study could be devoted to understanding the impact of 
improved dietary supplement training for pharmaceutical representatives as well as field 
managers. 
Reflections 
From this experience, I learned more about how physicians determine which 
drugs and dietary supplements they will prescribe and recommend. I was also exhilarated 
by the richness of dialogue revealing the inherent goodness and dedication of physicians 
as caring human beings for their patients. Although I was careful not to interject my 
personal bias regarding the preventive cardiovascular health benefits of n-3s, the 
discussion of clinical evidence was strong enough on its own to impassion physicians’ 
convictions to increase their recommendations of n-3s. From an interview-execution 
standpoint, when physicians freely admitted they did not have adequate n-3 knowledge, I 




inappropriate, would have embarrassed physician subjects, and would have negatively 
affected essential rapport.  
Coding and interpretation of data was more complex than I originally conceived. 
As recommended by professors and cited authors in this document, long periods of 
reflection aided the crystallization of eight meaningful themes. Additionally, conferring 
with another coder reinforced the rightness of developed themes and added validity to 
study findings. As one in the pharmaceutical industry, I may have found physician 
subject responses more interesting and relevant than to readers outside the industry. Last, 
my personal skills certainly improved in data collection, data analysis, and reporting of 
study findings. 
Summary and Study Conclusions 
The purpose of this qualitative, phenomenological research study was to improve 
understanding of how physicians reach decisions to prescribe or recommend products and 
which influencers may be the most important to physicians. The findings revealed three 
essential influencers including clinical evidence, personal experience, and cost of drug or 
dietary supplement. Other influencers varied in importance depending upon physician 
individuality: influence of peers, pharmaceutical representatives, supply of samples, 
direct-to-consumer advertising, and knowledge of dietary supplements. I developed eight 
themes related to decision influencers and provided pragmatic recommendations for 
pharmaceutical marketers. The outcomes from this study may also benefit government 
regulators, practicing physicians, and medical school educators. Last, the findings of this 
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Appendix A: Cochrane Complementary Medicine Field List of Complementary or 
Alternative (CAM) Therapies 
Açaí /Euterpe oleracea 
Acupressure 
Acupuncture 
Acustimulation / acupoint stimulation 
African prune / Prunus Africana / Pygeum africanum)  
Aiyishu (a Chinese herbal medicine) 
Alexander technique 
Alpha-linolenic acid (ALA) (an omega-3 fatty acid) supplements 
Amino acid supplements 
Angelica 
Antioxidant supplements 







Astragalus / Milkvetch (a Chinese herbal medicine) 
Auricular acupuncture / ear acupuncture 
Ayurveda / Ayurvedic medicine (a type of Indian (East Asian) traditional medicine) 
Balneotherapy 
Bee stings / bee venom 
Beta-sitosterol (a component of saw palmetto) 
Biofeedback 
Biotin (Vitamin B7) supplements 
Botanical supplements 
Bovine cartilage 
Breathing exercises in mind-body medicine (exclude for physical therapy, eg 
treatment of cystic fibrosis) 
Calcium supplements (many people would not include for prevention of 
osteoarthritis) 
Calendula 






Chelation therapy (exclude for treatment of medically diagnosed heavy metal 
poisoning (eg, mercury or lead) and for medically diagnosed excess iron (eg, 
thalassemia)) 




Cold laser therapy 




Danshen (a Chinese herbal medicine) 
Dehydroepiandrosterone (DHEA) supplements 
Dengzhanhua preparations (a Chinese herbal medicine) 
Devil’s claw 
Devil’s nettle  




Dianxianning pill (a Chinese herbal medicine) 
Dietary supplements 
Dihomogammalinolenic acid (DGLA) (an omega-6 fatty acid) supplements 
Dimethylaminoethanol / dimethylethanolamine / Deanol (DMAE)  
Docosahexaenoic acid (DHA) (an omega-3 fatty acid) supplements 
Echinacea 
EDTA (ethylenediaminetetraacetic acid) when used in chelation therapy as 
described above(see Chelation therapy) 
Eicosapentaenoic acid (EPA) (an omega-3 fatty acid) supplements 
Electric stimulation therapy 
Electroacupuncture 









Evening primrose oil 
Eye Movement Desensitization and Reprocessing (EMDR) 
Feverfew 
Fish oil (omega-3 fatty acids) supplements 
Flor Essence formula 
Folic acid / folate (Vitamin B9) supplements (many people would not include for 
prevention of neural tube defects) 
Free and Easy Wanderer (a Chinese herbal medicine) 
Gamma-linolenic acid (GLA) (an omega-6 fatty acid) supplements 
Garlic 











Green tea / Camellia sinensus) 




Hippotherapy / equine-assisted therapy  (exclude when physical therapy only) 
Holistic therapy 
Homeopathy 
Homoharringtonine (HHT) (a plant alkaloid) 
Honey 
Horse chestnut 
Huangqi (a Chinese herbal medicine) 
Huperzine A (a Chinese herbal medicine) 
Hydrazine sulfate 
Hydrotherapy  





Hypnosis / hypnotherapy 
Imagery  
Iron supplements 
Jin Li Da liquor (a Chinese herbal medicine) 






Lentinan (derived from Shitake) 
Light therapy / phototherapy (exclude for treatment of seasonal affective disorder, 
eczema, psoriasis, neonatal jaundice) 
Linoleic acid (an omega-6 fatty acid) supplements 
L-isoleucine (an amino acid) supplements 




L-leucine (an amino acid) supplements 
Low fat diets 
Low protein diets 
Low-glycemic index diets 
L-threonine (an amino acid) supplements 
L-valine (an amino acid) supplements 
Magnesium supplements 
Magnetic therapy 
Marijuana, marihuana / cannabis / cannabinoids / C. sativa / C. indica (exclude for 











Niacin / Nicotinamide (Vitamin B3) supplements 
Omega-3 fatty acids 
Osteopathic manipulation 
Ozone therapy 

















Krestin / PSK / PSP (Coriolus Versicolor extracts) 
Puerarin (a Chinese herbal medicine) 





Relaxation techniques  
Riboflavin (Vitamin B2) supplements 
Rolfing®Structural Integration 
S-Adenosyl methionine (SAM-e)  
Safflower Yellow injection (a Chinese herbal medicine) 
Salacia oblonga 




Sanchi preparations (a Chinese herbal medicine) 
Saw palmetto / serenoa repens  
Selenium  supplements 
Shamanistic medicine (Shamanism) 
Shark cartilage 
Shengmai / shenmai (a Chinese herbal medicine) 
Shenqi Fuzheng (a Chinese herbal medicine) 
Shensu / shenfu (a Chinese herbal medicine) 
Shexiang (injection) (a traditional Chinese medicine] 
Shitake 
Shuanghuanglian (a Chinese herbal medicine) 
Sidda medicine (a type of Indian (East Asian) traditional medicine) 







St. John’s wort (Hypericum perforatum L) 
Suxiao jiuxin wan (a Chinese herbal medicine) 
Tai chi / tai ji 
Testosterone 
Therapeutic touch 
Thiamine (Vitamin B1) supplements 
Tianmadingxian capsule (a Chinese herbal medicine) 
Traditional African healing 
Traditional Arabic medicine 
Traditional Chinese medicine 
Traditional Indian medicine 
Traditional Japanese medicine  
Traditional Korean medicine 
Traditional Tibetan medicine 
Transcranial magnetic stimulation (exclude for  treatment of depression) 





Ultrasound / ultrasonic therapy) (exclude diagnostic ultrasound) 






Vitamin A supplements 
Vitamin B complex supplements 
Vitamin B12 supplements 
Vitamin C supplements 
Vitamin D supplements 
Vitamin E supplements 
Vitamin K  supplements 
Vojta method / Reflexlocomotion  




Xiaxingci granule (a Chinese herbal medicine) 
Yoga 
Zhixian I pill (a Chinese herbal medicine) 
Zinc supplements 
Zishen Tongli Jianonang (a Chinese herbal medicine) 
 
Adapted from “Development and classification of an operational definition of 
complementary and alternative medicine for the Cochrane collaboration,” by L.S. 
Wieland, E. Manheimer, & B.M. Berman, 2011, Alternative Therapies in Health and 





Appendix B: Active Diet Ingredients 
Ingredient   Health Benefits   Daily Content (g) in Women, Men 
 
Soybean/soy protein  Cholesterol-lowering, anti-inflammatory     21, 25 
Viscous fibers   Cholesterol-lowering, prebiotic, GI-reducing   10-25* 
b-glucans          5.8, 6.2 
Guar gum          5.6, 6.7 
Long chain -3 fatty acids Triglyceride-lowering, anti-inflammatory   2.4, 3.0 
Almonds   Cholesterol-lowering       28, 28 
Plant stanols   Cholesterol-lowering      2.0, 2.7 
Cinnamon   Antioxidant      3.0, 3.0 
Blueberries   Antioxidant, prebiotic      74.5, 94.5 
Vinegar    GI -reducing       22.5, 22.5 
Probiotic   Cholesterol-lowering, anti-inflammatory    0.1, 0.1 
Whey protein  GI-reducing      4.3, 4.3  
 
Note. Adapted from “A diet based on multiple functional concepts improves 
cardiometabolic risk parameters in healthy subjects,” by J. Tovar, et al., 2012, Nutrition 
& Metabolism, 9(1), p. 6. © 2012 Tovar et al; licensee BioMed Central Ltd. This is an 
Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, 





Appendix C: Informed Consent Form 
Dear Potential Participant, 
You are invited to take part in a research study entitled Physician Ladders of 
Inference Regarding Omega-3 Dietary Supplements. The researcher will seek to gain an 
understanding of how physicians make decisions to prescribe or recommend dietary 
supplements, especially omega-3 (n-3) dietary supplements.  This form is part of a 
process called “informed consent” to help you understand the intent of the study before 
deciding to take part.  This study is being conducted by Warren P. Lesser, a doctoral 
student at Walden University. You may already know Mr. Lesser is associated with a 
pharmaceutical company, but this study is separate and conducted in a student role. 
Protective measures have been implemented to prevent conflict of interest bias. 
Absolutely no persuasive or coercive measures will be used to influence you to prescribe 
or recommend any products. 
Background Information: 
The purpose of this study regards n-3 marketing strategy to determine decision 
criteria and the ladder of inference physicians use to recommend n-3 supplements. The 
business problem is the difficulty in communicating the complex mechanisms of n-3s and 
their profound health benefits to physicians and subsequently from physicians to their 
patients.  Positive potential study outcomes regard preventive cardiovascular health 
opportunities: a) N-3 marketers may understand how to improve n-3 marketing and 




lower healthcare costs, and c) patients and the general population may improve 
cardiovascular health and quality of life.   
Number of Subjects/Length and Description of Participation 
This study will include 20 physician subjects from a geographical region 
including Indiana, Kentucky, and Tennessee. Interview time lengths will be limited to 1 
hour.  The interview will be audiotaped to maintain the accuracy of all data collected.  
Additionally, each subject will be asked to provide feedback via e-mail to confirm 
interview data collected and provide additional feedback if desired. Themes may be 
disclosed among group members but group member names will be kept strictly 
confidential and not disclosed to other group members). You may be asked to respond to 
no more than two follow-up e-mails. E-mail feedback will take no more than 10 minutes 
per e-mail. 
Inclusion Criteria 
Physician subjects will be purposefully selected based upon interest in the study 
subject, an open perspective regarding diverse opinions, and access. Geographical scope 
and a willingness to set aside sufficient time without interruptions in a private setting 
define acceptable participant access criteria. 
Procedures: 
If you agree to voluntarily participate in this study, you will be asked to: 
Participate in a one-on-one interview with the researcher regarding decision 




no more than two follow-up emails to verify/clarify collected interview data and 
identified themes.  
Here are sample questions: 
2a, 2b, 2c. (a) What credible clinical evidence have you seen regarding fish oil 
dietary supplements?  (b) What made the evidence credible or incredulous?  (c) What 
kind of evidence would you consider the most convincing?   
3. What are the risks of taking fish oil dietary supplements?  What are the risks 
regarding specific patient groups or disease states?   
4a, 4b. (a) What are the important differences between quality fish oil dietary 
supplements and low quality fish oil dietary supplements?  (b) What are right daily 
amounts of DHA and EPA? 
Voluntary Nature of the Study: 
This study is voluntary. If you decide to join the study now, you can still change 
your mind during or after the study. You may stop at any time. You may withdraw at any 
time during the study. If you choose not to participate or withdraw, you will not receive 
the $50 stipend and the relationship between the study subject and researcher will not be 
deleteriously affected.  
Risks and Benefits of Being in the Study: 
Being in this type of study involves some risk of the minor discomforts that can 
be encountered in daily life, such as stress or becoming upset. Being in this study would 
not pose risk to your safety or wellbeing. Any risk of physical injury or harm during the 




and disclosure of personal prescribing preferences and decision processes to the 
interviewer, transcriber, and one other coder. The interviewer, transcriber, and coder must 
execute confidentiality agreements before data access. Positive potential study benefits 
include: a) Gained knowledge among n-3 marketers to better communicate with 
physicians, b) increased physician education and n-3 utilization, which may improve 
patient health, patient quality of life, and lower U.S. healthcare costs. 
Payment: 
Participation in this study is voluntary but an appreciation stipend of $50 will be 
paid at the conclusion of data collection. If you withdraw from this study you will not be 
paid the $50 stipend. 
Privacy: 
Any information you provide will be kept confidential. The researcher will not 
use your personal information for any purposes outside of this research project. Also, the 
researcher will not include your name or anything else that could identify you in the 
study reports. The privacy of all participants will be protected with all sensitive data 
coded in place of source identification. All study protocol, collected data, and consent 
forms will be stored in a locked container for 5 years from completion of the study. 
Contacts and Questions: 
You may ask any questions you have now. Or if you have questions later, you 
may contact the researcher, Warren P. Lesser, via telephone or email: or 
warrenlesser@yahoo.com. If you want to talk privately about your rights as a participant, 




discuss this with you. Her phone number is 1-800-925-3368, extension 3121210. Walden 
University’s approval number for this study is [TBD]. The researcher will give you a 
copy of this form to keep. 
Statement of Consent: 
I have read the above information and I feel I understand the study well enough to 
make a decision about my involvement. By signing below, “I consent,” I understand I am 
agreeing to the terms described above. 
Printed Name of Participant 










Warren P. Lesser 
Experience 
Campbell Soup Company, Scarsdale, NY (Sales, 1976-1978) 
Boots Pharmaceuticals, Shreveport, LA (Sales and Manager of Sales Training,1978-
1987) 
MAS Home Health, Shreveport, LA (VP Marketing, 1987-1988) 
SpectraCare, Inc. (Home health and I.V. infusion pharmacies, owner/founder, 1988, 
harvested in 1996) 
SpectraBrace, Ltd. (Orthopedic services, owner/founder, 1996, harvested in 2005) 
Paradigm HealthCare Solutions, Inc., Louisville, KY (ICD-9 coding, owner/founder, 
1996, harvested in 2004) 
MAGNA Pharmaceuticals, Inc. (President/CEO, primary owner, 2000 – present) 
Z-Xpress Car Wash, LLC, Louisville, KY (conveyor and conveyor/detailing locations, 
owner/founder, 2005 - present) 
Hogg’s Upstairs Taverne Gatlinburg, TN (owner/founder, 2008 - present) 
Hogg’s Pub & Grub, Gatlinburg, TN (owner/founder, 2012 – present) 
LandVest, LLC, renamed LV Capital, LLC, Louisville, KY (1/3 partner in patio home 
development company, 1996-2008) 
Education 
Taylor University, Upland, IN, Bachelor of Arts, 1976 




Centenary College of Louisiana, Shreveport, LA, Master of Business Administration, 
1987 
DBA course work, Walden University, 2010-2014  
 
 
 
 
